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About 30% of commercial and developmental drugs exhibit poor solubility and thus poor 
bioavailability. Strategies that enhance solubility of such compounds have become more 
popular. Cocrystallisation is one of these strategies, so characterisation of in vitro 
performance of cocrystals is essential. Conventional dissolution systems (USP apparatus 1 
and USP apparatus 2) are often not suitable for testing poorly soluble drugs due to failure in 
providing sink conditions and inability to change the media during the experiment. This 
project involves designing appropriate dissolution methods that will help understand the 
mechanism of dissolution of cocrystals. Successful dissolution methods were used to test 
marketed formulations of Carbamazepine (CBZ) (IR and PR Tegretol® tablets) and 
Indomethacin (IND) (IR Indocid® capsules). Flow-through cell (USP 4) apparatus proved to 
be more suitable to test poorly soluble formulations than basket (USP 1) apparatus. 
Formulations and their cocrystals were tested in four combinations of media: compendial 
(SGF/SIF), modified I (MGM/MIM-I), modified (MGM/MIM-II) and biorelevant media 
(FaSSGF/FaSSIF-V2). USP apparatus 4 allowed capturing and quantifying the precipitation 
of IND samples upon the media change. All Indomethacin formulations exhibited 
precipitation; however, this occurred into the smaller extent in biorelevant media. The greatest 
enhancement in CBZ dissolution was observed for Saccharin cocrystals of CBZ. On the other 
hand, Nicotinamide cocrystal of IND improved dissolution of IND greater than Saccharin 
cocrystal. Dissolution profiles with physicochemical and pharmacokinetic parameters were 
used to develop a Physiologically Based Pharmacokinetic (PBPK) model using in silico 
program Simcyp®. Successful models were then used to predict in vivo performance of 
cocrystals. Successful PBPK models were developed for IR and PR formulations of Tegretol® 
tablets and IR Indocid® capsules using dissolution data tested in biorelevant media using 
dissolution USP apparatus 4. It was found that in vivo absorption of CBZ from cocrystals did 
not increase dramatically. An overall 2 % increment was observed when compared against the 
CBZsp sample. However, the rate of absorption for CBZ-SACss samples was significantly 
faster than the rate of CBZsp absorption. API and cocrystals of IND completely absorbed 
within 3 hours and IND-NICss cocrystal were found to absorb slightly faster than the other 
cocrystals. Absorption was 8% higher at 1 h in comparison to IND. However, overall the 
improvement was not statistically significant. In summary, this research demonstrates that 




Pharmaceutical sector encounters many challenges in discovering and developing new active 
substances. The challenging aspects in development of a new active pharmaceutical 
ingredient (API) are often associated with selection of an active form, manufacture or storage. 
Some solids are unstable due to different polymorphic states; some APIs are poorly soluble 
and therefore poorly bioavailable. According to the Biopharmaceutics classification system 
(BCS), drugs that exhibit poor solubility and high permeability belong to BCS class II (1), 
which  is currently estimated to account for about 30% of both commercial and 
developmental drugs (2, 3). Increasing solubility can significantly enhance the oral absorption 
of class II drugs and consequently result in increased number of more bioavailable 
medications on the market. The traditional approaches (i.e. micronisation, salt formation, and 
polymorphism) that are used to improve solubility often fail to produce adequate 
enhancement of bioavailability (4). For instance, the dissolution enhancement reported for 
different polymorphs of Carbamazepine (CBZ) was not observed in vivo due to solution - 
mediated transformation from a more soluble anhydrous form to a less soluble but more stable 
dihydrate form of CBZ (5). Over the last decade, cocrystals have emerged as a promising 
approach to modify physicochemical properties, resulting in improvement of stability, 
solubility and dissolution and possibly, providing better bioavailability. Moreover, 
pharmaceutical cocrystals might offer advantages over the API that may help overcome a 
range of limitations (i.e. stability) encountered with traditional approaches (6). Cocrystals are 
solid-chemistry materials of which physicochemical properties have been extensively studied. 
The prototype cocrystal, Quinhydrone, was studied by Friedrich and Wöhler in 1844 (7). 
However, cocrystals’ biopharmaceutical properties are under – studied. 
The next sections will define cocrystal-related terminology and provide detailed descriptions 
of their potential applications, chemistry and advantages. As Carbamazepine and 
Indomethacin (IND) cocrystals were studied in this project, designated sections will be 




To discuss cocrystals, it is crucial to understand what they are. They have also been referred 
to as co-crystal (8), molecular complex (8, 9) or multi-component molecular crystals (10). 
The definition of the cocrystal concept was the subject of debate in journal articles and 
presentations at conferences (8, 9, 11-15). The arguments varied from the use of hyphenation 
(i.e., cocrystal versus co-crystal) to the nature of components and interactions between them. 
The first issue was resolved using The Columbia Guide to Standard American English, which 
states that co- prefix should be attached to the base word without a space or hyphen (16).  The 
second part of the discussion was more chemistry related and evolved gradually. Initially, 
Dunitz defined cocrystal as a multi-component complex of two or more molecular species (8). 
Then Aakeröy and Salmon expanded the term by highlighting that cocrystal should be 
composed of components that are solids at ambient temperature when in their pure form (17). 
The latest part of the debate focused on the characterisation of interactions between 
components. The definition suggested by Almarsson and Zaworotko indicated that at least 
two components of cocrystal should interact by hydrogen bonding as well as possibly by other 
noncovalent and non-ionic interactions (12). Three years afterwards, Lara-Ochoa and 
Espinosa-Pérez emphasised the importance of these interactions in lattice stabilisation (18). 
They have reported that two cocrystal components can be bonded using π-π aromatic 
interactions and van der Waals forces, π – π stacking interactions and halogen binding (18). In 
other words, cocrystals are crystalline solids generated from API and cocrystal formers (CCF) 
(19, 20). Cocrystal former has been reported often as coformer (21), ligand (22, 23, 24) or 
guest (25, 26). Many organic compounds have been screened for the best coformer 
characteristics including acetone, dimethyl sulfoxide (DMSO) or acetic acid. When a 
cocrystal is intended for a pharmaceutical application, the scale of potential coformer is 
limited due to toxicity issues. Therefore, compounds that are non-toxic and generally 
recognized as safe are strongly recommended by Food and Drug Administration (27).  
However, not all GRAS compounds can be used in pharmaceutical dosage forms. Some 
GRAS compounds are only approved to be used as flavourings at part per million levels, 
which would not be sufficient to engineer the cocrystal. Nicotinamide, Saccharin and Acetic 
acid are so far the most successful GRAS compounds used as coformers in cocrystals (28). 
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1.3 Chemistry of cocrystals 
Hydrogen bonds seem to play an important role in cocrystal formation (29). Etter and co-
workers emphasised the importance of the hydrogen bond donors and acceptors of two 
components that may form a cocrystal and have published guidelines to aid design of 
cocrystals (30). According to these instructions, all proton donors and acceptors participate in 
hydrogen bonding. Also, six-membered ring intramolecular hydrogen bonds are formed in 
preference to intermolecular hydrogen bonds (31, 32).  
The term supramolecular synthon was introduced and defined by Desiraju (29) as “structural 
units within supermolecules which can be formed and/or assembled by known conceivable 
synthetic operations involving intermolecular interaction”. There are two types of synthons 
possible depending on types of functional groups that form this synthon: homosynthons are 
formed from carboxylic acids and amides, while heterosynthons contain pyridine – carboxylic 















Figure 1. Homosython (a) and heterosynthon (b) motifs observed in cocrystal structures. Redrawn from (12). 
Typical examples of such supramolecular synthons include amide-amide dimers, carboxylic 
acid- carboxylic acid dimers and carboxylic acid-amide dimers (Figure 2). The 
heterosynthons are preferred for cocrystal formation probably due to enthalpic advantages. 
The energy gain in heterosynthons is greater than in homosynthons. Analysis of the 
Cambridge Structural Database (CSD) revealed that 97% of cocrystals would be formed 
between carboxylic acid – aromatic nitrogen heterosynthons, in contrast to 3% of cocrystals 
formed between carboxylic acid – carboxylic acid homosynthons (33). This indicates that 






























O O  
(c) acid – amide heterosynthon 
Figure 2. Schematic illustrations of supramolecular hydrogen – bonded synthons occuring in cocrystals. 
Hydrogen bonds are shown as dotted lines. Redrawn from (12). 
1.4 Hydrates, solvates and salts versus cocrystals 
It is important to define what distinguishes cocrystals from other solubility enhancement 
strategies such as solvates, hydrates and salts. Hydrates and solvates are also multi-component 
crystals; however, in the case of hydrates, one component is water, while, in solvates, one 
component is an organic compound used as a solvent (11). Salt formation is a widely 
implemented and convenient method used for improving solubility of poorly soluble 
compounds. However, only ionic APIs can be used for salt formation. On the other hand, 
cocrystals can be formed with neutral or ionic forms of an API (35). Nonetheless, not all APIs 
and coformers can create cocrystals. Therefore, it is important to understand the rules which 
govern salt and cocrystal formation. Salt formation is an acid – base reaction, involving the 
transfer of protons (little or no proton transfer occurs during cocrystal formation) (Figure 3). 
Thus, the dissociation constants (14) of the acid and base are important parameters that define 
whether or not salt formation occurs (14).  
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              (a)          (b)    
Figure 3. Illustrations of a) Salt and b) Cocrystal between N – heterocycle and carboxylic acid. Redrawn from 
(11). 
 
The difference in pKa between the acid and base must be greater than 2 or 3 pKa units to form 
a salt that is stable in water (14). Moreover, Bhogala et al. noted that ΔpKa less than 0 will 
always result in cocrystal formation (36). Although, when ΔpKa range varies from 0 to 2, no 
prediction is achievable. These types of products can be either salts or cocrystals or cannot be 
assigned to either group.  However, it has been reported by Aakeröy et al. that the exact 
location of protons may be subjected to temperature conditions (11).  
1.5 Applications 
It is worth noting that cocrystals have been the subject of research for the past 165 years (7). 
However, the debate about pharmaceutical cocrystals started in 2003 (8).  
Cocrystals have been used in a wide variety of industries, including chemical processing, 
photographic film formulation, propellant, electronic (37), paper and textile (38). Table 1 lists 












 Table 1. Examples of pharmaceutical cocrystals. 
Cocrystal  References 
4,4’-Bipyridine – Pimelic acid (1:1) (39) 
AMG517 – Sorbic acid  (40) 
Benzoic acid – isonicotinamide (2:1) (41) 
Caffeine – Oxalic acid (2:1) (42) 
Caffeine – Maleic acid (2:1) (43) 
Caffeine – Malonic acid (2:1) (43) 
Caffeine – Glutaric acid (1:1) (43-44)  
Carbamazepine –Benzoquinone (2:1) (45) 
Carbamazepine –Bipyridine (2:1) (45) 
Carbamazepine – Saccharin (1:1) (45, 46) 
Carbamazepine – Nicotinamide (1:1) (45, 47) 
Carbamazepine – Terephthalaldehyde (2:1) (45) 
Celecoxib – Nicotinamide (1:1) (48) 
Exemestane – Maleic acid (49) 
Fluoxetine hydrochloride – Benzoic acid (1:1) (13) 
Fluoxetine hydrochloride – Succinic acid (2:1) (13) 
Fluoxetine hydrochloride – Fumaric acid (2:1) (13) 
Indomethacin – Saccharin (50) 
Itraconazole – 1,4-dicarboxylic acids (51) 
Magestrol acetate – Saccharin (1:1) (50) 
Melamine – Cyanuric acid (1:1) (52) 
Monophosphate salt - phosphoric acid (1:1) (53) 
Norfloxacin – isonicotinamide (1:1) (54) 
Piracetam – Gentisic acid (1:1) (55) 
Piroxicam – Saccharin (1:1) (56) 
Sildenafil – Acetylsalicylic acid (1:1) (57) 
Sulfamethazine – Anthranilic acid (57) 
Sulfamethazine – Aspirin (1:1) (57) 
Sulfamethazine – Benzoic acid (1:1) (57) 
Theophylline – Oxalic acid (58, 59) 
Theophylline – Malonic acid (59) 
Theophylline – Maleic acid (59) 
Theophylline – Glutaric acid (59) 
Trimethroprim – Sulfamethoxypyridazine (1:1) (60) 
 
 6
1.6 Methods of preparation 
Cocrystals can be prepared by a wide range of methods including solution cocrystallisation 
(61, 62), cogrinding also known as dry grinding (63), solvent evaporation (64), sonic-
slurrying (65), spray-drying (66) and ultrasound mediated amorphous to crystalline transition 
(UMAX) (67, 68). Cocrystals that were studied in this project were prepared by sonic-
slurrying, spray-drying and UMAX methods. 
1.6.1 Sonic-slurrying technique 
A slurry is prepared by adding appropriate amounts of API and coformer into the jacketed 
vessel containing organic solvent (e.g. ethyl acetate). The slurry is then stirred using a 
magnetic stirrer at specified conditions (temperature, duration of stirring, speed of stirring). 
Slurry is then filtered and dried under vacuum overnight (65). 
1.6.2 Spray-drying technique 
The spray-drying process coverts a liquid into a powder and it is composed of the following 
four stages. The first phase consists of atomisation of the feed into a spray. Then spray-air 
contact occurs followed by the drying stage. The final step involves separation of the dried 
product from the drying gas (66).  
1.6.3 UMAX technique 
UMAX process encompasses the following three stages: the first stage involves judicious 
spray-drying of an API and coformer solution. The second stage consists of collecting the 
unstable amorphous or part-amorphous spray-dried particles in a non-solvent, and applying 
power ultrasound to particles to effect crystallization. The final stage is known as solid 





1.7 Biopharmaceutical characteristics of cocrystals 
1.7.1 Stability studies 
It has been reported that cocrystals greatly improve stability (13). Many cocrystals, including 
Caffeine-Oxalic acid cocrystal, Caffeine-Maleic acid cocrystal and Caffeine-Glutaric acid 
cocrystal as well as Theophylline cocrystals with Glutaric acid, Maleic and Malonic acids 
transformed to the hydrate form after exposure to 98% RH (43, 69). It was noted that the 
strongest acid used (Oxalic acid) formed the most stable cocrystal, while the weakest acid 
(Glutaric acid) produced the least stable cocrystal (43). Also, Carbamazepine-Saccharin and 
Carbamazepine-Nicotinamide cocrystals were observed to be stable until exposure to 98% RH 
(70). Moreover, minimal (< 0.05%) water uptake was reported for Indomethacin-Saccharin 
cocrystal up to 95% RH (50). Few studies investigated long-term stability (53, 69). For 
instance, Monophosphate salt with Phosphoric acid showed physical stability after 8 weeks of 
storage at 40 °C/ 75% RH (53). 
1.7.2 Solubility studies 
It has been claimed that cocrystals enhance solubility of poorly soluble compounds. Great 
enhancement in solubility of cocrystals in organic solvents has been noted (71). In order to 
understand the behavior of cocrystal in vivo, testing solubility in aqueous media was essential. 
Basovoju et al. reported the case when Norfloxacin – Isonicotinamide cocrystal improved 
solubility three times in comparison to the solubility of the parent compound (54). Also, 
Cheney et al. successfully prepared pharmaceutical cocrystal made of two active components: 
Meloxicam and Aspirin.  Aspirin in this case played a coformer role. This cocrystal resulted 
in significant solubility enhancement (0.22g/mL) in phosphate buffer pH 7.4 at 37 °C, when 
compared with solubility of Meloxicam (0.005g/mL) (72). There were some exceptions, 
through where the enhancement in solubility did not occur. For instance, Rahman et al. 
reported no significant improvement in equilibrium solubility between CBZ and 
Carbamazepine – Nicotinamide cocrystal tested in four different media: water, HCl (pH 1.2), 
acetate buffer (pH 4.5) and 0.2 M phosphate buffer (pH 6.8) at 25 and 37 °C (73). In contrast 
to pH, the temperature had a significant effect on solubility of CBZ and CBZ-NIC cocrystal. 
Insensitivity of CBZ to pH changes can be explained by the fact that CBZ behaves like 
neutral drug in physiological pH range (pH 1.2 – 7.5). A Lamotrigine – Nicotinamide 
cocrystal also did not improve the solubility of Lamotrigine in water and HCl (pH 1.2) (74). It 
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was concluded that the cocrystal is a single molecular entity in the solid state and, upon 
contact with water, hydrogen bonding dissociates into individual components (59, 73). The 
cocrystal cannot improve the solubility over a mixture of the individual components because 
solubility is an equilibrium thermodynamic property.  
1.7.3 Dissolution studies 
Dissolution enhancement has been reported using a range of dissolution methods and 
apparatus. It has been observed by Remenar and co-workers that dissolution (0.1M HCl,       
25 °C, methodology not specified) of Itraconazole from cocrystals of Itraconazole with 
Succinic acid, Malic acid and Tartaric acid was similar to the dissolution of amorphous 
Itraconazole from commercial product Sporanox®. Moreover, cocrystals resulted in four to 
twenty fold higher concentrations in comparison to its crystalline form (75). 
Shiraki et al. showed that the intrinsic dissolution rate (IDR) of Megestrol acetate – Saccharin 
cocrystal (2.53 ± 0.91 µg/cm2/min) is three to four times greater than the intrinsic dissolution 
rate of its parent compound (0.66 ± 0.33 µg/cm2/min) (49).  This enhancement was also 
observed during dissolution studies (USP 2, 50 rpm) performed in 100 mL vessels filled with 
50 mL of Fasted State Simulated Intestinal Fluids (FaSSIF) (Figure 4). Supersaturation of fine 
(average particle size: 15 µm) Megestrol acetate – Saccharin cocrystal occurred within 15 
minutes, after which the cocrystal started transforming to the parent compound. Larger 
particles of cocrystal did not exhibit supersaturation. 
 
Figure 4. Dissolution profile of cocrystal 2 (Megestrol acetate – Saccharin) (n=4) in FaSSIF using USP 2 
(50rpm, 50 mL). Reprinted with permission from (49). 
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On the other hand, dissolution studies of Carbamazepine – Saccharin cocrystal with six 
different particle size fractions ranging from 53 µm to 1000 µm in SGF with 1% Triton X (pH 
2) (USP 2, 100 rpm, 900 mL) showed slower dissolution rates of Carbamazepine from 
samples with particle size > 500 µm (46).  
Lu and Rohani have presented the case of Theophylline – Nicotinamide cocrystal which 
proved that not only an enhancement in dissolution (50 mL, water, 25 °C) is an important 
advantage of cocrystallisation, but sometimes the benefit of producing more stable product 
should be sufficient (76) (Figure 5). Theophylline tends to convert from its more soluble 
anhydrous form to a stable but less soluble hydrate state during processing and dissolution. 
Theophylline – Nicotinamide cocrystal resulted in a more stable material that inhibited the 
conversion to the hydrate state (59). 
 
Figure 5. Dissolution of Theophylline and Theophylline – Nicotinamide cocrystal in water. Reprinted with 
permission from (76).  
1.7.4 Bioavailability studies 
It was important to investigate if the enhancement of solubility and dissolution of cocrystals 
can lead to improvement of in vivo performance. So far, none of the cocrystals were tested in 
humans. All available in vivo data were performed using various animal species. Suspension 
(1 mg/kg) of Meloxicam – Aspirin cocrystal administered via oral gavage in rats (n = 5) 
resulted in an oral bioavailability of 69%, compared with 16% for Meloxicam (72). Moreover, 
AMG517 – Sorbic acid cocrystals proved not only to significantly increase solubility of 
AMG517 but also to enhance eight times Cmax of AMG517 in rats (40). Also, cocrystal of 
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Glutaric acid with sodium channel blocker that showed an eighteen times increase in its 
intrinsic dissolution rate, resulted in a three-fold increase in exposure over the parent 
compound in a canine pharmacokinetic study (69) (Figure 6). 
 
Figure 6. Mean plasma concentration (+SD) versus time profiles after administration of 50 mg/kg of API (●) 
and cocrystal of glutaric acid (○) in dogs (n=6). Reprinted with permission from (69).  
Jung et al. examined bioavailability of orally administered capsules of IND-SAC cocrystals in 
beagle dogs (77) (Figure 7). The in-vivo bioavailability of IND in dogs was significantly 
higher (p < 0.05) than that of physical blend of IND and SAC, but exhibited similar (p > 0.05) 
performance to a commercial formulation of IND (Idomee®, Sweden). Indomee® is a highly 
optimised formulation that has been marketed for a long time and hence would be expected to 
have good bioavailability (77). 
 
Figure 7. Plasma concentration - versus time profiles for indomethacin after oral administration of various 
formulations in dogs: ● IND – SAC cocrystal; ■ Physical mixture of IND and SAC; and ▲Indomee® capsules. 
Error bars show standard deviations. Reprinted with permission from (77).  
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Despite the limited number of examples, cocrystals proved successful in increasing the 
bioavailability of poorly soluble drugs in animal studies.  
1.8 Cocrystals studied 






Figure 8. Structure of Carbamazepine. 
Carbamazepine is a well-known drug used for epilepsy and trigeminal neuralgia (Figure 8). It 
is classified as a BCS class II compound due to its high permeability and low solubility in 
aqueous media (anhydrous: 0.38 mg/mL; dihydrate: 0.13 mg/mL at 25 °C) (78). It exhibits in 
four anhydrous polymorphs: monoclinic (III), triclinic (I), trigonal (II) forms and a dihydrate 
(DH) form (79, 80). The monoclinic form (MP~174 °C) is the most thermodynamically stable 
at ambient conditions (80). It was reported that the intrinsic dissolution rate of the metastable 
monoclinic polymorph was greatest (67.4 µg/cm2/min) when compared to the triclinic (I) 
(61.8 µg/cm2/min) and dihydrate form (DH) (41.8 µg/cm2/min) (80). However, this form 
tends to convert to the least soluble dihydrate (DH) form, faster than the stable triclinic form 
(I) (MP~190 °C) (79, 81). This trend was in agreement with in vivo studies (46). Commercial 
formulations of CBZ, Tegretol® tablets are formulated with the anhydrous monoclinic form. 
From a supramolecular perspective, CBZ is a simple molecule with one hydrogen bond. It is a 
weak acid with pKa value of 11.83, thus during in vitro and in vivo dissolution in 
physiological pH range (1.2 – 7.5) CBZ does not lose a proton to form the corresponding 
anion, so the compound is unionised (82). 
Saccharin (MP~229.47 °C) is a potent sweetener that is often used as taste-masking agent to 
improve patient compliance (56). It is an ionizable compound (pKa = 1.8-2.2) (83) with 
aqueous solubility of around 3.45 mg/mL (74). In the cocrystal, Saccharin acts as both a 
hydrogen bond donor and acceptor. SAC forms an N – H ··· O hydrogen bond to the CBZ 
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Carbamazepine Carbamazepine - Saccharin cocrystal  
Figure 9. Formation of CBZ-SAC cocrystal. Redrawn from (46). 
The Carbamazepine-Saccharin (CBZ-SAC; 1:1) cocrystal has been extensively studied (45, 
46, 84). The presence of two distinct morphologies - plates and needles (polymorphs, CBZ-
SAC I (MP~166.8 °C) and CBZ-SAC II (MP~173 °C) have been revealed by optical 
microscopy (84) (Figure 10). According to this study, form II of CBZ-SAC heterosynthon is 
formed differently, by a hydrogen bond between N – H of SAC with carboxyl group of CBZ 

























Figure 10. Illustration of (a) the homosynthon between two CBZ molecules in CBZ-SAC I and (b) the 
heterosynthon between a CBZ and SAC molecule in CBZ-SAC II. Redrawn from (84). 
Nicotinamide (NIC, pyridine-3-carboxylic acid amide) is also known as vitamin B3 and is 
very potent hydrotropic agent used to increase the aqueous solubility of many drugs (85). It is 
an ionisable compound (pKa = 3.35) (86) with high aqueous solubility of around 1000 mg/mL 
(74). Hathwar et al. produced Nicotinamide – Salicylic acid cocrystal, in which the nitrogen 
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atom in the pyridine ring of Nicotinamide can form heterosynthons with salicylic acid, 
resulting in an amide – pyridine, an acid – pyridine or hydroxyl – pyridine hydrogen motif 
(86). However, the possibility of formation of homosynthons between amide – amide and 
pyridine – pyridine moieties was also reported (87). 
Carbamazepine – Nicotinamide exhibits three polymorphs, named CBZ-NIC-I, CBZ-NIC-II 
and CBZ-NIC-PN (47, 84). Raman spectroscopy has revealed that the latter converts to CBZ-
NIC-I in the temperature range 124 – 128 °C (84). NIC is non-covalently bonded to CBZ 
through C = O ··· H – H hydrogen bonds. Crystal packing reveals π···π interactions between 
the CBZ and NIC rings (45) (Figure 11). The hydrotropic effect of NIC has been claimed to 
be mainly due to its ability to destroy water structure and/or to form complexes with certain 















































Figure 12. Structure of Indomethacin. 
 
Indomethacin is a nonsteroidal drug with anti-inflammatory (NSAID), antipyretic and 
analgesic properties (Figure 12). It is widely prescribed for patients with moderate to severe 
rheumatoid arthritis, ankylosing spondylitis, osteoarthritis and acute arthritis (91). It is well 
known to cause gastrointestinal disturbances. Indomethacin is a poorly soluble BCS class II 
drug. Indomethacin exists in two polymorphic forms, termed a-form (α) (MP~ 154.5-155.5 
°C) and c-form (γ or g-form) (MP~160.82 °C), and an amorphous form (92). C-form is 
thermodynamically stable at room temperature but is practically insoluble in water (2.5-4 
mg/mL) (93). Indomethacin – Saccharin cocrystal (MP~184.20 °C) is characterised by 
specific carboxylic acid and imide dimer synthons interconnected by weak hydrogen bonds 



































imide dimer homosynthon 
carboxylic acid dimer 
homosynthon 
Figure 13. Indomethacin – Saccharin cocrystal. Redrawn from (50). 
 
Alhalaweh and Velaga successfully prepared IND-NIC (1:1) cocrystals using spray-drying 
and solvent evaporation methods (66). Cocrystals exhibited an amorphous state for a short 
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period of time and then crystallised to cocrystal upon storage. The same group of scientists 
prepared IND-SAC (1:1) and IND-NIC (1:1) cocrystals using grinding method (71). 
Solubility of these cocrystals was tested in various organic solvents including methanol, 
ethanol and ethyl acetate. It was found that IND-NIC cocrystals were more soluble than the 
IND-SAC cocrystals in all media.  
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2 In vitro dissolution testing 
2.1 Introduction 
Over the last half century, dissolution became a very important tool in the pharmaceutical 
industry. Simply defined, dissolution is the process by which a solid enters into a solution in 
the presence of solvent (94). The dissolution rate may be defined as the amount of drug 
substance that goes in solution per unit time under standardized conditions of liquid/solid 
interface, temperature and solvent composition. This section will describe the types of 
dissolution systems officially approved by pharmacopoeias and the applications of the in vitro 
dissolution testing. Two dissolution systems: basket (USP apparatus 1) and flow-through cell 
(USP apparatus 4) will be closely characterised in terms of their advantages and 
disadvantages, as well as hydrodynamics and their potential applications. A short review of 
existing dissolution media is also included in this chapter together with statistical approaches 
of comparing in vitro dissolution profiles. 
2.2 Dissolution theories 
Dissolution process is controlled by the affinity between the solid substance and the solvent 
and consists of two consecutive steps. The first step involves the liberation of molecules from 
the solid phase to the liquid layer near the solid surface. Followed by the transport of solutes 
from solid – liquid interface into the bulk solution. The dissolution of the solid substance is 
generally modelled based upon the significance of these two transport stages (95). The most 
common dissolution theories will be described in the following section. 
2.2.1 Diffusion layer model (DLM) 
The diffusion layer model was originally proposed by Nerst and Brunner in 1904 (96). The 
model assumes that a diffusion layer of thickness h is surrounding the surface of a dissolving 
particle. The transport at the solid-liquid interface is assumed to be instantaneous, providing 
equilibrium at the interface. Concentration at the surface is the saturated solubility of the 
substance (97). The solute molecule that diffuses through the film layer reaches liquid – 
solvent interface. Rapid mixing provides uniform bulk concentration (C). Fick’s first law was 
applied to model the diffusion process through the liquid film. This law relates flux of a solute 
to its concentration gradient (Equation 1): 
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dx
dCDJ                                                      (Equation 1) 
 
where J is the amount of substance passing perpendicularly through a unit surface area per 
unit time. D is the diffusion coefficient, and dC/dx is the concentration gradient, which 
represents a driving force for diffusion. At steady state this equation can be expressed as 
(Equation 2): 
h
CCDJ S                                                  (Equation 2) 
where C is the bulk concentration, Cs is the saturation concentration, and h is the thickness of 
the stagnant diffusion layer. Thus, dissolution rate, which is directly proportional to the flux 
of solutes across the diffusion layer can be characterised by equations: 
SJ
dt




dC S )(                                            (Equation 4) 
where S is the total surface area of particles, and V is the volume of dissolution medium. Cs-C 
represents the concentration gradient within the stagnant diffusion layer with thickness h. This 
equation is known as Nerst-Brunner equation.  
2.2.2 Interfacial Barrier model 
In contrast to DLM, the interfacial barrier model assumes that the reaction at the solid surface 
is significantly slower than the diffusion across the interface (98). Thus, no equilibrium exists 
at the surface, and liberation of solutes at the solid-liquid interface controls the overall rate of 
the transport process. This model can describe dissolution rate using Equation 5.  
)( CCkG Si                                          (Equation 5) 




2.2.3 Danckwerts’ model 
Assuming that the solid surface reaction is instantaneous, the Danckwerts’ model suggests 
that the transport of solute is achieved by the macroscopic packets that reach the solid surface, 
absorb solutes at the surface (according to law of diffusion) and deliver them to the bulk 
solution (99). The packet is then replaced with the new packet of solvent. According to this 
theory dissolution can be characterised by Equation 6: 
)()( 21 CCsDS
dt
dm                                          (Equation 6)       
where m is the mass of dissolved substances and γ is the interfacial tension.  
2.3 Applications of in vitro dissolution testing 
The importance of in vitro dissolution testing has been recognized by the pharmaceutical 
industry since the early 1930s (100). Dissolution testing has been included in the United 
States Pharmacopoeia (USP <711>, <724>) since 1970 and from that time onwards plays an 
important role as a quality control (QC) tool (97). Initially, the aim of dissolution was to 
differentiate between acceptable and unacceptable batches during the manufacture process 
(101).  Formulators treat the dissolution test as a valuable tool that is able to show the effect 
of certain excipients on manufacture variables. Dissolution is still a critical test that 
determines the effect of aging of the product on stability (102, 103). For instance, dissolution 
testing was used to proved that type of packaging and storage conditions significantly affected 
the stability of Prednisone tablets (104). Moreover, dissolution serves as an in vitro surrogate 
for in vivo bioequivalence studies by development of in vivo – in vitro correlation (IVIVC) 
and can support a biowaiver for formulation based on the biopharmaceutics classification 
system (BCS) (97, 105-107). This approach minimises the number of human studies required 
for drug approval. This is because a biowaiver allows the use of dissolution curves in place of 





2.4 The dissolution apparatus 
There are seven dissolution systems officially approved by United States Pharmacopeia (USP 
<711>) that can be used to test several types of formulations (Table 2) (108). 
Table 2. List of the dissolution apparatuses and their applications (109). 
Dissolution Apparatus Formulations that can be tested 











USP apparatus 3 (reciprocating cylinder) 
USP <711> 
Modified release dosage form 
Bead type 
USP apparatus 4 (flow-through cell) 
USP <711> 
Modified release (poorly soluble drugs, 
suppositories, soft gelatin, bead type) 
USP apparatus 5 (paddle over disk) 
USP <724> 
Transdermal 
USP apparatus 6 (cylinder) 
USP <724> 
Transdermal 
USP apparatus 7 
(reciprocating holder) 
USP <724> 








2.4.1 USP apparatus 1  
2.4.1.1 Operation mode 
The apparatus 1 was made an official regulatory test by USP in 1970 (110). The rotating 
basket device is simple, robust and adequately standardised (Figure 14). It can be also 
automated which makes it useful for routine experiments. The rotating basket apparatus 
consists of a cylindrical basket held by a motor shaft. The basket holds the sample (tablet, 
capsule, etc.) and rotates in a cylindrical, round bottomed vessel, which is usually made of 
glass and contains the dissolution medium. The entire vessel is immersed in a constant 
temperature bath set at 37±0.5 °C. The position of the basket (25±2 mm) is specified by the 
USP (109). USP apparatus 1 is used for dosage forms that tend to float or disintegrate slowly 
(i.e. capsules, tablets). The system can accommodate from 500 to 1000 mL of medium using 
the standard size vessel. The volume of the media is particularly important for poorly soluble 
drugs that require large amounts of medium in order to maintain sink conditions. It is possible 
but very uncommon to accommodate 4 or 5 L vessels (111). On the other hand, small dosage 
formulations can be tested in non – compendial 100 – 250 mL vessels (112-114). The vessel 
is filled with a fixed volume of media to which formulation is exposed throughout the 
experiment. There are several disadvantages of this system. The media change procedure 
within a single run that cannot be easily performed, and it is difficult to mimic the change in 
luminal conditions during transit from stomach to the intestine (115).  
 
Figure 14. Diagram of rotating basket apparatus (USP apparatus 1). 
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2.4.1.2 Hydrodynamics 
In vivo hydrodynamics is often reflected using a non-dimensional parameter, Reynolds 
number (Re), which provides an estimate of the ratio of flow acceleration to frictional force in 
the flow around a dosage form (116, 117). Abrahamsson et al. have reported that 
hydrodynamics in the gastrointestinal (GI) tract varies from Re 0.1 to 30, whereas Re values 
in  USP apparatus 2 are around 2000 (118-120). Reynolds number for USP apparatus 1 has 
not been reported, but we can assume that it is greater than those reported for USP apparatus 2 
However, D’Arcy et al. compared the hydrodynamics of both of these systems in terms of 
fluid velocities (121). According to this study, a similar magnitude of velocities was observed 
inside the basket as at the base of the vessel of the paddle apparatus at the same rotation 
speed, although slightly lower. It is important to note that this research did not consider the 
mesh size of the basket and presence of the spring clips which hold the basket. This has been 
reported elsewhere (122).  
  
Agitation speed is an important factor when developing a dissolution test. Paddle agitation 
speed can change the hydrodynamics of the dissolution medium significantly. Too fast speed 
may not be able to discriminate between the batches, while too slow may not disperse the 
solute well (123). For instance, prednisone tablets are fast disintegrating. If the agitation is 
below 100 rpm, the tablet sinks to the bottom of the vessel and disintegrates within less than 
five minutes (124). Insufficient speed leads to coning of the formulation in the central area of 
the vessel. This traps the drug in the cone and releases it slowly by diffusion. Sometimes 
increasing the speed can solve this problem. There are also special peak vessels available 
which unable cone formation. 
2.4.2 USP apparatus 4  
2.4.2.1 Operation mode 
The flow-through cell apparatus consists of a pump that forces the medium through the cell 




Figure 15. Diagram of the USP apparatus 4. 
The dissolution part of USP apparatus 4 consists of seven cells that are assembled in a row as 
one compartment (Sontax® model) or individually (Erweka® model). Two types of cells are 
available for orally administered dosage forms: a large cell (22.6 mm i.d.) and a small cell 
(11.3 mm i.d.). The flow-through cell has three parts: the lower cone, the middle cylindrical 
portion and the filter head on the top. Dissolution medium enters the cone on the bottom and 
flows up to the cell. The lower cone houses a 5 mm glass bead which protects the inlet tube 
and prevents backflow (125). Positioning of the dosage form in the middle cylinder is a key 
factor that affects its dissolution (126). Various types of cells are available that are suitable for 
a range of formulations such as powders, tablets, suppositories, ointments etc. Often 1 mm 
glass beads are used. Before reaching the cells, medium is pumped through heat exchangers 
which are placed in an electronically regulated thermostatted bath, assuring a test temperature 
of 37 °C. Additionally, the water from the water bath is raised up and surrounds the cell 
positioned in the jacket tube allowing maintained constant temperature. After passing through 
the cell, the eluents are filtered within the filter heads and then either collected or transferred 
directly to the spectrophotometer for analysis. The filter head is generally equipped with a 
glass microfiber filter. Depending on the sample, filters of different pore sizes can be used. A 
combination of two filters with glass wool may be used separated in order to improve 
filtration quality (127). Piston pump is generally used to pump the medium. Different flow 
rates can be applied, varying from 2-50 mL/min with typical flow rates of 4, 8 and 16 
mL/min. Flow rates between 4 and 8ml/min have been proposed for tests that simulate fasted 
and fed state conditions (128-130). Duration of the dissolution test and flow rates used are 
designed to balance between GI fluid volumes and the physiological residence times in the GI 
lumen, and to compensate not only for radial loss (absorption) of the drug but also for the 
water re-absorption (131). USP apparatus 4 can work in two configurations either as an open 
or closed system. The former allows always fresh media to be pumped from a reservoir 




The flow-through cell dissolution apparatus was designed and developed in 1957 (132) but it 
was not included into USP as an official dissolution method until 1990 (119, 128). Flow-
through cell dissolution methods for three formulations were included in the FDA database 
(133). All the formulations are injectable suspensions of Methylprednisolone acetate, 
Betamethasone acetate and Betamethasone sodium phosphate. Recently, official monograph 
for 200 mg and 400 mg Rufinamide tablets was included in US Pharmacopoeia (134). It is 
designated for the testing of poorly soluble drug products, granules, powders and some 
special dosage units such as suspension, implants, injectable formulations and suppositories 
(135). It has been also reported that USP apparatus 4 has been successfully used for 
evaluating the disintegration of cross-linked gelatin capsules of Amoxicillin (136). Moreover, 
Zolnik et al. effectively used the USP apparatus 4 to monitor the release of Dexamethasone 
from microspheres over a 30 day period (137). The design of flow-through cell dissolution 
apparatus is more physiologically relevant than design of basket and paddle dissolution 
apparatus. Often biorelevant dissolution leads to the successful development of an IVIVC. For 
instance, Emara et al. have developed successful IVIVC for two Vincamine Prolonged 
Release (PR) formulations using dissolution data obtained using open USP apparatus 4 (138). 
Formulations were exposed to four different compendial media for certain duration of time:  
pH of 1.2 (1 h)/ pH 4.5 (1 h)/ pH 6.8 (2 h) and pH 7.5 (1 h). A flow rate of 8 mL/min was 
maintained throughout the run. In vitro dissolution data were then directly correlated with in 
vivo absorption data obtained from 16 healthy human volunteers.  
2.4.2.3 Advantages 
In contrast to USP apparatus 1 closed dissolution system, USP apparatus 4 allows media/or 
flow rate changes as well as maintenance of sink conditions (126, 127, 131). The former is 
particularly important, for example, for enteric coated dosage forms, as well for some pH-
dependent solubility formulations that have a tendency to precipitate. Maintenance of sink 
conditions is particularly important when poorly soluble drugs are tested (119). Flow-through 
cell apparatus is able to work with unlimited amounts of solvent (open system) which helps to 
overcome this problem. On the other hand, closed system can be very beneficial when testing 
formulations with low drug loading that may have sensitivity issues in USP apparatus 1.  
USP apparatus 4 allows testing of suppositories (139), powders and implants and lipid soft 
gelatin capsules (SGC) (140) in specially designed cells, which would be challenging or 
 24
impossible using dissolution USP apparatus 2. For instance, Hu et al. investigated the release 
of a free base of a secondary amine from lipid SGC using USP apparatus 2 and USP 4 
systems (140). Due to filtration and sampling issues of oil droplets, it was impossible to use 
USP apparatus 2; and USP apparatus 4 equipped with a standard cell. The improved results 
were obtained when specialised SGC flow-through cells (known also as suppositories cells) 
were used.  
2.4.2.4 Disadvantages 
One major disadvantage of the USP apparatus 4 is filter blockage/clogging that has been 
reported, especially when testing powders or large formulations (127, 130). Due to the fact 
that the standard cell is made of high-grade acrylic glass, testing formulations in hydro-
ethanolic media is not possible (Personal communication with Erweka Ltd; 06-05-2013). 
2.4.2.5 Hydrodynamics  
So far, USP apparatus 4 provides the most physiological hydrodynamic conditions (Re < 30) 
(120). Linear flow velocity of the dissolution medium is the major parameter which 
characterizes the hydrodynamic agitation of the dissolution medium (130). It has been 
reported that the average axial velocity is about 1.5 cm/min under fasted state and 1.3 cm/min 
under fed state conditions (130). These values correspond to flow rates below 2 mL/ min in 
small cells (11.3 mm) and below 8 mL/min in a large cell (22.6 mm) of USP apparatus 4 
(130) (Table 3). Generally, higher than in vivo flow rates are used to compensate for the 
resulting high total fluid volume (130) 
Table 3. Correlation between the linear flow velocity and volumetric flow provided in USP apparatus 4 cells 
(130) 
Cell diameter (mm) 11.3 22.6 Volumetric flow 
(mL/min) Area (cm) 1 4 
Linear flow velocity 
(cm/min) 
2 0.5 2 
4 1 4 
8 2 8 
16 4 16 
32 8 32 
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Interestingly, faster flow rates do not affect the release of drug from the matrix tablets (141). 
This is due to the fact that release from this dosage form depends not only on the transport 
through the diffusion layer but also on the drug release mechanism.  
The hydrodynamics in the cell can be controlled by the presence or absence of glass beads. 
There are two types: laminar, when glass beads are placed in the cone part of the cell and 
turbulent in the case when the cell is set up without small glass beads. Generally, tablets and 
hard gelatin capsules, powder and granulates are tested under laminar flow; whereas turbulent 
flow offers benefits for testing suppositories and SGC (142). Recently, Kakhi argued that 
fully laminar conditions are unlikely achievable and as a consequence suggested replacing 
existing terminology of laminar and turbulent flow with packed and open columns, 
respectively (Figure 16) (143). 
 
Figure 16. Schematic of (a) packed and (b) open column (143). 
It was reported by Zhang et al. that the release rate from erodible tablets was not influenced 
by different flow rates ranged between 7 to 21 mL/min (144). Whereas, discriminative 
dissolution profiles were observed when turbulent flow pattern was applied (126). Shiko et al. 
argues that the local values of Re (Reynolds number) did not exceed 200, thus the turbulent 
flow term should not be used even in the more aggressive conditions in the USP apparatus 4 
(145). It was also suggested by this group that 1mm glass beads should be used to provide less 
chaotic and asymmetric flow in the cell. 
Swedish scientists from five different pharmaceutical laboratories made an attempt to 
compare results generated for dissolution of USP Prednisone calibrator tablets using flow-
through cell apparatus and USP 2 paddle apparatus (146). They have reported that similar 
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dissolution profiles were observed when tablets were tested in 12 mm cells at the flow rate of 
9 mL/min; and in 22.6 mm cells at a flow rate of 32 mL/min. This is due to the similarities of 
the linear flow rate of the medium in these two cells at these flow rates. A correlation was 
found that the dissolution profile obtained using flow-through 12 mm cell at 16 mL/min falls 
within the range between the dissolution profiles obtained using USP apparatus 2 at 50 and 
100 rpm. On the other hand, they found that the USP 2 dissolution method provided more 
consistent data for Prednisone tablets between the laboratories than the USP 4 dissolution 
method. For instance, variability in dissolution of Prednisone tablets (n = 30) using a 12 mm 
cell at 16 mL/min was reported to be 17 % after 30 min testing. For the USP 2 dissolution 
method, the corresponding values were 6 % and 11 % at 50 and 100 rpm, respectively (146). 
However, it has been reported that the hydrodynamics in 12 mm cells is more variable than in 
22.6 mm cells. Therefore, the variability in dissolution rate could be related to the type of cell 
selected. It is important to note that Prednisone tablets are official calibrator formulations for 
USP apparatus 2 only and that there are no official calibrator formulations for USP apparatus 
4 (127). Eaton et al. reported Salicylic acid tablets to be suitable for Performance Verification 
Test (PVT) of USP apparatus 4 (147). 
2.5 The dissolution medium 
Many studies have been conducted to understand the in vivo drug release, in order to develop 
more physiologically relevant media that can predict in vivo dissolution (148-150). Various 
media have been proposed for simulating gastric and intestinal contents. Some media are 
simple and simulate mainly pH and ionic content of the GI tract (compendial media) while 
others are more complex in composition and are designed to mimic osmolality, buffer 
capacity and surface tension (biorelevant media) of individual GI segments.  
2.5.1 Compendial media 
There are three most commonly used compendial media that simulate gastric, intestinal and 
colonic environments (Table 4). Compendial media mainly simulate the pH and ionic 
environment of gastric and intestinal environments but do not simulate the in vivo 
performance accurately. Simple Simulated Gastric Fluid (SGF) consists of an aqueous 
hydrochloric acid solution with a pH of 1.2. There are two versions of these media proposed 
in United States Pharmacopeia: one contains pepsin (3.2 mg/mL) that characterizes conditions 
in the stomach and one without it (108). Small intestinal conditions are represented by 
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Simulated Intestinal Fluid (SIF) which is composed of phosphate ions providing a pH of 6.8. 
This medium can also be present with or without pancreatin (108). It has been reported that 
addition of pepsin and pancreatin improves dissolution of hard gelatin capsules that exhibit 
cross – linking (151). 
Table 4. Composition of compendial media. 
 SGF (108) SIF (108) 
Sodium chloride (mM) 34.2 - 




Sodium hydroxide (mM) - 15.4 
pH 1.2 6.8 
 
2.5.2 Biorelevant media  
2.5.2.1 Stomach 
Over the last decade, biorelevant dissolution media (BDM) have been proposed in order to 
simulate fasted and fed physiological conditions of the GI tract. Biorelevant media that 
simulate fasted conditions were subject of this review. The Fasted State Simulated Gastric 
Fluid (FaSSGF) (Table 5) was developed by Vertzoni et al. to reflect the actual gastric 
composition in the fasting state according to published physiological data (152). This medium 
contains physiologically relevant amounts of pepsin and bile salts generating a surface tension 
close to that found in vivo. 
Table 5. Composition of the Fasted State Simulated Gastric Fluids (152). 
Fasted State Simulated Gastric Fluids (152) 
Sodium taurocholate (µM) 80 
Lecithin (µM) 20 
Pepsin (mg/ mL) 0.1 
Sodium chloride (mM) 32.4 
Hydrochloric acid qs  pH 1.6 
pH 1.6 
Osmolality (mOsmoL/kg) 120.7±2.5 
Surface tension (mN/m) 42.6 
 
 28
2.5.2.2 Small intestine 
In 1998, Dressman and co-workers developed Fasted State Simulated Intestinal Fluid 
(FaSSIF) to simulate fasting conditions in the small intestine (153). This medium has shown 
to provide a more accurate simulation of pharmacokinetic profiles than SIF (154, 155). The 
differences in the composition were due to the presence of mixed micelles formed by addition 
of bile salts (sodium taurocholate) and lecithin and the changes in surface tension, pH and 
osmolality values. These changes helped to simulate better physiological environment in the 
GI tract (Table 6). The FaSSIF – V2 media prior to addition of bile salts and lecithin is 
referred to as blank FaSSIF –V2. 
 
Table 6. Composition of medium simulating fasted conditions of small intestine (153). 
FaSSIF 
Sodium taurocholate (mM) 3 
Lecithin (mM) 0.75 
Dibasic sodium phosphate (mM) 28.65 
Sodium hydroxide (mM) 8.7 
Sodium chloride (mM) 105.85 
pH 6.5 
Osmolality (mOsmoL/kg) 270 ± 10 
Buffer capacity (mmoL/L/pH) 12 
 
As further data on characterisation of in vivo gastrointestinal contents were published, the 
composition of FaSSIF was revised and updated (Table 7). Jantratid et al., have modified the 
composition of FaSSIF by reducing the amounts of lecithin from 0.75 mM in FaSSIF to 0.2 
mM in FaSSIF-V2 (156).  The ratio of mixed micelles formed of sodium taurocholate to 
lecithin was changed in these media from 4:1 to 15:1, respectively. Moreover, maleate buffer 
was used instead of phosphate buffer. These changes resulted in a decrease in osmolality 
values of FaSSIF-V2. It is worth noting that the surface tension of both FaSSIF and FaSSIF-






Table 7. Composition of the medium to simulate the contents of the small intestine in the fasted state (157). 
 FaSSIF-V2 (157) 
Sodium taurocholate (mM) 3 
Lecithin (mM) 0.2 
Glyceryl monooleate (mM) - 
Maleic acid (mM) 19.12 
Sodium hydroxide (mM) 34.8 
Sodium chloride (mM) 68.62 
pH 6.5 
Osmolality (mOsmoL/kg) 180±10 
Buffer capacity (mmoL/L/ΔpH) 10 
Surface tension (mN/m) 54 
2.5.2.3 Large intestine 
Fotaki et al. proposed Simulated Colonic Fluids (SCoF) that mimics the pH and buffer 
capacity of the colonic environment (158). In 2010, Vertzoni et al. proposed the composition 
of Fasted State Simulated Colonic Fluid (FaSSCoF) that were designed to reflect fluids 
collected from the ascending colon in healthy adults (Table 8) (159). It has been reported that 
FaSSCoF more closely predict solubility of poorly soluble compounds in human colonic 
fluids (HCF) than plain buffers (159). However, none of the media contain colonic bacteria as 
it is challenging to simulate anaerobic environment (149).  
Table 8. Composition of media simulating conditions in colon. 
 SCoF (158) FaSSCoF (159) 
TRIS (g) - 5.5 
Maleic acid (g) - 8.8 
0.5N Sodium hydroxide (176) - 240 
Sodium hydroxide (mM) 157 - 
Ox bile salt extract (g)                 - 0.113 
Phosphatidylcholine (g) - 0.222 
Palmitic acid (g) - 0.026 
Dichloromethane (177) - 6 
Bovine serum albumin (g)          - 3 
Acetic acid (mM) 170 - 
pH 5.8 7.8 
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2.6 Comparison of dissolution profiles 
Characterization of dissolution profile is recommended in cases described in Table 9. 
Numerous mathematical approaches for the comparison of dissolution profiles have been 
described in the literature (160-169).  
Table 9. Areas where characterization of dissolution profiles is recommended (165). 
Recommended case 
Establishing the Quality of ER drug products 
Defining dissolution specifications for generic formulations 
Waiving bioequivalence requirements for lower strengths of an IR formulation  
Point-to-point in vitro-in vivo correlations 
Predicting the entire in vivo plasma profile based on dissolution data 
Establishing IR and MR products sameness after level 2 and 3 post approval changes 
 
2.6.1 Model-independent methods 
There are two commonly used indices: the difference factor (f1), the similarity factor (f2) 
(160). The difference factor f1 is the sum of the absolute values of the vertical distance 
between the test and the reference mean values at each dissolution time point and is defined 

























1 100                                              (Equation 7) 
Where Ri and Ti are the percentage dissolved of the reference and test profiles at the i time 
point, respectively. When f1 is equal to zero this indicates that two profiles are identical. 
Additionally, f 1 can be modified in order to quantify areas between two profiles and then is 












                                            
(Equation 8)
                       
Where τ represents time intervals between sampling time points. 
 31
The similarity factor f2 measures the similarity in the percentage dissolution between two 


















11/1100log50                     (Equation 9) 
Where n is the number of the time points considered in comparison. The similarity factor fits 
the result between 0 and 100 with 100 to indicate that the two profiles are identical. The FDA 
suggests that the two dissolution profiles are similar when f2 is between 50 and 100 (160-162, 
164-167). 
When data have low variability (%CV < 15), mean profiles can be used. Coefficient of 
variation (CV) should not then exceed more than 20% at early time points and no more than 
10% at other time points (101). Number of replicates plays an important role in the selection 
of an appropriate index. For instance, all three indices can be used for data sets with only 
three replicates; however, confidence intervals must be determined (167). At least four 
equally spaced data points should be used for both indices, and only one after 85% dissolution 
of the test of reference (whichever occurs first) should be used (170). The main advantages of 
these indices are that they are easy to compute and result in a single number that describe the 
comparison of two dissolution profiles (169). However, several disadvantages have been 
identified such as shape of the curve, unequal spacing between the sampling points.  
2.6.2 Dissolution kinetics 
Over the last two decades different models have been proposed to aid characterization of 
dissolution profiles. These models are able to characterize parameters that for instance can 
define shape, plateau and kinetics of dissolution (166). Zero-order, first-order and 3-parameter 
Weibull function will be described in the following section. 
2.6.2.1 Zero-order kinetics 
Zero-order kinetics is often used to describe dissolution of modified release dosage forms 
such as matrix tablets or osmotic systems that do not disintegrate and release the drug slowly 
(166). 
tkWt 0                                                     (Equation 10) 
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Where Wt is the amount of drug dissolved in time t and k0 is the zero – order 
release/dissolution constant. The formulations that follow zero-order kinetics release constant 
amount of drug per unit of time. The plot of % cumulative of drug dissolved versus time 
results in a straight line. This is an ideal method of drug release in order to achieve a 
pharmacological prolonged action (171).  
2.6.2.2 First-order kinetics 




                                          (Equation 11) 
Where Wmax is maximal amount of drug dissolved and k1 is the first-order release/dissolution 
constant. 
2.6.2.3 Weibull distribution function 
The Weibull function is very useful models for describing drug dissolution data (169). It can 
be successfully applied to most of dissolution curves. It combines the advantages of both first-
order and log-normal presentation (172). The Weibull function can be written in several ways. 









t eWW                                   (Equation 12) 
where Wmax is the maximal percentage of the drug dissolved, α is the time scale parameter, 
which provides information about the rate of the process (173). Scale parameter (α) represents 
the time interval necessary to dissolve or release 63.2% of the drug. β is the shape parameter 
(when β = 1 the curve is exponential; β > 1 the curve is S-shaped with upward curvature 
followed by a turning point; β < 1 parabolic with a higher initial slope. Applying the Weibull 
equation to highly variable data or to not well characterized dissolution curves (limited 
number of dissolution points) can lead to over-parameterization of Weibull model (173).  
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3 Oral drug absorption and in vitro – in vivo correlations (IVIVC) 
3.1 Factors affecting oral absorption 
Gastrointestinal absorption of drugs is a complex process and is affected by many factors that 
fall into three categories (174). The first category represents physicochemical parameters of 
the drug such as pKa, solubility, stability, diffusivity and lipophilicity. The second category 
consists of physiological factors of the GI tract such as gastrointestinal pH, gastric emptying, 
active transport and efflux, small and large intestinal transit time as well as gut metabolism. 
The last category comprises of formulation related factors such as drug particle size, crystal 
form, surface area and type of dosage form (tablet, capsule, solution, suspension etc.) (175). 
This review will focus on a description of the absorption limiting factors after oral 
administration. 
3.1.1 Physicochemical parameters 
Solubility and intestinal permeability are important physicochemical parameters that affect 
the rate and extent of absorption of an oral drug product. Moreover, these two factors also 
closely interrelate with many other influential factors, such as lipophilicity, hydrophilicity and 
molecular size (175).  
3.1.1.1 Solubility  
The pH-dependent solubility and stability of a drug plays an important role in its absorption. 
In order to permeate across the biological membrane, drug must be in a solubilised, stable and 
unionised form (175). Differences in regional pH can affect solubilisation or provide an 
environment for degradation of the drug (176). This is why understanding the ionization 
properties of a drug candidate are essential for the absorption potential. Most of drugs are 
weakly acidic or weakly basic compounds that cannot be ionized completely in aqueous 
media. Dissolution of ionised drugs is greatly dependent on the pH of the medium. The 
Henderson – Hasselback equation describes the relationship between pH and drug ionization 
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(Equation 16)                      
According to Equation 13, weak acids solubilise in basic pH, when the drug exists in an 
ionized form, and hardly solubilise in an acidic environment while remaining in the un-
ionized form (178). On the other hand, weakly basic compounds exist in their ionised form in 
lower pH, where they solubilise better and tend to have a minimal dissolution in higher pH 
(Equation 15). In the case of poorly soluble weak acids such as Indomethacin, dissolution in 
the stomach will be negligible. However, the small intestine with its high pH offers a better 
environment to Indomethacin, resulting in greater dissolution. Thus, for weak acids, the 
longer exposure to acidic environment is disadvantageous, thus gastric emptying is the 
absorption rate – limiting step.  On the other hand, poorly soluble weak bases dissolve more 
readily in the stomach than in the intestine. This can result in supersaturation as the drug 
moves from acidic to basic conditions. Upon the movement to basic pH, the degree of 
ionisation and equilibrium solubility are reduced causing supersaturation of the drug (179). 
3.1.1.2 Permeability 
Permeability of the drug through an intestinal membrane is an important factor in achieving 
desirable bioavailability of a drug after oral administration. There are two types of transport 
across the intestinal membrane. The first, describes the passive diffusion across lipid 
membrane often referred to as transcellular absorption (180). The second is known as 
paracellular absorption and is described as diffusion through the aqueous pores at the tight 
junctions between the cells (181). The ability of drug to diffuse across the lipid core of the 
membrane depends on the physicochemical properties of the compound such as lipophilicity. 
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Lipophilic compounds permeate through the intestinal membrane more readily than poorly 
lipophilic compounds. This explains why transcellular transport is the predominant pathway 
for more lipophilic drugs (182). On the other hand, paracellular transport is favoured by 
hydrophilic compounds. 
3.1.2 Physiological parameters 
The absorption process depends on a large number of factors that are related to the physiology 
of the GI tract, such as composition of the GI fluids, gastric emptying, transit time across 
intestinal segments, and passage of the drug across the membrane etc (183).  
3.1.2.1 Composition of the GI fluids 
3.1.2.1.1 Stomach 
Gastrointestinal fluid is a complex mixture of various components that originate from various 
sources within the GI tract. Stomach content is composed of saliva, gastric secretions, dietary 
food and liquid, and refluxed fluids from the duodenum (184). Major components of the 
gastric fluids include hydrogen ion concentration, which are responsible for the acidic 
environment; pepsin, an enzyme that aids digestion; lipase, which aids the release from lipid-
based dosage forms (185-187); and bile salts that decrease the surface tension of the fluids, 
which enhances solubility (Table 10). Also, bile salts combined with lipids form micelles, 
improving the solubility of poorly soluble drugs (188). Quantification of these components in 
vivo is very challenging due to inter-individual variability. For instance, Kalantzi et al. 
reported stomach pepsin levels during the fasted state in a range from 0.11 to 0.22 mg/mL,  
whereas other researchers have found them to vary between 0.1 to 1.3 mg/mL (186,187, 189). 
This may be due to the type of analytical method used. Some of the reported research was 
carried out over four decades ago, when the sample collection, treatment and quantification 







Table 10. Concentrations of components present in stomach during fasted and fed states. 
Components State Reported range 
Pepsin Fasted state 0.11 – 0.22 mg/mL (189) 
0.1 – 1.3 mg/mL (186,187) 
Fed state 0.26 – 1.72 mg/mL (187) 
Hydrogen ions Fasted state 0.01 – 0.1 M (pH 1 – 2) (184) 
Fed state 0.0000001 M – 0.001 M (pH 3 – 7) (184) 
Lipase Fasted state 0.1 mg/mL (152) 
Fed state 11.4 – 43.9 U/mL (188) 
Bile salts Fasted state 0.08 – 0.275 mM (152, 189) 
Fed state 0.06 mM (190) 
Bicarbonate Fasted state 7 – 20 mequiv/L (191, 192) 
 
3.1.2.1.2 Small intestine 
The upper small intestine fluids are composed of the chyme from the stomach as well as 
secretions from different parts of body including the liver (bile salts, phospholipids, 
bicarbonate, and cholesterol), the pancreas (bicarbonates, proteases) and the wall of the small 
intestine (bicarbonates, sodium, chlorides, water). Its composition is affected by fluid 
segmentation, absorption of fluid into the wall and transit down the intestinal tract (Table 11). 
The wide range of the data reported in Table 11, could be attributed to the use of different 
sampling and analysis techniques as well as various equipment used. Some of the data were 
reported as far back as 1973. 
Table 11. Concentrations of components present in the small intestine during fasted and fed states. 
Components State Reported range 
Lipolytic products 
(i.e. monoglycerides) 
Fasted state 0 – 1.8 mg/mL (193) 
Fed state 0.5 – 100 mg/mL (188, 193)  
Phospholipids Fasted state 0.03 – 0.6 mM (193, 194) 
Fed state 0.8 – 2.4 mM (123) 
Bile salts (ileum) Fasted state 2 – 10 mM (195) 
Fed state 0.2 – 30 mM (196) 
Bicarbonates Fasted state in the duodenum and jejunum 2 – 30 mM (197, 198) 
in  the ileum 30 – 75 mM (198, 199) 
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 3.1.2.1.3 Large intestine 
The large intestine is about 152 cm in length and average 6.3 cm in diameter. It is divided into 
four principal regions: caecum, colon, rectum and anal canal. The absorption of water is an 
important function of the large intestine. In addition, absorption of vitamin K, biotin and 
vitamin B5 occurs in the colon (200). Despite the fact that transit through the lower part of the 
GI tract is claimed to last for 24 hours, the colonic environment only the ascending part of 
colon has fluid to facilitate dissolution (200). Composition of colonic fluids is affected by 
feeding (Table 12).  
Table 12. Concentrations of components present in the colon during fasted and fed states. 
Parameters State Reported range (149) 
Proteins Fasted state 9.7  ± 4.6 mg/mL 
Carbohydrates  Fasted state 8.1 ± 8.6 mg/mL 
Fed state 14.0 ± 7.4 mg/mL
Acetate levels Fasted state 20.8 ± 11.6 mM 
Fed state 35.9 ± 14.0 mM  
Short chain fatty acids Fasted state 30.9 ± 15.4 mM  
Fed state 48.1 ± 21.7 mM  
Bile acids Fasted state 115.2 ± 119.3 µM  
Fed state 587.4 ± 412.8 µM  
Palmitic acid Fasted state 49.6 ± 43.7 µM  
Fed state 103.8 ± 112.1 µM  
Linoleic acid  Fasted state 37.4 ± 29.6 µM  
Fed state 47.8 ± 30.0 µM  
Oleic acid Fasted state 32.8 ± 36.7 µM  
Fed state  73.4 ± 81.7 µM 
Phosphatidylcholine Fasted state 362 ± 210 µM  
Fed state 539 ± 393 µM 
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3.1.2.2 Characteristics of GI fluids 
Parameters such as the pH, buffer capacity, osmolality, surface tension, volume and 
temperature of the gastrointestinal fluids affect the in vivo performance of the pharmaceutical 
oral dosage forms (Table 13). For instance, different levels of buffer capacity can affect the 
dissolution rate of ionisable drugs (201). The general trend is that the higher the buffer 
capacity, the more the buffer will influence pH changes at the drug – fluid interface (184, 
202). The pH of the fluid, the pKa of the individual components of the buffer and its 
concentration affect buffer capacity the most. Osmolality proved to affect drug release and 
excipients performance (156). For instance, common ion effect can result in slower 
dissolution (156, 203). Surface tension may affect dissolution by influencing wetting 
properties of the formulation (185), with a lower surface tension leading to enhanced wetting. 
Bile salts such as sodium taurocholate and phospholipids that are present in GI fluids affect 
the contact angle of the drug and lower the surface tension. The volume of the fluids in the 
gastrointestinal tract affects the concentration of solubilised drug which often may limit the 
absorption. The temperature is probably the most stable of all parameters in human body. The 
only time when the temperature can fluctuate is generally during exercise (204). Temperature 
can also affect the diffusion coefficient of the drug and the solubility of the API and the 
formulation.  
Table 13. Parameters affecting in vivo performance of dosage forms. 
Parameters State Reported range  
pH Fasted state  Stomach 1 – 8 (205, 206) 
                 1.2 – 3.5 (183) 
              1.5 – 3 (207) 
            
Duodenum 6.1 – 7.0 (193) 
Jejunum 4.4 – 8.1 (208, 209) 
Ileum 6.5 – 8 (210, 211) 
Colon 7.8 (149) 
Fed state  Stomach 6 -7 (208) 
                 2 – 5  (207) 
                 2.7 - 6.4 (148, 208) 
Duodenum 3.1 – 6.7 (208) 
Jejunum 5.2 – 6.0 (212)  
Ileum 6.8 – 8.0 (213) 
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Colon 6.0 (149) 
Osmolality Fasted state Stomach 29 – 276 mOsm/kg (214, 215) 
Upper small intestine 124 – 278 mOsm/kg (204, 216) 
Colon 81 mOsm/kg (217) 
Fed state  Stomach 559 mOsm/kg 30 min after meal (148) 
                217 mOsm/kg 210 min after meal  (148) 
Small intestine 250 – 367 mOsm/kg (204) 
Colon 99 – 349  mOsm/kg (149) 
Surface tension Fasted state  Stomach 41 – 46 mN/m (148) 
Upper small intestine 28 – 46 mN/m (193, 218) 
Colon 42.7 mN/m (217) 
Fed state Stomach 30 – 31 mN/m (148) 
Upper small intestine 27 – 37 mN/m (193, 218) 
 
3.1.3 Gastric motility 
3.1.3.1 Migrating motor complex (MMC) 
The MMC occurs during fasting state and it is divided into different phases: basal (Phase I), 
pre-burst (Phase II), burst (Phase III) and transition (Phase IV) intervals (183). Phase I is 
characterized by a lack of secretory, electrical and contractile activity which lasts from 30 to 
60 minutes. In Phase II contractile motions increase in frequency and exhibits intermittent 
action for 20 to 40 minutes. During this phase bile enters duodenum and mucus is discharged. 
Phase III continues mucus discharge and is characterised by intense, regular contractions 
known as housekeeper waves, which sweep off undigested food and last 10 to 20 minutes. 
Finally, Phase IV is the transition period between Phase I and Phase III and lasts up to five 
minutes (183).  
3.1.3.2 Gastric emptying time 
Gastric emptying (GE) is influenced by various physiological and pathological factors, drug 
delivery system properties, and most of all, by food intake (183). Emptying of the stomach 
under fasting and fed conditions is subject to MMC, during which the short lasting intense 
contractions (Phase III) cause the emptying of the stomach content (184). Gastric emptying is 
a highly variable parameter that is not only varied between the subjects (inter – variability) 
but also within the same subject (intra – variability) on different days (219). It was found that 
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formulation characteristic can significantly affect GE time. In the case of the non-
disintegrating tablets, different tablet size affects gastric emptying time (220, 221). For 
instance, Khosla and Davis observed that the shortest gastric emptying time for 7 mm tablets 
(116 ± 19 min), followed by 11 mm tablets (128 ± 17 min) and 13 mm tablets (171 ± 13 min) 
(221). On the other hand, the same studies performed using floating systems indicated no 
statistically significant difference in GE time among different dosage form sizes (221).  
3.1.3.3 Transit time 
Yu et al. have examined small intestine transit times of over 400 volunteers and reported the 
mean transit time of 3.3 hours (174). They also determined that the seven compartment transit 
model best described the small intestine passage (Figure 17). The first half of the first 
compartment represents the duodenum, the second half of this compartment together with the 
second and third compartment represent the jejunum, and the rest of the compartments 
represent the ileum. The corresponding transit times in the duodenum, jejunum, and ileum are 
14, 71 and 114 min, respectively (174). To complete the model, two additional compartments 
are taken into account to represent the stomach and colon, making a total of nine 
compartments. 
 





3.1.4 Formulation parameters 
Physicochemical, physiological and formulation parameters strongly influence each other. For 
instance, different dosage forms are characterised by different transit times across the 
segments of the GI tract (Table 14) (183). 
Table 14. . Small intestine transit time reported for different dosage forms in fasted state (184) 
Formulation  Time (min) 




Generally, absorption from oral solution is a rapid and complete process when compared with 
other orally administered dosage forms. Poorly soluble drug can be formulated as a 
suspension in order to improve bioavailability. Capsules and tablets can provide similar 
dissolution performance; however its behaviour strongly depend on many variables such 
compression forces, excipients choice, surface area, particle sizes etc. Various excipients can 
be used to in order to produce desired dissolution profiles. For instance, disintegrants such as 
lactose helps to break the tablet apart. Wetting agents such as SLS can be added to the 
formulation to aid the penetration of water into the tablets. Immediate – release formulations 
are designed to be absorbed quickly, whereas prolonged – release formulations are intended to 
release larger dose (than IR) for a much longer time. Despite that larger dose is introduced at 











Development of a pharmaceutical dosage form requires a good understanding of the in vitro 
and in vivo performance of the formulation. Correlating in vitro drug data with in vivo drug 
performance still remains a challenge. The following sections will focus on development of 
IVIVC and its applications.  
3.2.1 Definitions 
The USP and the FDA proposed definitions of IVIVC: 
3.2.1.1 USP definition 
The establishment of a rational relationship between a biological property, or a parameter 
derived from a biological property produced by a dosage form, and a physicochemical 
property or characteristic of the same dosage form (222). 
3.2.1.2 FDA definition 
IVIVC is a predictive mathematical model describing the relationship between an in vitro 
property of a dosage form and a relevant in vivo response. Generally, the in vivo property is 
the rate or extent of drug dissolution or release while the in vivo response is the plasma drug 
concentration or amount of drug absorbed (223). 
3.2.2 Levels of IVIVC 
FDA has defined four correlation levels (A, B, C and Multiple C) which reflect the type of the 
correlation. Each level correlates to different types of parameters. For the purpose of this 
thesis Level A correlation will be described in details. 
Level A correlation 
This level represents a point-to-point relationship between in vitro dissolution and the in vivo 
input rate of the drug from the dosage form (223). Generally, percent of the drug absorbed (or 
cumulative amount absorbed) may be calculated using model-dependent techniques such as 
Wagner-Nelson method for one-compartmental model drugs (224) or Loo-Riegelman method 
for two-compartmental model drugs (225) or by model-independent numerical deconvolution 
(226). Good understanding of the drug’s pharmacokinetics is essential for appropriate use of 
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deconvolution techniques. Level A correlation describes a direct relationship between in vivo 
data such that the measurement of in vitro dissolution rate alone is sufficient to determine in 
vivo performance of this dosage form (227). Visualization of the dissolution and absorption 
profiles together, which assesses the degree of superimposition, is an important part in 
development of Level A correlation (228). Failure to superimpose them may not warranty the 
successful correlation; however, further attempts can be made by developing a dissolution 
method, which will mimic the in vivo performance closely. Sometimes the profiles are 
superimposed but a lag time can be observed. In this case, more quantitative correlations such 
as linear regression need to be explored (229, 230). The aim of an IVIVC should be 
establishing a relationship between in vivo behavior of a formulation and in vitro performance 
of the same formulation, which would allow in vitro data to be used as a surrogate for in vivo 
performance (227, 231). Level A is the most useful and informative from the regulatory point 
of view. It can be used to predict entire in vivo performance from the in vitro data. Once 
IVIVC is successfully developed, the validation of the model is required. According to FDA 
guidelines, two types of validation approaches are available: internal and external (223). The 
former, is accomplished by measuring predictability error (%PE) of data that has been 
employed for development of this certain IVIVC model. The latter uses different sets of data 
to test how well the developed IVIVC is able to predict additional data sets based on %PE 
calculation (Equation 17) (223, 232). Internal predictability should be applied where IVIVC 
was developed using two or three formulations with different release rates (223). External 
predictability should be adopted when two formulations with different release rates were used 
for IVIVC development (227). External validation is recognized as a better tool than internal 
validation.  % PE below 10 % indicates good predictability of Cmax and AUC values (230). 
    % PE = [(Observed value – Predicted value)/Observed value] x 100   (Equation 17) 
It is worth noting that Level A IVIVC can also be obtained through convolution techniques, in 
which the in vitro dissolution profile is used to generate the corresponding plasma 






IVIVC can be used for several purposes. During the formulation development process, 
alterations are introduced that involve i.e. composition, manufacture or equipment changes. 
Generally, these types of changes require additional clinical trials to prove bioequivalence of 
new product with the original formulation. However, in this case, if IVIVC is successfully 
developed it can be used to replace human studies. IVIVC serves as surrogate for in vivo 
bioavailability and to grant a biowaiver. It also aids to set dissolution specifications. IVIVC is 
an excellent tool in quality control (QC) to monitor certain scale-up and post-approval 
changes (SUPAC) (223, 227).  
IVIVC is established for modified release (233-237) dosage forms where the drug release is a 
rate limiting step during the absorption process (227). Attempts at the development of IVIVC 
for immediate-release (IR) were also made (238-240). Development of IVIVC for IR 
formulation is more challenging. There is no official regulatory guidance for development of 
IVIVC for IR dosage forms. Normally, IVIVC is expected for highly permeable drugs, as in 
this case absorption is not limited by the permeability. Also, dissolution must be the rate-
limiting step. For instance, IVIVC for IR formulation of highly water soluble drug (BCS class 
I or class III) may not be possible, because dissolution occurs too fast and gastric emptying or 
membrane permeation is usually the rate – limiting step (241).  
Biopharmaceutical Classification System (BSC) became a very useful tool that helps to 
categorize drugs according to their intestinal permeability and solubility characteristics as 
well as allowing estimation of IVIVC (242). Generally, BCS classifies drugs into four 
categories (Figure 18).  
 
Figure 18. Biopharmaceutical classification of drugs (1). 
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Compounds with high solubility and permeability values belong to Class I, whereas those 
characterized by low solubility and high permeability fit in Class II. Class III and Class IV 
includes drugs with low permeability but high and low solubility, respectively. The BCS 
classification is used to predict in vivo performance of dosage forms based on their 
permeability and solubility characteristics (1). It is adopted by many regulatory bodies as a 
tool that allows grant biowaivers for IR formulations with wide therapeutic windows. BCS 
assists also in prediction if IVIVC is expected (Table 15) (227).  
Table 15. BCS and expected IVIVC for IR products (241). 
Class I II III IV 
Solubility High Low High Low 
Permeability High High Low Low 
IVIVC Correlation (if dissolution is 
rate – limiting step) 





According to Table 15, IVIVC is usually expected for IR formulations that belong to Class I 
(if dissolution is slower than absorption) and Class II compounds (241). 
3.3 Development of IVIVC 
3.3.1 Traditional IVIVC 
3.3.1.1 Model-dependent method  
3.3.1.1.1 Wagner-Nelson method 
In the absence of intravenous or oral solution data, the apparent in vivo cumulative absorption 
profile can be deconvoluted from data obtained from orally administered dosage forms using 
model-dependent Wagner-Nelson deconvolution technique (224, 243). This approach is 
derived from a one-compartmental model and the mass balance (Equation 18): 
 Xa = Xt + Xe                                                                        (Equation 18) 
Where Xa, Xt and Xe are amounts of drug absorbed, in the “body”, and eliminated at time t, 
respectively (244). 
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In order to calculate the amount of drug absorbed up to time T, (Xa)T  the equation has to be 
further derived as follows:  
 TTTa CtdtkVVCX 0)(                              (Equation 18) 
Where V is the volume of the central compartment, CT is concentration of the drug in the 
central compartment at time T and k is the first-order elimination rate constant. In IVIVC 
terms, this equation is often expressed in terms of fraction (F) of the dose (D) absorbed 




















a                                     (Equation 19) 
Fa(T) or FD is the fraction of the bioavailable drug absorbed at time T. 
Equation 20 is frequently applied to extravascular data in the case of absence of intravenous 
data in IVIVC modeling. According to the above formula, the apparent in vivo fraction 
absorbed can be estimated from terminal phase elimination rate constant k and partial AUC 
(232).  
Deconvoluted data are then either superimposed with the fraction released profile or linear 
regression between fraction absorbed and fraction released is applied to establish the 
correlation. Correlated data can be validated using external or internal predictability error.  
3.3.1.2 Model-independent method 
3.3.1.2.1 Numerical deconvolution 
For cases when clinical data for intravenous or oral solution formulations are available, 
numerical deconvolution can be applied in order to develop an IVIVC. Softwares such as 
PCDCON generate deconvoluted profiles (245). Deconvolution involves estimating the rate at 
which a drug dissolves in vivo using the observed in vivo (either IR or ER) data, which 
contains information on dissolution, absorption, distribution, metabolism and excretion of the 
 47
drug and reference in vivo observed data (which does not involve dissolution). 





                           (Equation 20) 
Where C(t) is called input response and defines function for any measurable quantity that is a 
direct result of input (i.e. plasma concentration from orally administered drug) (227, 244). δ is 
unit impulse, which determines unit dose of any amplitude and zero duration such that 
integral of δ(t) is equal one. This function describes distribution and elimination phases, 
respectively. Thus, Cδ(t) is a function known as unit impulse response that describes the 
cumulative effects of response changes, following all previous drug input f(t0 to t) at time t. 
Unit impulse dose can be illustrated by concentration at time t following unit i.v. bolus dose 
(245). Input rate f(t) is a function that determines the rate at which drug is absorbed.  







                                              (Equation 21) 





)()(                                       (Equation 22) 
Where f defines drug absorption rate and Xin cumulative amount absorbed.  
PCDCON software uses inverse Laplace transform, which means that Equation 20 is reversed 
(Equation 24) (244). Once deconvoluted in vivo data are obtained, the attempt of establishing 












0)(                                              (Equation 23) 
A deconvolution – based IVIVC is also known as two stage approach as involves estimation 
of the in vivo release/absorption profile from plasma concentration data using deconvolution 
technique (232). The deconvoluted profile is then assessed and validated by comparing the 
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predicted with observed plasma profiles. A simple linear model (Equation 25) with intercept 
(a) and slope (b) can be applied to define IVIVC: 
fraction absorbedinvivo = a + b* fraction dissolvedinvitro          (Equation 24) 
A slope closer to 1 indicates 1:1 correlation and a negative intercept implies that the in vivo 
process is slower than in vitro dissolution (or otherwise depending on the selection of axis). In 
the cases when in vitro and in vivo profiles exhibit different rates and/or difference in the 
starting of a phenomenon or difference in the lag time, various scaling factor can be applied to 
achieve 1:1 correlation (249). For instance, a Levy plot is one type of scaling technique (247). 
This plot is generated by fitting the time at which certain amount (i.e. 5, 10, 15 mg etc.) of the 
drug dissolved in vitro on the X-axis against the time to absorb the same amount of drug in 
vivo. This allows assessing the time scale and shifting differences between in vitro dissolution 
and in vivo absorption (227). A straight line will be observed if a similar process is observed 
between in vivo and in vitro data. Otherwise, turning point in the Levy plot can be observed 
(246). Turning point indicates at which time point the data start to diverge. 
If dissolution performance is independent of dissolution conditions such as pH, surfactants, 
enzymes and ionic strength, then the result for a single formulation may be sufficient. 
Otherwise, at least two formulations with release rate differing by 10% should be tested (223).  
It is important to select adequate bioavailability studies for the development of IVIVC. 
Crossover studies involving 6 to 36 subjects are preferred. Parallel studies or cross-study may 
be acceptable (223). The reference product for developing an IVIVC should be an intravenous 
solution or aqueous oral solution under fasted conditions. In the absence of intravenous 
solution or aqueous oral solution, IR formulations can be used.  
3.3.2 PBPK models 
Physiologically based pharmacokinetics (PBPK) models are comprised of mathematical 
models that integrate anatomical and physiological parameters of humans or animals, 
physicochemical properties of drug substances, and formulation properties of drug products to 
predict absorption, distribution, metabolism and excretion (ADME) of compounds in vivo 
(248-250).  
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3.3.3 Absorption models 
Several physiologically based mathematical models have been described in the literature, 
some of which have become commercially available, such as GastroPlusTM, PK-Sim® and 
Simcyp®.  
3.3.3.1 CAT and ACAT 
Yu and Amidon developed a compartmental absorption and transit (251) model to simulate 
the rate and extent of drug absorption. Initial CAT model was further developed to the 
Advanced CAT (ACAT) to take into account parameters such as dissolution rate, the 
solubility pH-dependence, controlled release, absorption in stomach and colon, gut and liver 
metabolism and degradation etc. (Table 16) (249). This theory is implemented in 
GastroPlusTM software. 
Table 16. Detailed characteristics of the GI tract (184). 




pH Villi present Transit time 
(h) 
Oral cavity 15-20 10 5.2-6.8 Absent Short 
Esophagus 25 2.5 5-6 Absent Very short 
Stomach 20 15 1.2-3.5 Absent 0.25-3 
Duodenum 25 5 4.6-6.0 scarcely present 0.23 
Jejunum 300 5 6.3-7.3 abundantly present 1.18 
Ileum 300 2.5 -5 7.6 abundantly present 1.9 
Caceum 10-30 7 7.0-8.0 scarcely present short 
Colon 150 5 6.1-7.3 absent variable 
 
3.3.3.2 ADAM model 
Advanced Dissolution, Absorption and Metabolism (252) model is implemented in Simcyp® 
software. According to the ADAM model, the GI tract is divided into nine segments from the 
stomach through the intestine to the colon (250, 252). Each segment has its specific 
characteristics in terms of pH, length, transit time etc. the model assumes that absorption from 
the stomach is minor (249). The ADAM model allows entering either raw dissolution data 
previously obtained experimentally or predicts dissolution based on various solubility values 
(pH profile, intrinsic solubility, values at certain pH) and particle size values (mean or 
distribution). One of the differences between the GastroPlusTM and the Simcyp® is the way 
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how dissolution data are predicted. The ADAM model uses the Wang-Flanagan model (253) 
(Equation 26), as opposed to the Noyes-Whitney equation (97, 254). When raw dissolution 
data are inserted into the ADAM model the effect of pH on solubility and supersaturation are 


















s        -h = r of r < 30µm;  (Equation 25) 
                                                                                                h = 30 for r > 30 µm  
Where dX/dt is the dissolution rate; r is time – varying particle radius; D is diffusion 
coefficient constant; h is diffusion layer thickness; Cs is the saturated concentration 
(solubility) at the interface between the solid and the solution; Xd is the amount of dissolved 
drug; V is fluid volume related to the segments in the GIT. 
Simcyp® has several prediction tools built-in that help to estimate some parameters such as 
permeability, intrinsic solubility, diffusion coefficient, fraction of drug unbound to protein 
and many others. For instance, permeability value can be predicted from various studies such 
as cell monolayers (Caco-2, MDCK), artificial membranes (PAMPA) or just using 
physicochemical properties (255). Equation 27 is used to calculate the flux (JAB) of 
compounds across the cell membrane (250).  
)(, BAmaneffAB CCSPJ                                        (Equation 26) 
Where Peff, man (cm/h) is the effective permeability; S is the surface area available for 
absorption; CA and CB are compound concentrations on the apical and basolateral sides, 
respectively. 
The relationship between measured values of human permeability in the jejunum for a range 
of drugs and the permeability values obtained experimentally in vitro allows estimation of Peff, 
man value. Based on the assumption that the absorption rate constant (ka) in each segment is 




,2                                          (Equation 27) 
Where R (cm) is the segment radius. 
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3.3.4 Applications 
Originally, computational tools were used to support toxicology, safety and risk assessments 
at the early stage of drug discovery and development (256). Nowadays, computational 
techniques are used for other purposes such as absorption modelling at the early stage of drug 
discovery to aid with assessing a drug’s potential for absorption as well as in the drug 
development stage to design dosage formulation and evaluate its behaviour in vivo (257). It 
allows shortening the time prior to new drug application (NDA) submission and reduces the 
number of experimental procedures required for compound selection and development (258, 
259). PBPK models proved to be successful predictive tools in oncology and antibiotics areas 
as they allow the simulation of plasma concentration – time profiles within the targeted organ 
(260, 261). More often, PBPK modelling is used to obtain mechanistic insights into drug 
behaviour by characterising its pharmacokinetics and drug – drug interactions (262). Ability 
to select different populations allows predicting drug pharmacokinetics of paediatric 
formulations (263, 264). This feature allows predicting drug pharmacokinetics under different 
physiological and pathological conditions such as food effect, pregnancy, liver cirrhosis and 
others (265-267). PBPK can also monitor not only a parent drug but also its metabolite (268, 















Aims and objectives 
The general objective of this work was to develop an appropriate dissolution method that will 
allow the prediction of in vivo performance of pharmaceutical cocrystals.  
In order to predict in vivo performance of cocrystals, the specific objectives of this work were 
to: 
- characterise APIs and cocrystals in terms of their solubility and particle-size 
distribution, 
- develop biorelevant dissolution methods to test commercial, API and cocrystal 
formulations, 
- collect physicochemical and pharmacokinetic parameters for selected marketed 
formulations, 
- develop IVIVC using both: traditional approaches such as deconvolution techniques 
and more sophisticated in silico tools such as PBPK modelling, 
- predict in vivo performance of cocrystals using the developed PBPK models. 
On the basis of the results of this work, it should be possible to assess if investigated 
pharmaceutical cocrystals enhance in vivo performance of selected poorly soluble compounds. 
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4 Experimental Part  
4.1 Materials  
Chemicals, samples and formulations used are listed in Table 17 and Table 19, respectively.  
Table 17. List of chemicals used. 
Material/Chemical name Batch no./Lot 
no./Grade 
Manufacturer/Supplier 
Acetic acid ≥99.7% 09214CJ, SZBB2210V Sigma-Aldrich (UK) 
Bovine serum albumin (96%) 62828 Fisher Scientific (UK) 
Dichloromethane 1020198 Fisher Scientific (UK) 
Ethanol HPLC grade SZBB0170V Sigma-Aldrich (UK) 
Hydrochloric acid (37%) 0925336  Fisher Scientific (UK) 
Lecithin 563098-01/936 Lipoid (Germany) 
Maleic acid 0065974, 1137140 Fisher Chemical (UK) 
Methanol (HPLC grade)  Various Fisher Scientific (UK) 
Microcrystalline cellulose  Avicel PH 302/ 200/105  FMC BioPolymer (Belgium) 
Nicotinamide 051M1837V Sigma-Aldrich (UK) 
Orthophosphoric acid 1001564 Fisher Scientific (UK) 
Ox bile salt extract LP0055 Oxoid (UK) 
Palmitic acid A0290542 Across Organics (UK) 
Pepsin, from porcine gastric mucosa 030M1571V Sigma-Aldrich (UK) 
Potassium phosphate monobasic 091341A, 103498 
080M0041 
Fisher Scientific (UK). 
Sigma 
Saccharin 98+% A0259796 Acros Organics (UK) 
Sodium acetate trihydrate 1142730 Fisher Chemical (UK) 
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Sodium chloride  0758662 
BCBG4549V 
Fisher Scientific (UK). 
Sigma-Aldrich  
Sodium dihydrogen orthophosphate dihydrate 1133834 Fisher Chemical (UK) 
Sodium dodecyl sulphate ≥99% 098K0067 Sigma-Aldrich (UK) 
Sodium hydroxide BCBC7310V Sigma-Aldrich (UK) 
Sodium taurocholate 2011040152 Prodotti Chimici E Alimentari 
S.P.A. (Italy) 
Trifluoroacetic acid BCBB2269 Sigma-Aldrich (UK) 
Tris (hydrozymethyl)-aminomethane (TRIS) A020562001 Acros Organics (UK) 
Filters used and other materials are listed in Table 18 and Table 20. 
Table 18. List of filters used. 
Material Grade Manufacturer/Supplier Application 
Glass microfiber filters GF/D (ø24 mm, 2.7 µm) Whatman®, UK Dissolution using USP 
Apparatus 4  




(ø13 mm, 0.45 µm) Whatman®, Germany Precipitation, and  
solubility studies; 
Dissolution studies using 
USP 1 
Cellulose filters Qualitative  standard 
grade (ø 110mm) 








Table 19. List of samples and formulations used.  
Material/Chemical name Batch no./Lot 
no./Grade 
Manufacture/Supplier 
Tegretol PR tablets (400 mg) U0281 Novartis Ltd (UK) 
Tegretol IR tablets (200 mg) U0552 Geigy (UK) 
Carbamazepine Standard (99% w/w), 
CBZsp (sp: sample powder) 
A0272746 Acros Organics/Prosonix (UK) 
CBZ-SACss (ss: sonic slurry method) PXLB 028-98C1 
PXLB 045-60C1 
Prosonix (UK) 
CBZ-SACumax (umax: umax method) PXLB 0280-98C1 Prosonix (UK) 
CBZ-NICss (ss: sonic slurry method) PXLB 031-043-6-S 
PXLB 045-58C1 
Prosonix (UK) 
Indocid capsules (25 mg) K5895 MSD (Australia) 
Indomethacin Standard (≥99% w/w), 
INDsp (sp: sample powder) 
1000573578 Sigma-Aldrich/ Prosonix (UK) 
IND-SACsd (sd: spray-drying method) PXLB 028-91A Prosonix (UK) 
IND-SACss (ss: sonic slurry method) N/A Prosonix (UK)  
IND-SACumax (umax: umax method) 028-102C1 Prosonix (UK) 
IND-NICss (ss: sonic slurry method) N/A Prosonix (UK) 








Table 20. List of materials used. 
Material Supplier Applications  
Centrifuge tubes Corning Inc. New York, US Solubility studies 
Swinny stainless steel 13 
mm filter holders 
Millipore, Billerica, US For filtration during solubility and 
USP 1 dissolution studies 
Sampling cannulae for 
500 mL  
Varian, CA, US For dissolution using USP 1 studies 
Glasss syringe 5 mL with 
Luer -Lock 
Fortuna® Optima®, Poulten & 
Graf Ltd, Essex, UK 
For dissolution using USP 1 studies 
Sieve 425µm   
 
4.2  Apparatus 
A Vankel rotating basket dissolution system (model 10-1200, Edison, NJ, US) and an 
Erweka flow-through dissolution tester (model DFZ720, Erweka GmbH, Heusenstamm, 
Germany) equipped with Ø 22.6 mm cells and connected to an Erweka Piston Pump (model 
HKP720) were used. 
The HPLC system consisted of an Agilent 1100 Quat pump, an Agilent 1100 DAD 
spectrophotometer, an Agilent 1100 ALS autosampler and ChemStation® software (Agilent 
Technologies, Santa Clara, US).  
For Carbamazepine studies a Zorbax® Eclipse XDB C18, 5 μm, 250x4.6 mm (Agilent 
Technologies, US) column was used. For the detection of Indomethacin, Saccharin and 
Nicotinamide a Zorbax® SB-C18, 3.5 μm, 150x4.5 mm (Agilent Technologies, US) column 
was used.  
Laser light diffraction (Helos, Sympatec, Clausthal-Zellerfeld, Germany), wet dispersing 
system (Cuvette®, Sympatec, Clausthal-Zellerfeld, Germany) and Windox 5.0 software 
(Sympatec, Clausthal-Zellerfeld, Germany) were used for particle-size distribution 
experiments.  
A shaking water bath (model Grant SS40-2, Grant Instruments, Cambridge, UK) was used for 
solubility studies. 
The thermal behaviour of solid phases was studied using differential scanning calorimetry 
(DSC) (TA Instruments 2920, New Castle, US). 
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A rotary evaporator (Buchi R-114, Buchi, Switzerland) equipped with water bath (Buchi B-
480, Buchi, Switzerland) and vacuum pump (Vacuubrand CVC 2II, Vacuubrand GMBH, 
Germany) were used for the preparation of biorelevant media.  
A Hydrus pH meter (model 300, Fisher Scientific, UK) was used for adjustment of the pH of 
the media used for solubility and dissolution studies. 
Turbula blender (Willy A. Bachofen AG, Basel, Switzerland) was used for preparation of 
physical blends. 
A Sigma 701 tensionmeter (Biolin Scientific, Sweden) equipped with Titronic Universal 
Burette was used to measure surface tension of modified media. 
A Sartorius balance (AG Gottingen, Germany) was used for all weighing. 
Vortex rotamixer (Hook & Tucker Instruments, England) was used for mixing samples before 
transferring to HPLC vials.  
Various sizes of Finnpipette tips (Fisherbrand, UK) (1-5 mL: S/N 9066708; 100-1000 µL: 
S/N 9097462; 20-200 µL: S/N 9113779) were used for sample preparations involving 
standard preparations, treatment of precipitated samples and buffer capacity studies. 
Ultrapure water was obtained from a NANOpure® DIamond UF and UV/UF Water 
Barnstead System (Thermo Scientific, Dubuque, US). 
Heating Magnetic Stirrer (Fisher Scientific, UK) was used for buffer capacity studies. 
4.3  Software 
Excel 2007 (Microsoft, US) was used to process all data solubility, dissolution and IVIVC 
data. 
DDSolver Excel add-in was used for analysis of dissolution kinetics. 
Simcyp Population-based ADAM Simulator (SimCYP®, Sheffield, UK) was used for the 
development of PBPK models. 
Graph Pad Prism 5.02 (GraphPad Inc.) was used for comparison of solubility data. 
PCDCON® 1.1 Deconvolution Utility (by Gillespie) was used for numerical deconvolution of 
plasma concentration data after oral administration of Indomethacin. 
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xyExtract Graph Digitizer V5.1 (by Wilton P.Silva, 2011) was used for extracting data from 
2D graphs. 
4.4 Methods 
4.4.1 Preparation of cocrystals 
All cocrystals were produced and provided by Prosonix Ltd using three different preparation 
techniques: sonic slurrying (ss), spray-drying (sd) (61, 66) and ultrasound mediated 
amorphous to crystalline transition (umax). The author of this thesis was not involved in 
cocrystal production process.  
Sonic-slurrying technique 
CBZ-SAC, CBZ-NIC, IND-SAC and IND-NIC cocrystals were prepared with the sonic-
slurrying method (65). Slurry was prepared by adding appropriate amounts of API and 
coformer into the jacketed vessel containing organic solvent (ethyl acetate). Slurry was then 
stirred at 60 rpm using a magnetic stirrer for one hour at 15 °C. Obtained slurry was then 
filtered and dried under vacuum overnight.  
Spray-drying technique 
Spray-drying technique was used to prepare Saccharin cocrystal of Indomethacin. The 
technique was briefly described in section 1.6.2. 
UMAX technique 
UMAX method was used to prepare Saccharin cocrystals of Carbamazepine and 
Indomethacin. Short description of UMAX process was included in section 1.6.3. 
4.4.2 Cocrystals sample preparation 
4.4.2.1 Preparation of capsules for dissolution studies using USP apparatus 1 
CBZ, CBZ-NICss, CBZ-SACss and CBZ-SACumax were weighed and filled into standard 
gelatin capsules (size 0). Amounts equivalent to 200 mg of CBZ were used in all cases (Table 
21). Calculations of the amount of CBZ in the cocrystal form were made based on the molar 
mass (Appendix 1).  
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CBZ : coformer 
Amount of 
CBZ [mg] 






1:1 200 155 355 
CBZ-NICss 1:1 200 103 303 
*amount of cocrystal that corresponds to 200 mg of CBZ on a molar basis (Appendix 1) 
4.4.2.2 Preparation of samples for solubility and dissolution studies using USP 
apparatus 4  
Carbamazepine (CBZ) case 
4.4.2.2.1 Preparation of samples to assess effect of MCC on dissolution 
In order to reduce static charges of the CBZ cocrystal material to enable weighing and further 
encapsulation, blending with microcrystalline cellulose was essential. MCC is also present in 
commercial forms of CBZ, Tegretol®.  Thus, it was important to assess if MCC has any effect 
on the dissolution performance of Carbamazepine. Three grades of MCC characterised by 
different particle size were selected for these studies (Table 22). 
Table 22. Characteristics of different MCC grades. 
Product grade Nominal particle size [µm] Moisture [%] Loose bulk density [g/cc] 
PH-105 20 < 5.0 0.20 – 0.30 
PH-302 100 3.0 to 5.0 0.35 – 0.46 
PH-200 180 2.0 to 5.0 0.29 – 0.36 
 
One batch for each MCC grade was prepared. Carbamazepine was sieved through a 425µm 
stainless steel sieve (Pascal Eng Ltd., Sussex, UK) prior to weighing. Equivalent amounts to 
2.00 g of CBZ were weighed and placed between two layers of 300 mg MCC in a plastic vial. 
Samples were blended for 45 minutes using a Turbula blender at 46 rpm/min. 
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4.4.2.2.2 Preparation of cocrystal samples for dissolution studies 
Based on the previous study MCC grade with particle size of 100 µm (PH-302) was selected 
for further studies. Carbamazepine cocrystal (CBZ-SACss, CBZ-SACumax and CBZ-NICss) 
samples were then blended with MCC according to the method described in section 4.4.2.2.1 
(Preparation of samples to assess effect of MCC on dissolution). 
4.4.2.2.3 Blend uniformity test 
For each blend, ten samples equivalent to 20 mg of CBZ were collected from different 
fractions of the blend and were dissolved in 60 mL of methanol and then 40 mL of water was 
added. MCC that did not dissolve in the organic solvents was filtered through qualitative filter 
paper. All CBZ fully dissolved in this amount of methanol. Filtrate was analyzed by HPLC 
and the percentage of relative standard deviation (%RSD) of the area was calculated 
(Appendix 2). %RSD below 2% indicated that the blending procedure produced a 
homogenous blend. After blending with MCC, the name of the formulations remained the 
same as follows: CBZ, CBZ-SACss, CBZ-SACumax and CBZ-NICss. 
Indomethacin (IND) case 
Equivalent amounts to 25 mg of IND were used for dissolution studies of all IND-SACss, 
IND-SACumax and IND-NICss cocrystals (Table 23). Calculations of the amount of IND in the 
cocrystal form were made based on the molar mass (Appendix 3). 




IND : coformer 
Amount of 
IND [mg] 















IND-NICss 1:1 25 8.53 33.53 
*amount of cocrystal that corresponds to 25 mg of IND on a molar basis (Appendix 3) 
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4.4.2.3 Preparation of physical blends for dissolution studies using USP 
apparatus 4  
The mechanism of cocrystal dissolution was characterized against the physical blends of 
adequate API’s and coformers. Physical blends were prepared using blending procedure. 
API’s (CBZ and IND) and coformers (SAC and NIC) were sieved through a 425 µm stainless 
steel sieve prior to weighing. Equivalent amounts of API and coformers to that present in the 
cocrystals were weighed (Table 24). API was always placed between two layers of coformer 
in a plastic vial. Samples were blended for 45 minutes using a Turbula blender at 46 rpm/min. 
Table 24. Amounts of components used for preparation of physical blends.  
Amounts of components used 
 SAC NIC 
CBZ [2 g] 1.50 g (2 x 0.75g) 1.30 g (2 x 0.65g) 
IND [2.5 g] 1.28 g (2 x 0.64g) 0.85 g (2 x 0.43g) 
 
Obtained this way physical blends were then placed between two layers of MCC (2 x 0.3g) 
and were blended using the same blending protocol. 
4.4.2.3.1 Blend uniformity 
For each blend, ten samples equivalent to 20 mg of CBZ and 20 mg of IND were collected 
from different fractions of the blend and dissolved in 60 mL of methanol and then 40 mL of 
water (for CBZ) or 70 mL of ethanol and 30 mL of water (for IND). All components fully 
dissolved and 1.5 mL samples were transferred to HPLC vials for analysis. % RSD of the area 
of ten replicates was calculated (Appendix 4). %RSD below 2% indicated that the blending 
procedure produced a homogenous blend. Physical blends in this study are referred to as 
CBZ--SAC, CBZ--NIC, IND--SAC and IND--NIC. 
4.4.3 Media composition 
Three different types of media were selected for in vitro studies: compendial (SGF, SIF, 
SCoF), modified (MGM: SGF+0.01%SLS, MIM-I: Na-SIF+0.2%SLS, MIM-II: blank 
FaSSIF+0.1%SLS) and biorelevant media (FaSSGF, FaSSIF-V2, FaSSCoF).  
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4.4.3.1 Compendial media 
SGF (108), SIF (108) and SCoF (158) media were prepared according to the composition as 
presented in Table 4 and Table 8. 
4.4.3.2 Modified media 
Surface tension is an important property of characterise human gastrointestinal fluids for 
solubility and dissolution of drugs. Typical surface tension values in the fasted state stomach 
range between 35 – 45 mN/m (270). This is due to the presence of surface active agents such 
as lecithin and lysolecithin (271). According to Solvang and Finholt, the levels of these 
surfactants in vivo are below critical micelle concentration (CMC) (272). Several authors 
developed gastric media that were modified by addition of artificial surfactants such as 
sodium lauryl sulphate (SLS) or Triton X-100 in order to achieve a surface tension close to 
that of human fluids (273). In this project SGF+ 0.01% SLS (MGM) was used based on 
studies performed by Fotaki and Long (274). 
Kalantzi et al. reported a surface tension value of human intestinal fluids (HIF) of 33.6 mN/m 
(150); biorelevant media (FaSSIF, FaSSIF –V2), which thus far seems to offer the most 
similar environment to the intestinal conditions, reported a surface tension of 54 mN/m (157). 
Biorelevant media contain mixed micelles, which concentrations were recorded to be above 
CMC. One aim of this project focused on the development of simple media modified by 
addition of simple surfactants (SIF; blank FaSSIF) would produce media with surface tension 
comparable to HIF. 
4.4.3.2.1 Surface tension (ST) studies  
Du Nouy ring method was used to determine the CMC from surface tension (ST) studies of 
SIF and blank FaSSIF-V2 (Compendial media section 2.5.1 and Biorelevant media section 
2.5.2) by addition of SLS (99% pure) using a built – in automatic titrator. Accurate amount of 
SLS was titrated dropwise (up to a total concentration of 3% SLS) into buffer, and surface 
tension was measured after each addition of surfactant. The 99% pure SLS was used as 
previous reports had shown that SLS purity could affect the CMC and dissolution of drugs 
used in the study (275). Due to the precipitation of potassium from the phosphate salt (SIF) 
with lauryl sulphate from SLS, potassium salts were replaced with sodium phosphate salts 
(Na-SIF) (276).  
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                                                       (Equation 28) 
Where I is ionic strength, ci is the molar concentration of the ion and zi is the charge number 
of that ion (277).  
4.4.3.2.2 Buffer capacity (β) 
For an aqueous solution, the buffer capacity is defined in terms of the concentration of acid or 
base that must be added to influence pH by one pH unit (277). Buffer capacity of Na-SIF and 
Na-SIF+0.2%SLS (MIM-I) was determined according to the USP 29, in which a 
potentiometric titration method is described (278). The buffer capacity was estimated by 
dropwise addition of 1N NaOH or 1M HCl measuring the volume required to change the pH 
by one unit, under constant agitation. 0.2 mL of 1M HCl or 1N NaOH was added using a 
pipette to 100 mL of buffer (Na-SIF, MIM-I) within 1 minute intervals during which solution 
was stirred at constant rate on the stirrer plate using a magnetic stirrer bar. The pH was 
measured and recorded using a pH probe immersed in the solution. Buffer capacity was then 
calculated using equation (279): 
   2333.2 

 OHKa
OHKaC                                                 (Equation 29) 
Where β is the buffer capacity, C is the total buffer concentration i.e. the sum of the molar 
concentrations of acid and salt, Ka is dissociation constant and [H3O+] is the molar 
concentration of the hydronium ion. 
4.4.4 Biorelevant media 
FaSSGF (152), FaSSIF-V2 (157) and FaSSCoF (159) media were prepared according to the 





4.4.5 Particle-size distribution (PSD) 
The particle-size distribution of the batches of CBZ, IND powder and their cocrystals was 
measured by laser light diffraction (HELOS, Sympatec, Clausthal-Zellerfeld, Germany) using 
a wet dispersing system (CUVETTE, Sympatec, Clausthal-Zellerfeld, Germany). In case of 
CBZ, powder samples (50 mg) were suspended in 5mL of dispersion media, comprising of 
cyclohexane and 0.1% w/v lecithin. The suspension was sonicated for 10 minutes at 25 °C 
prior to analysis. In the case of IND, powder samples (50 mg) were suspended in SGF and 
sonicated for 10 min at 25 ºC. The suspended powder materials were then introduced into a 50 
mL quartz-glass cuvette containing a solution of 0.1% w/v lecithin in cyclohexane (CBZ) or 
SGF (IND) and stirred with a magnetic bar at 1000 rpm for 2 min before sizing. Particle 
sizing was triggered when the optical concentration was greater or equal to 5%, and 
measurements were performed in triplicate. The cumulative undersize particle diameters were 
calculated using Windox 5.0 software (Sym patec, Clausthal-Zellerfeld, Germany). 
4.4.6 Differential Scanning Calorimetry (DSC) 
A differential scanning calorimeter (DSC, 2190, TA Instruments, Surry, UK) was used to 
perform thermal analysis on the CBZ and IND (as received), and their cocrystal samples, after 
initial calibration with indium. Powder samples (n = 3) of approximately 5-10 mg were 
accurately weighed in aluminium pans, ensuring a total covering of the base by pressing down 
the samples and then hermetically sealed. The temperature was equilibrated to 50°C before 
heating at a rate of 10 °C/min to 350 °C under dry nitrogen purge (0.30 L/min). 
4.4.7 Development and validation of chromatographic methods 
HPLC methods used to quantify CBZ, IND, SAC and NIC in samples from solubility and 
dissolution studies are presented in Table 25. The HPLC method used for the analysis of CBZ 
is a modification of the method of Vertzoni et al. (280). Analysis of IND was conducted using 
a modified method of Al Za'abi, et al. (281) (Table 25).  For quantification of coformers from 
dissolution studies of cocrystals and physical blends in biorelevant media, gradient methods 
were developed (Table 26). NIC and SAC peaks tend to elute in the first 4 minutes of the 




Table 25. Summary of HPLC methods for detection of CBZ, IND, SAC and NIC. 
 CBZ  IND  SAC NIC 
Column name Zorbax® Eclipse Zorbax® Zorbax® Zorbax® 
Column type XDB-C18 SB-C18 SB-C18 SB-C18 
Column size [mm]; 









Column temp. [ºC] 20 23 23 23 
Flow rate [mL/min] 1 1 1 1 
Injection volume [µL] 50 100 100 100 





 0.1 % TFA 
gradient 
MeOH:H2O+  
0.1 % TFA 
gradient 
Wavelength [nm] 240 270 270 270 
Run time [min] 9 10 18 18 
Retention time [min] 6.6 7.8 3.8 1.9 
 
Table 26. Gradient used for detection of SAC and NIC. 
SAC gradient method NIC gradient method 
Time[min] MeOH Water+0.1 % TFA Time[min] MeOH Water+0.1 % TFA 
0 30 70 0 30 70 
3 30 70 2 30 70 
5 30 70 4 70 30 
7 90 10 6 90 10 
11 90 10 10 90 10 
13 60 40 13 50 50 
15 30 70 15 30 70 
18 30 70 18 30 70 
 
4.4.7.1 Standard curve preparation for all media. 
Prior to each experiment, a calibration curve was performed in order to observe any changes 
to the formulation, sample, medium or system (Table 27). Adequate amounts of stock solution 
was transferred into a volumetric flask and diluted up to volume with adequate medium in 
order to achieve the desired standard concentration.  
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Table 27. Summary of standard curve conditions. 
 Stock solution conc. 
[µg/mL] 
Stock solution solvents Standards conc. 
range [µg/mL] 






methanol (60):water (40) 
 
10-200 
10, 20, 30, 40, 50, 75, 100, 









pH 1.2-1.6: 0.5, 0.75, 1, 2.5, 
5, 7.5 and 10 
pH 6.5-6.8: 1, 2.5, 5, 10, 20, 
30, 40 and 50 
SAC 500 Water 2.5-50  2.5, 5, 10, 20, 30, 40 and 50 
NIC 500 Water 5-50 5, 10, 20, 30, 40 and 50  
 
Linearity and Range  
The linearity of each assay method was evaluated by six point standard curves using 
concentrations presented in Table 28. Calibration curves for CBZ and IND were constructed 
over a 6 weeks period to determine the variability of the slope and intercept. Due to the 
limited number of experiments that required NIC and SAC quantification, three replicates of 
each standard were made on one day to assess linearity. Mean (± SD) regression equations 
were constructed using linear regression analysis. The goodness of fit was reported in terms of 
R2 value. 
Table 28. Standards selected for linearity. 
 Standards conc. range [µg/mL]      Selected concentrations [ug/mL] 
CBZ 10-200  10, 50, 75, 100, 150 and 200 
IND 0.5-50 Acidic cond. 0.5, 0.75, 1, 2.5, 5 and 10  
Basic cond. 1, 5, 10, 20, 40 and 50 
SAC 2.5-50 2.5, 5, 10, 20, 50 and 75 
NIC 5-50 5, 10, 20, 30, 40 and 50 
 
Precision 
Working standards of each concentration (CBZ: 50 µg/mL in SIF; IND: 50 µg/mL in SIF; 
SAC: 50 µg/mL in FaSSGF and NIC: 50 µg/mL in FaSSGF) for each method were injected 
ten times under the same conditions during a short time period (1 day). Intra – day precision 
was assessed based on the %RSD of area of replicates.  
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Limit of detection (LOD) and quantification (LOQ) 
The sensitivity of all assays either in SIF or FaSSGF was evaluated by determining the limit 
of quantification (LOQ) which is defined as the lowest concentration of the calibration curve. 
Limit of detection (LOD) is defined as the lowest concentration that can be distinguished 








3.3                                                               (Equation 31) 
Where b is the slope and Sy/x is the residual standard deviation of the regression line calculated 
using working standards. 
4.4.8 Solubility studies 
Solubility over time studies 
Solubility over time of IND and two of its cocrystal (IND-SACss and IND-NICss) was 
measured in SIF (pH 6.8) and FaSSIF-V2 (pH 6.5). An excess (40 mg) of sample and 10 mL 
of medium transferred into centrifuge tubes. Capped tubes were then placed in a tray within a 
shaking water bath (37 ˚C) and were shaken at 200 strokes/min. Samples were analysed at 
various time: 5, 10, 20, 30, 40, 50, 60, 90, 120, 180, 240 and 1440 minutes using HPLC. 
Concentration values were plotted against the time. 
Saturation solubility studies 
The pH-profile solubilities were measured in triplicate using the shake-flask method (282). 
Various media were used to cover the physiologically relevant pH ranges from 1.2 to 6.8 
(Table 29). Medium (10 mL) and excess (40 mg) of CBZ, IND and their cocrystal samples 
were transferred into centrifuge tubes. Capped tubes were then placed in a tray within a 
shaking water bath (37 ˚C) and were shaken at 200 strokes/min for 24 h. After equilibrium 
was reached, the supernatant solution was filtered using syringes fitted with 13 mm stainless 
steel swinny filter holders equipped with cellulose nitrate membrane filters (0.45 µm). 
Samples after dilution were analysed by HPLC using methods described in section 4.4.7. 
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4.4.9 In vitro dissolution studies 
Dissolution studies were performed using two different dissolution systems: basket 
dissolution apparatus (USP apparatus 1) and flow-through cell dissolution apparatus (USP 
apparatus 4). 
4.4.10 Basket dissolution apparatus (USP apparatus 1) 
Protocol for the dissolution tests of capsules with USP apparatus 1: 
Dissolution media                                            SGF and SIF 
Dissolution medium volume 500 mL 
Temperature 370.5 C 
Basket rotating at 100 rpm 
Sample volume 5 mL 
Sampling location Half-way between the top of the medium and 
the top of the basket  
Sampling times CBZ: 10, 20, 30, 45, 60, 90, 120, 180, 240, 300 
and 360 min. 
                                                                         IND: 10, 20, 30, 45 and 60 min. 
Formulation tested                                           Indocid® capsules,  
                                                                         Tegretol® tablets 
                                                                                                              Encapsulated CBZsp 
                                                                         Encapsulated CBZ-SACss 
                                                                         Encapsulated CBZ-NICss 
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Experiments were run in triplicate  
Sampling procedure for the dissolution tests. 
Samples were removed using a 5 mL Fortuna Optima syringe fitted with a stainless cannula 
to facilitate representative sampling. The drawn sample volume was replaced with the same 
volume of blank dissolution medium, which was kept in a separate vessel at a temperature of 
370.5 C. Each sample was filtered through a Whatman cellulose nitrate membrane filter 
0.45 μm placed in filter swinny holder and, after discarding the first 1 mL, an appropriate 
volume of the filtrate was injected into the HPLC system.  
4.4.11 Flow-through cell dissolution apparatus (USP apparatus 4) 
Protocol for the tests of all CBZ and IND formulations.  
According to the USP 24 specifications a 5 mm–size glass bead was positioned in the tip of 
the cell (22.6 mm-size), 1.7 g of 1 mm–size glass beads were added. In the case of all CBZ 
formulations, a Whatman® glass fiber filter (GF/F: 0.7 μm pore size, 24 mm diameter) was 
placed on the top of the cell. For IND formulations an additional Whatman® glass fiber filter 
(GF/D: 2.7 μm pore size, 24 mm diameter) separated from the GF/F filter by 0.1 g of the glass 
wool was used. For the dissolution experiments of Tegretol, the tablets were mounted on a 
holder (Figure 19a), while the Indocid capsule was placed on the top of the glass beads and 
the tablet holder was reversely mounted to prevent sticking of the capsule to the filter head 
(Figure 19b). For the dissolution experiments of all APIs and cocrystals samples, the samples 
were placed between 1.7 g and 6.3 g of the glass beads (Figure 19c). 
 
Figure 19. Schematic diagram of the conditions used for the dissolution experiments with the flow-through cell 
apparatus.  
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The experiments were performed in compendial, modified and biorelevant media (The 
dissolution medium in section 2.5) with sequential changes of the media and flow rates 
according to Table 30. 
Table 30. The periods during which formulations were exposed to the various media and the flow rate that each 
medium was pumped through the cell. 
Type of medium Medium Period (min) Flow rate (mL/min)* 
Compendial media SGF 0-60 8 
SIF 60-240 4 
Modified gastric media (MGM) / 
Modified intestinal media (MIM-I) 
SGF+0.01%SLS 0-60 8 
Na-SIF+0.2%SLS 60-240 4 
Modified gastric media (MGM) / 
Modified intestinal media (MIM-II) 




Biorelevant media FaSSGF 0-60 8 
FASSIF-V2 60-240 4 
*The flow rate is defined by steps in the piston pump. Their relation is given by the equation: y=0.0157x+0.7842 
(y: flow rate, x: steps). 
Sampling times every 10 min up to 240 min 
Temperature: 370.5 C. 
Experiments were run in triplicate 
4.4.11.1 Sampling procedure 
The samples were collected in volumetric cylinders, and after appropriate dilution 
(where necessary) a sufficient volume was injected into the HPLC system.  
4.4.11.1.1 Treatment of precipitated IND samples 
Indomethacin is a weak acid which upon the media change tends to precipitate so 
additional treatment of the sample is essential. The treatment of the sample took place 
immediately after collection, as the rate of precipitation strongly depends on the time. Firstly, 
the fraction of sample-collected at 70 minutes was withdrawn using a 5 mL Fortuna Optima 
syringe, then 13 mm stainless steel swinny filter holders equipped with cellulose nitrate 
membrane filters (0.45 µm, Whatman) were used to discard 1 mL of sample and then transfer 
the remaining volume to a HPLC vial (referred to as filtered sample).  Secondly, 5 mL of the 
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precipitated sample was dissolved in 5 mL of ethanol (referred to as diluted sample) then 
stirred firmly and transferred to a HPLC vial. Obtained data were then used for calculations of 
% of sample and dose precipitated. 
4.4.11.1.2 Calculation of % of sample precipitated 
Concentrations of both filtered and diluted samples were calculated and then % of the sample 
that precipitated at 70 minutes in each cell was calculated accordingly to the equation: 
%prec.70min of the sample 
  sample samplesamplediluted
filtereddiluted  *100                        (Equation 32) 
4.4.11.1.3 Interpretation of non-cumulative data 
Dissolution profiles of all IND formulations were also presented in non-cumulative way. 
Amount dissolved [mg] were calculated based on the volume of the sample collected between 
each time intervals i.e. 10 to 20 minutes, 20 to 30 minutes etc. The amounts dissolved were 
then plotted against the time intervals creating stairs like profile. 
4.4.11.1.4 Calculation of % of dose precipitated 
Concentrations of both filtered and diluted samples were calculated and the amount dissolved 
[mg] was calculated based on the volume of the sample collected between 60 to 70 minutes. 
The difference between the amount of sample dissolved and filtered is then further used to 
calculate percentage of the dose precipitated: 
%prec.70min of dose 
 
Dose
AmountAmount filtereddiluted 00100*                        (Equation 33) 
Mean and SD values of % dose and % that calculated were then plotted on bar charts 
for each formulation across all dissolution media. 
4.4.12 Release of CBZ from 400 mg PR Tegretol® tablets 
Release profile of CBZ from 400 mg PR Tegretol tablets was determined using USP 
apparatus 4.  Tablets were positioned in the cell using cell set up described in Figure 19a. 




Table 31. Dissolution specifications for 400 mg PR Tegretol®  
Experiment no. Media used Time of exposure [h] Selected flow rates [mL/min] 
1 SGF/SIF/SCoF 1/4/2 8/4/4 
2 FaSSGF/FaSSIF-V2/SCoF 1/4/2 8/4/4 
3 FaSSGF/FaSSIF-V2/FaSSCoF 1/4/2 8/4/4 
 
4.4.13 Effect of MCC on dissolution of Carbamazepine 
It was essential to ensure that MCC would not affect the dissolution performance of 
Carbamazepine. Therefore, three batches of Carbamazepine containing different grades of 
MCC (PH105, PH302 and PH 200) that were previously blended were analysed using USP 
apparatus 4 dissolution methods for powder samples. MCC grades had similar sensitivity to 
moisture but various particle size (20 – 180 µm). Amounts equivalent to 25 mg of 
Carbamazepine (n = 3) were tested using USP apparatus 4 for one hour in SGF (pH 1.2) at 8 
mL/min following one hour exposure to SIF (pH 6.8) at 4 mL/min. Samples were collected 
every 10 minutes. 
4.4.14 Treatment of in vivo data 
Plasma concentration-time profiles for a single administration of one 200 mg IR Tegretol® 
tablet were extracted from fasted state studies performed by Meyer et al. (283). Clinical 
studies involved twenty four healthy, non-smoking male volunteers ranging in age from 21 to 
35 and weighing 61-93 kg. Two sets of clinical studies were found for PR Tegretol® tablets. 
Kovacević et al. tested the drug during open label, randomized cross-over studies on a group 
of twenty four healthy volunteers of both sexes, whose age ranged between 20-52 and body 
weight 50-96 kg (82). Volunteers received a single administration of one 400 mg dose.  Data 
were also compared with that obtained by Larkin et al., who tested single administration of 
one 400 mg PR Tegretol® tablet during double-blind cross over studies where eight healthy 
subjects (7 males; 1 female) participated with an age range of 25 to 47 (284). All in vivo data 
were extracted as mean values using xyExtract Graph Digitizer. 
For the IND case, plasma concentration-time profile for IR Indocid® capsules were extracted 
from fasted state studies performed by (285). Clinical studies involved fourteen healthy male 
volunteers. Mean and SD values for this clinical study were reported. 
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4.4.15 In vitro-in vivo correlations 
Traditionally, IVIVC was developed by correlating dissolution data with fraction absorbed 
obtained through either model-independent or model-dependent approaches (227). The former 
model involves numerical deconvolution using pharmacokinetic softwares such as 
PCDCON®. The latter approach is based on algebraic equation such as Wagner-Nelson. 
Nowadays, the development of IVIVC with the help of in silico tools through Physiologically 
Based Pharmacokinetic (PBPK) models (i.e. Simcyp®) is becoming more popular. 
4.4.15.1 Model-independent approach 
Numerical deconvolution of Indomethacin data was performed using the software programme 
PCDCON® (271). Mean plasma concentration time profile following intravenous 
administration (285) was used as impulse response (Appendix 5). Unit impulse response was 
calculated based on the dose for intravenous IND formulation, which was 25 mg. Mean 
plasma concentration time profile after oral administration of Indocid® capsule was used as 
input response function (Appendix 5). Both profiles were then fitted to an interpolating cubic 
spline function and then deconvoluted. Data were generated for 4 hours using step size 0.04 
and were presented as cumulative amount of IND absorbed. 10 minutes intervals were used 
for the calculation of the in vivo cumulative fraction absorbed; therefore, the number of 
calculated points for 4 hours of deconvolution was set to 25. Deconvoluted this way in vivo 
drug absorption profile was presented as a fraction of IND absorbed and correlated with 
fraction of IND dissolved in vitro dissolution experiments using USP apparatus 1 and USP 
apparatus 4. 
Scaling factor such a Levy plot was applied this way that on the X-axis, the time to have 
certain amount dissolved (i.e 5, 10, 15 mg etc.) was marked, and on the Y-axis, the time to 
reach similar amount of the drug absorbed was pointed. It was not possible to obtain linear 
correlation; therefore, time shifting was applied. The time shifting was illustrated by the time 
to observe turning point on the generated plot. This time can be further used to shift the 





4.4.15.2 Model-dependent approach 
Carbamazepine case 
Wagner-Nelson model 
An intravenous formulation of Carbamazepine is not available; therefore application of 
numerical deconvolution method is not possible. In this instance, plasma concentration time 
profiles after oral administration can be deconvoluted using Wagner-Nelson model (224). The 
observed mean in vivo plasma CBZ concentration time profile was deconvoluted to its in vivo 
absorption time profile assuming a one-compartmental open body model. As CBZ follows 
two-compartmental model Wagner-Nelson method was applied with caution assuming that it 
follows one-compartmental model. 
The area under the curve (AUC0-168h) was calculated by the trapezoidal rule. The elimination 
rate constant (ke) was estimated from the terminal slope (based on the last three time points) 
of the logarithmic plasma CBZ concentration time profile, which was further used for 
calculating area under the curve from zero to infinity (AUC0-∞). Amount of CBZ absorbed at a 
time t (At) was then calculated as a sum of plasma concentration at a certain time and AUC0-∞. 
Based on this calculation, the total amount of CBZ absorbed can be determined, which then 
can be used to produce a graph of cumulative fraction absorbed. Due to the facts that sink 
conditions were not provided and only 50 % of the CBZ was dissolved in experiments using 
USP apparatus 1. This data were normalised as 100%. The relationship between fractions of 
CBZ dissolved in vitro and fraction of CBZ absorbed in vivo was examined by plotting the 
fraction of drug dissolved at 0.5, 1, 2, 3 and 4 hours versus fraction of the drug absorbed at 
equivalent time intervals. Linear regression analysis was then applied (Excel 2007). 
4.4.15.3 PBPK model 
4.4.15.3.1 Carbamazepine case 
The Simcyp® population-based ADME simulator was used to simulate the plasma 
concentration – time profiles of 200 mg IR and 400 mg of PR Tegretol® tablets. Parameters 
used for developing a minimal PBPK model of Carbamazepine are presented in Table 32. 
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 Table 32. Summary of CBZ parameters inserted into the Simcyp® software. 
Parameter Value/unit 
Molecular weight [g/mol] 236.27 
Log P 2.45 (286) 
pKa 11.83 
dose [mg] IR 200 
PR 400 
Human jejunal permeability (Peff) 4.3x10-4cm/s (287) 
fu 0.25 (288) 
Main plasma binding protein Human serum albumin (HSA) 
Clearance after oral dosage [L/h] 1.01  (%CV 27.27) (289) 
Volume of distribution [L/kg] 0.96  [%CV 9.38] (290) 
 
The simulations for single dose of both IR and PR formulations were performed using time – 
based simulations according to the trial design which corresponds to clinical studies, 
including the number of participants (24 subjects), age range, gender range and dose regimen. 
Sim-Healthy volunteer population was used and gastric emptying time was set up to 1 hour 
which was in agreement with media change during dissolution studies. The rate and extent of 
oral absorption of CBZ was simulated using the fasted human ADAM model, which describes 
the gastrointestinal tract as segments based on their anatomical and physiological 
characteristics. The ADAM model incorporates two types of dissolution data: (1) predicted 
dissolution data based on Wang-Flanagan (WF) equation based on solubility and particle-size 
distribution data obtained experimentally and (2) raw data obtained from the in vitro 
experiments. All of these data were obtained previously. Therefore, simulations of both 
Tegretol® tablets were performed using both approaches according to the schedule presented 






 Table 33. Schedule for simulations of Tegretol® IR and PR formulations. 
Approach Media 
1) Predicted dissolution data 
using solubility and particle size 
data 
Solubility pH profile (IR) Compendial media 
Biorelevant media 
2) Experimentally 
determined dissolution data 
USP apparatus 1 (IR) SGF and SIF 
USP apparatus 4 (IR & PR) SGF/SIF (IR) 
MGM/MIM-I (IR) 
MGM/MIM-II (IR) 
FaSSGF/FaSSIF-V2 (IR & PR) 
 
Level A point-to-point correlations between observed and predicted plasma concentration 
over time profiles were established. Both of the models were compared with the observed data 
using difference factor f1. To better understand the absorption process of CBZ, data were 
presented as regional fraction of the Tegretol® dose absorbed and cumulative fraction of CBZ 
absorbed. 
In addition, parameter sensitivity was performed to analyse the effect of selected parameters 
such as logP, clearance, volume of distribution etc on the predicted Cmax, Tmax and AUC 
values. Sensitivity analysis was performed for IR formulation under fasted conditions. During 
this analysis, one parameter was changed gradually within a realistic range. 
4.4.15.3.2 Indomethacin case 
The rate and extent of oral absorption of Indomethacin from 25 mg Indocid® capsules was 
simulated using the fasted human ADAM model in Simcyp®. Basic physicochemical 
properties such as lipophilicity, solubility and molecular weight were required for 
simulations. These values along with pharmacokinetics parameters were taken from scientific 





Table 34. Summary of IND parameters inserted into the Simcyp® software. 
Parameter Value/unit 
Molecular weight [g/mol] 357.787 
Log P 4.27 (291) 
pKa 4.42 (292) 
dose [mg] 25 
Human jejunal permeability (Peff) 21.146 x10-4cm/s [based on 
Caco-2  255.66x 10E-06 cm/s]  
fu 0.04 (293) 
Main plasma binding protein Human serum albumin (HSA) 
Clearance after oral dosage [L/h] 6.541   [ %CV 18.12] 
Volume of distribution [L/kg] 0.12 
 
If human Peff is not available in vitro permeability models such as MDCK II and LLC-PK1 or 
Caco-2 can be used to predict the Peff. The Simcyp® uses six reference compound assays to 
generate the relationship between Papp, Caco-2 to Peff, man. Human effective jejunal permeability 
(Peff) was estimated to be 255.66 x 10-6 cm/s based on high Caco-2 permeability, which was 
converted to an estimated Peff in human of 21.15 x 10-4 cm/s using the permeability predictor. 
Gastric emptying time was set up to the default value of 0.4 h. The simulations for single dose 
of Indocid® formulation were performed using time-based simulations according to the trial 
design which corresponds to clinical study, including the number of participants (14 subjects), 
age range, gender range and dose regimen. A Sim-Healthy volunteer population was used. 
The ADAM model incorporates two types of dissolution data: (1) predicted dissolution data 
using the Wang-Flanagan (WF) equation based on solubility and particle-size distribution 
data obtained experimentally and (2) raw data obtained from the in vitro experiments. All of 
these data were obtained previously. Therefore, simulations of both Tegretol® tablets were 






Table 35. Schedule for simulations of Indocid® IR capsules. 
Approach Media 
1) Predicted dissolution data 
using solubility and 
particle size data 





USP apparatus 1  SGF and SIF 





Level A point-to-point correlation between observed and predicted plasma concentration over 
time profiles were established. Simulated profiles were compared with the observed profile 
using difference factor f1. In order to better understand the absorption process of IND, data 
were presented as a regional fraction of the Indocid® dose absorbed and cumulative fraction 
of IND absorbed. In addition, parameter sensitivity was performed to analyse the effect of 
selected parameters such as logP, clearance, volume of distribution etc on the predicted Cmax, 
Tmax and AUC values.  
4.4.15.4 Predictions of in vivo performance of cocrystals based on PBPK 
models 
The developed PBPK IR Tegretol® and Indocid® models were implemented for the prediction 
of in vivo performance of pharmaceutical cocrystals of CBZ and IND, respectively. Predicted 
plasma concentration time profile of CBZsp and INDsp were used as a reference profiles 
against which in vivo performance of cocrystals were compared. Due to software limitations, 
it was not possible to indicate that the CBZsp and cocrystal formulations that were tested were 
present in a powder form. Thus, these data were inserted into the dissolution window in the 
formulation section designated for IR solid formulations. Mean values of percentage of CBZ 
dissolved with SD were inserted as a whole dissolution profile, which was characterised by 
linear interpolation of eighteen dissolution time points fairly distributed up to 4 h (0.17; 0.33; 
0.50; 0.67; 0.83; 1.00; 1.17; 1.33; 1.50; 1.67; 1.83; 2.00; 2.33; 2.67; 3; 3.33; 3.67 and 4.00 h). 
Predicted cumulative fractions absorbed from each cocrystal were compared with that of 
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CBZsp. Regional fraction absorbed and cumulative fraction absorbed profiles were also useful 
to aid the discussion. 
4.4.15.5 Statistical Analysis 
Comparison of solubility data 
Solubility data for all IND and CBZ formulations in different media were processed using 
GraphPad Prism software. Mean, standard deviations and standard errors of the mean were 
calculated. Two-Way ANOVA repeated measurements were performed for solubility 
concentrations for either selected medium or selected formulations (p < 0.05). The Bonferroni 
post-test was employed to perform pairwise multiple comparisons of all groups at a 
significance level of p < 0.05. Significant figures were presented to three significant digits. 
The same analysis was applied to compare mean values of simulated AUC, Cmax, and Tmax 
parameters for Tegretol® IR PBPK model. 
Dissolution profile comparisons 
Dissolution profile comparisons were performed with the use of f1,area assuming the 
dissolution profile of the CBZsp and INDsp samples as the reference profiles. Evaluation of 
f1,area was considered up to the time corresponding to the first experimental datum after 85% 
of the plateau level of the reference data set. In cases where this datum point was not observed 
within 5 h of experiment, f1,area was evaluated up to 4 h, to reflect the maximum 
physiologically reasonable small intestinal residence period. Since the coefficient of variation 
of data points at every sampling time was in all cases less than 15%, f1,area was evaluated from 
mean data sets. In the present study, a 15% average difference of a test from a reference data 
set (f1,area= 0.15) was set as the limit for identifying differences between the samples 
Plasma concentration profile comparisons 
The difference between mean simulated and mean observed plasma profiles was determined 
using difference factor f1 (Comparison of dissolution profiles section 2.6). The observed 
plasma concentration time data were used as a reference data set. Predicted profiles were 
compared in this manner that the equivalent time points to reference profiles were selected for 
comparison. Entire profiles were taken into account. 15% average difference of a test from a 




Zero-order, first-order with Wmax and 3-parameters Weibull functions were applied to all 
dissolution profiles using the Excel add-in (DDSolver). The dissolution kinetics was applied 
to individual dissolution profiles and Mean with SD values were summarized in the tables. 
Dissolution data modeling library contained all essential equations (Dissolution kinetics 
section 2.6.2). The software requires the input of the time and its unit as well as % dissolved 
data. Additional tab in Excel were produced with the summary of all the data and their best - 
fit parameters. AIC and R2 values were used to express the goodness of fit.  
Kinetic of absorption (ka) of CBZ, IND and their cocrystals were calculated from cumulative 







5 Results and discussion 
5.1 Blend uniformity 
Samples (n = 10) equivalent to 20 mg of CBZ were analysed by HPLC and their areas were 
converted into concentrations and were further interpreted in terms of mean, SD and %RSD 
values and are presented in Table 36. Values of %RSD < 2 indicated that blending protocol 
described in section 4.4.2.2 produced homogenous blends.  
Table 36. Blend uniformity data for CBZ and its cocrystals blended with MCC. 
 Concentration [µg/mL] 
Sample no CBZ-MCC CBZ-SACss-MCC CBZ-SACumax-MCC CBZ-NICss-MCC 
Mean 19.49 18.96 19.18 18.97 
SD 0.24 0.22 0.08 0.25 
%RSD 1.26 1.16 0.44 1.29 
 
Samples (n = 10) equivalent to 20 mg of CBZ or IND were analysed by HPLC and their of 
mean, SD and %RSD values and are presented in Table 37. Values of %RSD < 2 indicated 
that blending protocol described in section 4.4.2.2 produced homogenous blends.  Data in 
Table 37 demonstrates that physical blends of CBZ--SAC, CBZ--NIC, IND--SAC and IND--
NIC were blended homogenously. 
Table 37. Blend uniformity data for physical blends of CBZ and IND with SAC and NIC. 
 Concentration [µg/mL] 
Sample no CBZ--SAC CBZ--NIC IND--SAC IND--NIC 
Mean 19.30 22.11 25.97 25.84 
SD 0.30 0.19 0.43 0.38 







5.2 Modified media composition  
5.2.1 Surface tension (ST) studies 
Kalantzi et al. reported that the surface tension of human intestinal fluid (33.6 mN/m) is 
significantly reduced in comparison to surface tension of water (72 mN/m) (150). The value 
in the fed state is even lower than in the fasted state (28 versus 33.6 mN/m), corresponding to 
the higher levels of bile salts present in the fed state. Preparation of biorelevant media may be 
time- and cost-consuming; therefore attempts at developing modified compendial media that 
mimic surface tension of human intestinal fluids were made in this study. Modified media 
may be useful not only for research purposes but as a tool for routine QC tests providing sink 
conditions for poorly soluble drugs. Figure 20 illustrates the effect of the addition of SLS to 
the medium (SIF and blank FaSSIF-V2) on the surface tension measurements.  
It is important to note that the micelles created using SLS are single-type micelles, whereas, in 
biorelevant media and in HIF, mixed micelles are present (294). The mixed micelles can 
increase drug solubilisation more effectively than single micelles. Simplification of the 
biorelevant media by replacement of mixed micelles with single micelles produced by SLS 
was previously attempted. For instance, Taupitz and Klein investigated blank FaSSIF media 
containing SLS varying from 0.1 to 1.5% (295). They concluded that these media can be 
particularly useful for developing predictive and discriminative methods in QC and early 
stages of formulation development of poorly soluble drugs (295). 
CMC can be defined as the concentration of surfactant above which micelles are formed 
(296). At concentrations greater than the CMC value, the surface tension of the medium does 
not decrease with an increase in surfactant concentration. The surface tension of media 
prepared with SLS was influenced by the species present in the media. The larger the amounts 
of the ions present in the media, the greater its ionic strength. Blank FaSSIF-V2 has greater 
ionic strength (0.12 M) than Na-SIF (0.07 M), which is in agreement with the observation that 
buffer with greater ionic strength, will result in lower CMC but larger micellar size (297-299). 
This is due to the presence of electrolytes, which reduce the forces of electrostatic repulsion 
between the charged head groups at the micelle surface, thus allowing the micelle to grow 
(297). It is important to note that purity of the SLS will affect surface tension measurements. 
Crison et al. reported 10% difference in the intrinsic dissolution rate of CBZ when tested in 
two different grades of SLS purity: 95 and 99% (275). 
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 Figure 20.  Surface tensions of SIF and blank FaSSIF during SLS titration. [Arrows indicate CMC] 
Less surfactant was required in order to reach critical micelle concentration (CMC) of blank 
FaSSIF-V2. A CMC value of 0.0061 moles/L corresponding to 0.1751% of SLS has been 
obtained at a surface tension of 31.578 mN/m in SIF, whereas a CMC value of 0.0023 
moles/L calculated to be equivalent to 0.00678% of SLS was determined in blank FaSSIF-V2. 
After the addition of surfactant, both media resulted in surface tensions close to physiological 
values (33.6 mN/m). They were named MIM-I (Na-SIF + 0.2% SLS) and MIM-II (blank 
FaSSIF-V2 + 0.1% SLS). Due to the fact that concentrations of natural surfactants that are 
present in vivo are above CMC, amounts of SLS that were further used in MIM-I and MIM-II 
were rounded up to 0.2 and 0.1%, respectively. The final composition of modified media is 
presented in Table 38.  
Table 38. Composition of modified media (per 1L). 
Components (units) MGM MIM-I MIM-II 
Sodium chloride (mM) 34.2 - 68.62 
Hydrochloric acid (80, 323) 7 - - 
Sodium phosphate monobasic (mM) - 49.95 - 
Maleic acid (mM) - - 19.12 
Sodium hydroxide (mM) - 22.4 34.8 
SLS (mM) 0.35 6.94 (0.2%) 3.47 (0.1%) 
Water Up to volume Up to volume Up to volume 
pH 1.2 6.8 6.5 
Volume (L) 1 1 1 
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5.2.2 Buffer capacity studies 
The eexperimentally determined buffer capacity of Na-SIF (20 mmoL/L/pH) proved to be 
similar to the buffer capacity of SIF reported previously (18 mmoL/L/pH) (300). Zoeller and 
Klein claimed that buffer capacity of blank FaSSIF along with its pH and osmolality are not 
influenced by the presence of surfactant tested (299). This is also the case for Na-SIF 
containing SLS as surfactant, for which the buffer capacity value of 18 mmoL/L/pH has been 
determined.  
Buffer capacity is important for the performance of ionisable compounds and excipients (i.e. 
enteric coating) (301), as their solubility strongly depends on the pH of the medium. Failure 
to provide buffer capacity (i.e. water) allows random, uncontrollable changes of pH. HIF 
contain bicarbonates which are natural species responsible for providing buffer capacity in 
human GI fluids. It is challenging to reproduce the same conditions in vitro due to the 
increasing pH of bicarbonate buffers as a consequence of the loss of CO2 from solution (302). 
However, several scientists successfully characterised the dissolution of various formulations 
such as enteric coated tablets and modified-release and ionizable drugs using bicarbonate 
buffers (303-305). Moreover, Garbacz et al. developed the device called Physio-stat that helps 
maintain and regulate the pH of bicarbonate buffers (306). 
Buffer capacity of HIF in the fasted state has been reported to be 5.6 mmoL/L/pH, which is in 
agreement with previously reported by Moreno et al. (4-13 mmoL/L/pH) (307). Up to date 
biorelevant media attempts to mimic HIF closely. Although its buffer capacity is higher than 
HIF (FaSSIF: 12 mmoL/L/pH; FaSSIF-V2: 10 mmoL/L/pH this is still within the reported 








5.3 Particle size studies 
5.3.1 Carbamazepine case 
The particle-size distribution (PSD) of CBZ and its cocrystals were determined (Figure 21). 
The mean and standard deviation values are shown in Table 39. Particle-size distribution 
profiles of all formulations are presented in Appendix 6.  
 
 
Figure 21. Cumulative PSD of CBZ and its cocrystals. 
Table 39. Particle size of CBZ and its cocrystals. 
 D10 ± SD D50 ± SD D90 ± SD 
CBZ 9.08 ± 0.08 µm 30.86 ± 0.34 µm 60.09 ± 0.94 µm 
 
CBZ-SACss 1.56 ± 0.08 µm 7.38 ± 0.57 µm 38.42 ± 1.18 µm 
 
CBZ-SACumax 2.34 ± 0.04 µm 8.05 ± 0.15 µm 20.99 ± 0.25 µm 
 
CBZ-NICss 1.42 ± 0.12 µm 9.27 ± 0.81 µm 26.51 ± 0.88 µm 
 
 
As can be seen from Figure 21 and Table 39, the median particle size (D50) of CBZ was at 
least up to three times higher when comparing with its cocrystals. This indicates that both of 
the techniques: sonic-slurrying and UMAX that were used to obtain cocrystals could be used 
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to micronise an API to a certain extent. Reduction of particle size via micronisation results in 
an increased surface area which according to the Noyes-Whitney equation may enhance the 
dissolution (257). All cocrystals demonstrated to have similar D10 (1.4-2.3 µm) and median 
particle size values around 7-9 µm, which consequently could generate similar dissolution 
profiles. The scanning electron microscopy (SEM) pictures of CBZ-SACss and CBZ-NICss 
cocrystals reveal that based on visual observation these two cocrystals are different (Figure 
22) (65). Spherical particles of CBZ-SACss tend to create small agglomerates, while CBZ-
NICss cocrystals have needle-like shape with much longer dimensions. This could indicate 
that the laser diffraction is not the most appropriate technique to analyse these cocrystals. The 
findings based on laser diffraction do not discriminate between the particle sizes, which could 
be due to breaking needle - like CBZ-NICss particles during the sonication stage. According to 
the method described in section 4.4.5, all samples were sonicated prior to analysis in order to 
obtain primary particle size. Sonication is a very invasive technique that separates 
agglomerated particles apart, allowing measurement of their primary size. Too long a 
sonication process can break more fragile particles, resulting in a misleading interpretation. If 
this remark will be reliable, CBZ-SACss will result in faster dissolution profile due to smaller 











Figure 22. SEM images of a) CBZ-SACss and b) CBZ-NICss cocrystals (65). 
5.3.2 Indomethacin case 
The particle-size distribution of IND and its cocrystals was determined (Figure 23). The mean 
and standard deviation values are shown in Table 40. The particle-size distribution profiles of 
all formulations are presented in Appendix 6.  Particle-size distribution of IND and its 
cocrystals was determined using the wet dispersion method. The median diameter (D50: 9.30 
µm) indicates that the cocrystals with the smallest particle size were produced using sonic-
slurrying technique during preparation of CBZ-NICss. These particles are over two and a half 
fold smaller than those characterising INDsp (D50: 24.86 µm). On the other hand, cocrystals 
made by UMAX technology demonstrate the largest PSD (D50: 32.27 µm), which is even 
greater than the median value of INDsp. This could be due to the fact that UMAX process 
consists of three stages, two of which involve spray-drying. IND-SAC samples after first 
spray-drying step resulted in similar particle size that INDsp. However, a second spay-drying 
process increased the particle size further (D50: 32.27 µm). 
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 Figure 23. Cumulative PSD of IND and its cocrystals. 
 
Table 40. Particle size of CBZ and its cocrystals. 
 D10 ± SD D50 ± SD D90 ± SD 
IND 4.74 ± 0.04 µm 24.86 ± 0.13 µm 55.21 ± 0.74 µm 
IND-SACss 1.89 ± 0.01 µm 15.40 ± 0.14 µm 57.45 ± 0.62 µm 
IND-SACsd 3.27 ± 0.09 µm 22.63 ± 0.28 µm 49.59 ± 1.36 µm 
IND-SACumax 5.89 ± 0.10 µm 32.27 ± 1.81 µm 67.34 ± 3.63 µm 
IND-NICss 1.95 ± 0.04 µm 9.30 ± 0.05 µm 23.71 ± 0.41 µm 
 
5.4 Differential Scanning Calorimetry 
DSC studies were performed to confirm the cocrystal nature of the samples that were used in 
solubility and dissolution studies. DSC thermograms of the CBZ and its cocrystals are 
presented in Figure 24. The CBZsp showed an endotherm at ~160 ºC followed by another 
endotherm at ~192 ºC. These thermal events could be explained by the polymorphic 
transformation of form III (MP~174 ºC) to form I (MP~190 ºC) (73). This has been 
previously reported in the literature (73). Interestingly, commercial formulation of CBZ, 
Tegretol® tablets is formulated with the anhydrous monoclinic form (85).  Both CBZ-SACss 
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and CBZ-SACumax cocrystals exhibited a melting point of ~176 ºC (Figure 24 and Figure 25), 
which is in agreement with reported melting point range 172-177.5 ºC (308) for CBZ-SAC 
form I (312).  This value is lower than its pure components SAC (MP~212-229 ºC) (308) and 
CBZ form I (MP~192 ºC) (73). Similarly, NIC has been reported to have a sharp melting 
endothermic peak at ~113-130 ºC (73), while CBZ-NIC cocrystals showed a sharp melting 
peak at ~162 ºC, which is similar to values found in the literature (73) (Figure 25). Cocrystals 
have a melting point lower than for pure Carbamazepine. All data confirmed that samples that 
were further used for dissolution and solubility studies were cocrystals. 
 
    CBZsp 
  
 CBZ-SACss 






Figure 25. DSC thermograms of CBZ-SACumax and CBZ-NICss. 
DSC thermograms of pure components of IND and its cocrystals prepared by various methods 
are shown in Figure 26, Figure 27 and Figure 28. The thermogram of INDsp exhibited a 
melting peak at ~162 ºC, which is in agreement with literature (Figure 26) (77, 89). IND-SAC 
cocrystals that were prepared by either sonic-slurrying, UMAX or spray-drying methods were 
found to have melting peaks at ~185 ºC, which confirmed the presence of cocrystal forms 
(Figure 26 and Figure 27) (50, 77). Cocrystal of IND-NICss exhibited a melting point at ~128 











Figure 27. DSC thermograms of IND-SACsd and IND-SACumax. 
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5.5  Validation of chromatographic methods 
Adequate volumes of all solutions were injected into the system; sample chromatograms are 








Figure 29. Chromatograms of represented samples: a) CBZ in FaSSGF and b) IND in FaSSIF-V2. 
HPLC methods were developed to quantify the concentration of coformer dissolved from 
cocrystal. Retention times for SAC and NIC peaks were 3.8 and 1.9 minutes, respectively 
(Figure 30). The peaks appeared in the early onset of chromatograms and there was no 








Figure 30. Chromatograms of different samples: a) SAC in FaSSGF and b) NIC in FaSSGF. 
Linearity and range 
Linear calibration curves for CBZ and IND were obtained throughout the concentration 
ranges studied (Table 41). Linearity criteria imposed a correlation coefficient (R2) close to 
one. 




Linear regression equation R2 Linear regression equation R2 
SGF y = 159.03x + 11.418 1.00 y = 180.30x + 9.81 1.00 
SIF y = 159.67x + 247.81 1.00 y = 219.83x – 53.11 1.00 
MGM y = 159.08x + 245.49  1.00 y = 217.57x – 1.72 1.00 
MIM-I y = 158.92x + 390.13 1.00 y = 236.00x – 3.49 1.00 
MIM-II y = 159.41x + 285.07 1.00 y = 239.67x – 60.75 1.00 
FaSSGF y = 158.13x +459.83 1.00 y = 195.92x – 10.01 1.00 
FaSSIF-V2 y = 158.07 + 278.42 1.00 y = 233.43x – 59.07   1.00 
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Standard calibration curves of SAC and NIC in FaSSGF reflected good linearity (R2 =1) in 
the concentration range studied. The linear regression of SAC and NIC in FaSSGF produced 
equations y = 39.32x – 9.92 and y = 154.43x + 51.42, respectively.  
Precision, Limit of Quantification (LOQ) and Limit of detection (LOD) 
The precision of the HPLC methods was examined in 50 µg/ mL standards prepared in either 
SIF or FaSSGF media. Results showed that intra – day relative standard deviation were less 
than 1% (Table 42). The LOQ for CBZ, IND, SAC and NIC was found to be 5.32, 0.44, 2.34 
and 3.99 µg/ mL, respectively.   
Table 42. Summary of precision, LOQ and LOD values. 
 CBZ IND SAC NIC 
Precison [% RSD] 0.59 0.66 0.98 0.48 
LOQ [µg/ mL] 5.32 0.44 2.34 3.99 
LOD [µg/ mL] 1.60 0.13 0.70 1.20 
 
5.6 Solubility Studies 
5.6.1 Carbamazepine case 
The solubility results for the CBZsp and its cocrystals are shown in Figure 31. 
 
Figure 31. Solubility values (± SD) of CBZsp in different media. 
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There is a statistically significant (p < 0.05) enhancement in solubility for all CBZ 
formulations tested in FaSSGF in comparison to compendial SGF.  Although, it can be noted 
that CBZ-SACss is slightly less soluble in FaSSGF than in SGF, according to ANOVA this 
result is not of statistical significance (p = 1) (Appendix 7). It has been reported that CBZ 
behaves as a neutral compound at physiological pH (pKa = 11.83) (82). Despite that 
biorelevant media simulating intestinal conditions (FaSSIF-V2) enhance the solubility of all 
CBZ formulations when compared to compendial SIF, the media simulating gastric conditions 
provided greater enhancement of solubility than those simulating intestinal conditions. As can 
be noted from Figure 31, the cocrystals made by sonic-slurry (CBZ-SACss and CBZ-NICss) 
did not enhance the solubility of CBZ. Some enhancement was observed for CBZ-SAC 
cocrystals made by UMAX technology.  
Similar results were reported for solubility studies of CBZ, CBZ-SAC and CBZ-NIC 
cocrystals that were performed for 72 hours at 37 °C (74). Both cocrystals were prepared by 
cooling crystallisation technique (Table 43). These cocrystals did not enhance the solubility 
but they proved to be more stable than CBZ against transformation to dihydrate form (72, 
308). 
Table 43. Solubility data of CBZ (73, 308). 
 Solubility of CBZ [mg/mL] 
HCl buffer (pH 1.2) Acetate buffer (pH 4.5) Phosphate buffer (pH 6.8) 
CBZ 0.243 ± 0.026 0.243 ± 0.014 0.238 ± 0.023 
CBZ-SAC 0.246 ± 0.013 0.250 ± 0.004 0.235 ± 0.011 
CBZ-NIC 0.236 ± 0.008 0.237 ± 0.002 0.234 ± 0.010 
 
5.6.2 Indomethacin case 
5.6.2.1 Solubility over time studies 
Solubility profiles of IND and its SAC and NIC cocrystals (made by sonic-slurry method) 
over time were determined (Figure 32 and Figure 33). There was no visible indication of the 
spring and parachute effect. Some of the researchers claim that spring and parachute concept 
can be explain the phenomena by which cocrystals enhance solubility and dissolution (309). 
According to this concept, cocrystal dissociate to amorphous or noncrystalline drug clusters 
(the spring), which transform via fast-dissolving metastable polymorphs to the insoluble 
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crystalline modification to give high solubility for cocrystals and optimal drug concentration 
(the parachute) in the aqueous medium (309). Spring and parachute effect can last from few 
minutes to hours. So there is a risk of omitting the solubility enhancement when measuring 
saturation solubility at the equilibrium 
The initial solubility values were measured at five minutes. Thus, there is a possibility that the 
spring and parachute phenomena might have occurred before five minutes. The high 
variability in concentrations at different time points was due to the fact that the solubility 
equilibrium has not been reached yet. There were no samples collected between 240 and 1440 
minutes, neither after 1440 minutes. Based on these data, it is difficult to make the decision 
on the definite equilibrium time points. 24 hour (1440 minutes) time point was treated as 
solubility equilibrium, as it was noticed that in samples which were left longer than 24 hours, 
needle-shaped crystals were observed. This could indicate that anhydrous form of 




Figure 32. Solubility of IND values (± SD) over the time in SIF. 
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 Figure 33. Solubility of IND values (± SD) over the time in FaSSIF-V2. 
5.6.2.2 Saturation solubility studies 
Due to the fact that IND has pH-dependent solubility (pKa 4.42) the solubility data are 
presented on two separate graphs to ease the observation. IND has a very low solubility when 
the compound is in its un-ionised form at pH < 3.4 (Figure 34). Despite that IND and its 
cocrystals are poorly soluble in acidic conditions (SGF and FaSSGF) (< 0.03 mg/mL), 2 to 10 
folds enhancement in solubility can be observed when solubility of IND is measured from its 
cocrystal form. Higher solubility values observed in acetate buffer pH 4.5 are due to the fact 
that at this pH IND is 50% in its ionised form. When the pH exceed pH 5.4 (one unit above 
pKa) the IND is fully ionised and reaches maximum solubility (Figure 35). Interestingly, 
solubility of all IND formulations is lower in FaSSIF than in SIF despite the presence of bile 
salts. Despite the decrease in solubility in the presence of bile salts, there is still a clear trend 
visible, that cocrystallisation with Nicotinamide enhances the solubility of IND the most (up 
to three times). 
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 Figure 34. Solubility values (± SD) of IND in SGF, FaSSGF-V2 and acetate media. 
 
Figure 35. Solubility values (± SD) of IND in SIF and FaSSIF-V2. 
 
Nokhodchi reported slightly higher saturated solubility of IND in SGF (0.004 mg/mL) and 
SIF (0.768 mg/mL) (310). The discrepancies could be due to differences in methodology 
(25°C, 72 h). Solubility of IND cocrystals was well studied in organic solvents (71) but up to 
now little was known about the solubility of IND cocrystals in compendial and biorelevant 
media.  
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5.7  In vitro dissolution studies 
Initial experiments were performed using USP apparatus 1. Dissolution profiles of all of the 
formulations of CBZ and IND tested using USP Apparatus 4 were tested in four different sets 
of media: compendia SGF/SIF, modified MGM/MIM-I and MGM/MIM-II and biorelevant 
FaSSGF/FaSSIF-V2. Data collected for each formulation were interpreted, compiled and 
presented as cumulative percentage dissolved versus time.  
5.7.1 Carbamazepine case 
5.7.1.1 Dissolution studies using USP apparatus 1 
Dissolution of CBZ from Tegretol® tablets in SGF was incomplete using the USP apparatus 1 
(Figure 36). Only 50% of the drug dissolved after four hours of experiment. This is due to the 
fact that 500 mL of medium in USP apparatus 1 did not provide sink conditions for 200 mg of 
poorly soluble drug. The volume of 500 mL of medium was selected to be more 
physiologically relevant than 900 mL.  In order to provide at least three times sink condition, 
dissolution should be performed using 3 L of medium. Dissolution of CBZ from Tegretol® 
tablets was much faster than those from CBZsp capsules due to the presence of various 
excipients such as diluents and disintegrants in the Tegretol® formulation. The dissolution of 
both CBZ-SACss and CBZ-NICss cocrystals capsules was much slower than the performance 
of CBZsp capsules and Tegretol® tablets. This can be explained by the over-compaction of 
cocrystal powder in size 0 capsule. The compaction forces were greater in CBZ-NICss 
capsules, as in order to fill in equivalent to 200 mg of CBZ, 303 mg of CBZ-NICss needs to be 
packed in size 0 capsule. It was observed that it was more challenging to fill the capsule with 
303 mg of CBZ-NICss cocrystal than with 355 mg of CBZ-SACss sample. This is potentially 
due to the differences in powder density of these two samples (Table 44) (308, 73).  
 
Table 44. Summary of cocrystal powder densities values found in literature (73, 308). 
 CBZ (74) CBZ-SAC (312) CBZ-NIC (74)  
True density [g/cm3] 1.381 1.441 1.337 
Bulk density [g/cm3] 0.452 0.592 0.174 
Tapped density [g/cm3] 0.782 0.790 0.292 
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According to the tapped density values (Table 44), it would be much harder to compress 
CBZ-NIC (the lowest tapped density) powder than CBZ and CBZ-SAC cocrystal into the 
same size of capsule. The lowest tapped density value of 0.292 g/cm3 indicates that CBZ-NIC 
cocrystals have a shape of needles. These findings are in agreement with SEM findings (65).  
 
Figure 36. Mean % dissolved (± SD) of different CBZ formulations in SGF using USP apparatus 1. 
Similar dissolution behaviour of CBZ was observed for Tegretol® tablets and CBZ capsules 
tested in SIF using the USP apparatus 1 (Figure 37). Similarity between profiles in SGF and 
SIF (Tegretol® in SGF vs SIF; f1, area: 0.09; CBZsp in SGF vs SIF; f1, area: 0.13) is attributed to 
the solubility of CBZ in both media (SGF: 0.251 mg/mL; SIF: 0.250 mg/mL). Failure of 
providing sink conditions and problematic encapsulation of samples makes continuation of 
dissolution studies using USP apparatus 1 debatable. Further studies were performed using 
USP apparatus 4 dissolution system, which allows testing powder samples and provides sink 
condition for poorly soluble CBZ formulations. 
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 Figure 37. Mean % dissolved (± SD) of different CBZ formulations in SIF using USP apparatus 1. 
Various dissolution profiles have been reported for 200 mg Tegretol® tablets (315). Due to the 
fact that different specifications were used to obtain that data (USP apparatus type, rpm, 
media type and volume) further direct comparison of data was not achievable. 
Dissolution of CBZ-SAC cocrystals (made by cooling crystalisation) tested using USP 
apparatus 2 has been reported (100 rpm, 37 °C) (308). CBZ-SAC sample was sieved into 
different particle size (50, 150, 300, 500 and 1000 µm) and encapsulated into a gelatin 
capsule. In order to provide sink conditions, formulations were tested in 900 mL of SGF 
containing Triton – X as a surfactant. Results indicated that CBZ-SAC cocrystal samples with 
the particle size smaller than 150 µm demonstrated the fastest dissolution profiles due to 
increased surface area. Dissolution performance of cocrystal was strongly dependent on the 
particle size of the cocrystal tested.  
5.7.1.2 Dissolution studies using USP apparatus 4 
5.7.1.2.1   Effect of MCC on CBZ dissolution  
As CBZ cocrystals samples exhibit static properties, the decision of adding MCC to all CBZ 
(CBZsp, CBZ-SAC (ss and umax) and CBZ-NICss) samples was made. MCC is the major diluent 
in CBZ commercial formulation Tegretol®. Different grades of MCC were investigated 
varying in particle size from 20 µm (PH 105), 100 µm (PH 302), to 180 µm (PH 200). 
Approximately 70% of the CBZ was dissolved from CBZ-MCC formulations within two 
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hours of the experiment (Figure 38). According to f1, area (Table 45) there was no statistical 
difference between dissolution profiles after blending with any grade of MCC when compared 
with the CBZ dissolution profile. For further studies, all CBZ samples were blended with the 
medium size of MCC (PH 302). Small variability (%CV < 7.2) was observed for the 
dissolution of these formulations.  
 
Figure 38. Mean % dissolved (± SD) of CBZ from different CBZsp-MCC formulations in SGF (8mL/min; 1h) 
and SIF (4mL/min; 1hr) using USP apparatus 4. [Red arrow indicates media change].  
Table 45. Summary of f1, area values comparing dissolution profiles of CBZsp-MCC in various media. 
 
CBZ (as reference) 
CBZ-MCC grade 
PH-105 PH-200 PH-302 
f1, area 0.01 0.05 0.05 
 
Despite that all CBZ samples (CBZsp, CBZ-SACss, CBZ-SACumax, CBZ-NICss) were blended 






5.7.1.2.2     Dissolution studies of commercial formulations 
Carbamazepine commercial formulations available in UK are known under its brand name 
Tegretol® and have been manufactured by Novartis since 1965. Tegretol® is available for oral 
administration as chewable tablets of 100 mg and 200 mg, liquid of 100 mg/ 5mL, immediate 
release tablets of 100 mg, 200 mg and 400 mg and prolonged release tablets of 200 mg and 
400 mg (formerly known as Tegretol® retard). It is also available for rectal administration as 
suppositories of 125 mg and 250 mg. Dissolution profiles of  CBZ from 200 mg Tegretol® IR 
tablets and 400 mg Prolonged Release Tegretol® tablets were tested using USP apparatus 4. 
5.7.1.2.2.1 Tegretol® IR tablets 
Dissolution profiles of Tegretol® IR formulations in various media are presented in Figure 39. 
Based on the f1, area values (Table 46) dissolution profiles in both modified and biorelevant 
media are significantly different when compared with compendial media (SGF/SIF). The 
greatest increment by 1.5 fold occurred in biorelevant media (f1, area: 1.46) due to the presence 
of bile salts. It is known that biorelevant media contain mixed micelles as opposed to single 
type of SLS micelles present in modified media (299). Distinctive nature of the micelles has 
different effect on the dissolution of poorly soluble compounds. The mixed surfactant systems 
(ionic & non-ionic) show synergetic behaviour and thus the total quantity of surfactant 
required for the same performance is smaller (312). 
 
Figure 39. Mean % dissolved (± SD) of CBZ from 200 mg Tegretol® IR tablets in various media using USP 
apparatus 4. [Red arrow indicates media change]. 
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 (as reference) 
Tegretol® tablets 
MGM/MIM-I MGM/MIM-II FaSSGF/FaSSIF-V2 
f1, area 0.15 0.18 1.46 
 
Recently, Medina et al. published dissolution studies of Tegretol® IR formulation using USP 
apparatus 4 (313). It has been reported that 80% of CBZ was released from the tablet within 
60 minutes. Although different flow rate (16 mL/min) and media (1% SLS) were used during 
this investigation.  
According to the AIC and R2 values which both indicate the best model and its goodness of 
fit, the dissolution kinetics of CBZ from 200 mg Tegretol® IR tablets can be best described 
using 3-parameter Weibull function (Table 47).  Based on β parameter that reflects the shape 
of the dissolution curve, three of the dissolution profiles (in compendial and both of modified 
media) have a parabolic shape (β < 1), whereas dissolution profile in biorelevant media is 
more characterised by S-shape (β > 1). Weibull function is purely mathematical equation that 
does not have any physiological meaning.  
All dissolution profiles obtained for 200 mg Tegretol® IR tablets follows first-order kinetics. 









Table 47. Dissolution kinetic parameters (± SD) of 200 mg Tegretol® IR tablets. 
Parameters Zero-order kinetics 
SGF/SIF MGM/MIM-I MGM/MIM-II FaSSGF/FaSSIF-V2 
k0 [h-1] 10.70 ± 1.50 11.39 ± 0.39 12.49 ± 0.58 26.51 ± 0.60 
R2 0.84 ± 0.08 0.17 ± 0.19 0.71 ± 0.08 0.79 ± 0.05 
AIC 151.71 ± 18.01 186.33 ± 2.80 171.61 ± 3.23 205.98 ± 7.01 
                              First-order kinetics 
Wmax [%] 42.16 ± 4.27 33.40 ± 2.12 43.45 ± 4.83 96.99  ±  3.25 
k1 [h-1] 0.49 ± 0.13 1.26  ± 0.20 0.65 ± 0.10 0.56 ± 0.07 
R2 1.00 ± 0.00 0.97 ± 0.02  0.99 ± 0.00 0.99 ± 0.00 
AIC 55.52 ± 13.71 97. 95 ± 15.45 83.46 ± 5.99 117 ± 20.03 
                      3-parameter Weibull  function 
Wmax [%] 67.60 ± 43.47 37.10 ± 2.03 50.30 ± 4.02 87.52 ± 4.20 
α  [h] 4.01 ± 3.71 1.03 ± 0.14 1.88 ± 0.21 1.61 ± 0.22 
β 0.89 ± 0.14 0.73 ± 0.10 0.82 ± 0.07 1.25 ± 0.13 
R2 1.00 ± 0.00 0.99 ± 0.01 1.00 ± 0.00 1.00 ± 0.00 
AIC 36.89 ± 23.07 83.82 ± 15.18 65.72 ± 19.52 74.63 ± 7.69 
 
5.7.1.2.2.2 Tegretol® PR tablets 
Prolonged and extended release formulations tend to benefit from partial absorption from the 
colon. Thus, exposure to media that simulate colonic environment is essential. Release rate of 
CBZ from 400 mg Tegretol® PR formulation was tested in either compendial media 
(SGF/SIF/SCoF), biorelevant media (FaSSGF/FaSSIF-V2/FaSSCoF) or mixed 
biorelevant/compendial media (FaSSGF/FaSSIF-V2/SCoF) (Figure 40). CBZ from prolonged 
release formulation of Tegretol® dissolved in a well-controlled manner, regardless the type of 
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medium selected for the experiment. There is no significant difference (f1, area: 0.11) between 
the dissolution profile in compendial media (SGF/SIF/SCoF) and in FaSSGF/FaSSIF-
V2/SCoF (Table 48). Interestingly, no significant difference (f1, area: 0.05) was observed 
between two dissolution profiles that both used biorelevant media for the first five hours and 
then used either SCoF or FaSSCoF as media.  
 
Figure 40. Mean % dissolved (± SD) of CBZ from 400 mg Tegretol® PR tablets in various media using USP 
apparatus 4. [Red arrows indicate media change]. 
 




 (as reference) 
Tegretol® PR tablets 
FaSSGF/FaSSIF-V2/SCoF FaSSGF/FaSSIF-V2 
f1, area 0.09 0.11 
 
According to Table 49 release of CBZ from 400 mg Tegretol® PR tablets can be best 
described by first-order kinetics, dissolution constant indicates that the dissolution profile in 




Table 49. Dissolution kinetic parameters (± SD) of 400 mg Tegretol® PR tablets. 
Parameters Zero-order kinetics 
 SGF/SIF/SCoF FaSSGF/FaSSIF-V2/SCoF FaSSGF/FaSSIF-V2/FaSSCoF 
k0 [h-1] 9.47 ± 0.31 10.42 ± 0.12 10.60 ± 0.03 
R2 0.88 ± 0.03 0.93 ± 0.01 0.94 ± 0.00 
AIC 308.74 ± 6.20 301.77 ± 2.48 296.78 ± 2.18 
                             First-order kinetics 
Wmax [%] 69.92 ± 6.65 86.06 ± 2.56 92.29 ± 1.94 
k1 [h-1] 0.24 ± 0.03 0.19 ± 0.01 0.18 ± 0.01 
R2 1.00 ± 0.00 1.00 ± 0.00 1.00 ± 0.00 
AIC 150.71 ± 2.27 67.82 ± 9.74 42.33 ± 3.56 
                             3-parameter Weibull function 
Wmax [%] 93.80 ± 14.84 94. 51 ± 1.96 97.87 ± 2.11 
α  [h] 5.44 ± 0.99 5.63 ± 0.17 5.98 ± 0.19 
β 0.84 ± 0.01 0.95 ± 0.01 0.97 ± 0.00 
R2 1.00 ± 0.00 1.00 ± 0.00 1.00 ± 0.00 







5.7.1.2.3    CBZsp and pharmaceutical cocrystals 
Carbamazepine cocrystals were tested under the same conditions as Tegretol® commercial 
formulations. CBZsp samples were used as a control formulation.  
5.7.1.2.3.1 CBZsp samples 
Dissolution profiles of CBZsp samples in different media are presented in Figure 41. 
Dissolution of CBZsp in compendial media (SGF/SIF) was initially faster (until first hour) 
than in all the other media and then slowed down after the media change and resulted in 
overall first-order kinetics (Table 51). On the other hand, dissolution profiles obtained in 
media containing surfactants or bile salts can be closely characterised using overall zero-order 
kinetics (Table 51).  This demonstrates that the dissolution kinetics has been altered by the 
presence of surfactant.  f1, area allows distinguishing between the profiles (Table 50). There 
was statistically significant difference (f1, area: 0.32) in the dissolution profile of CBZsp in 
MGM/MIM-I when compared with its performance in compendial media. 
 
Figure 41.  Mean % dissolved (± SD) of CBZsp in various media using USP apparatus 4. [Red arrow indicates 






Table 50. Summary of f1, area values comparing dissolution profiles of CBZsp in various media. 
 
SGF/SIF 
 (as reference) 
CBZsp 
MGM/MIM-I MGM/MIM-II FaSSGF/FaSSIF-V2 
f1, area 0.32 0.12 0.19 
 
Table 51. Dissolution kinetic parameters (± SD) of CBZsp profiles. 
Parameters Zero-order kinetic 
SGF/SIF MGM/MIM-I MGM/MIM-II FaSSGF/FaSSIF-V2 
k0 [h-1] 12.664 ±  2.33 8.13  ± 2.68 11.68 ±1.47 14.80 ± 2.66 
R2 0.59 ± 0.09 0.98 ± 0.01 0.88 ± 0.04 0.98 ± 0.02 
AIC 179.61 ± 10.46 92.88 ± 18.22 149.90 ± 13.13 119.26 ± 12.13 
                              First-order kinetics 
Wmax [%] 40.59 ± 7.73 - 49.49 ± 1.64 - 
k1 [h-1] 0.83 ± 0.10 - 0.41 ± 0.07 - 
R2 0.99 ± 0.00 - 0.99 ± 0.00 - 
AIC 81.91 ± 6.13 - 86.14 ± 9.65 - 
                                        3-parameter Weibull  function 
Wmax [%] 43.79 ± 8.77 - - - 
α  [h] 1.37 ± 0.18 - - - 
β 0.86 ± 0.01 - - - 
R2 0.99 ± 0.00 - - - 




5.7.1.2.3.2 CBZ-SACss samples 
Dissolution profiles of CBZ-SACss cocrystal samples tested in various media are presented in 
Figure 42. According to Figure 42, micelles that are present in both modified as well as 
biorelevant media significantly enhance the dissolution of CBZ-SACss (Table 52). The 
performance of CBZ-SACss in MGM/MIM-I was similar to that in biorelevant media (f1, area: 
0.04). All the dissolution profiles follow first-order dissolution kinetics (Table 53).  
 
Figure 42. Mean % dissolved (± SD) of CBZ from CBZ-SACss in various media using USP apparatus 4. [Red 
arrow indicates media change]. 
 
Table 52. Summary of f1, area values comparing dissolution profiles of CBZ-SACss in various media. 
 
SGF/SIF 
 (as reference) 
CBZ-SACss 
MGM/MIM-I MGM/MIM-II FaSSGF/FaSSIF-V2 
f1, area 0.35 0.28 0.32 
 
According to 3-parameters Weibull function, dissolution of CBZ from CBZ-SACss in 
MGM/MIM-II and biorelevant media has more parabolic (β < 1) shape, whereas dissolution 
profiles in compendial and MGM/MIM-II has sigmoidal shape (β > 1). 
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Table 53. Dissolution kinetic parameters (± SD) of CBZ-SACss profiles. 
Parameters Zero-order kinetics 
SGF/SIF MGM/MIM-I MGM/MIM-II FaSSGF/FaSSIF-V2 
k0 [h-1] 17.70 ± 1.05 24.78 ± 0.42 22.63 ± 0.65 24.68 ± 0.90 
R2 0.46 ± 0.04 0.74 ± 0.08 0.48 ± 0.07 0.85 ± 0.07 
AIC 203.89 ± 1.73 205.37 ± 6.15 214.17 ± 2.65 191.85 ± 9.83 
                              First-order kinetics 
Wmax [%] 54.43 ± 29.36 86.54 ± 3.29 70.01 ± 2.85 99.84 ±  12.24 
k1 [h-1] 0.97 ± 29.37 0.64 ± 0.10 0.95 ± 0.08 0.47 ± 0.12 
R2 0.99 ± 0.00 1.00 ± 0.00 0.99 ± 0.00 1.00 ± 0.00 
AIC 107.59 ± 58.40 97.54 ± 9.38 112.41 ± 4.81 44.82 ± 8.91 
                                   3-parameter Weibull  function 
Wmax [%] 52.97 ± 3.57 85.50 ± 7.28 71.63 ± 3.97 104.23 ± 16.18 
α  [h]  0.97 ± 0.05 1.57 ± 0.32 1.11 ± 0.12 2.34 ± 0.63 
β 1.12 ± 0.04 1.02 ± 46.30 0.94 ± 0.03 0.97 ± 0.02 
R2  0.99 ± 0.00 1.00 ± 0.00 0.99 ± 0.00 1.00 ± 0.00 
AIC 105.60 ± 0.91 91.74 ± 50.09 112.32 ± 6.67 36.94 ± 15.87 
 
5.7.1.2.3.3 CBZ-SACumax samples 
Dissolution performance of CBZ-SACumax cocrystals was determined in various media and 
shown in Figure 43. Dissolution profiles in all media were much faster than in compendial 
media (Table 54).  It seems that cocrystals produced by UMAX technique were more affected 
by sodium lauryl sulphate (SLS) surfactant present in modified media (MGM/MIM-I and 
MGM/MIM-I). It is also worth noting that dissolution profiles of all CBZ formulations in 
SGF and FaSSGF (up to the first hour) were similar. In this case dissolution of CBZ from 
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CBZ-SACumax in MGM is much faster than in SGF and FaSSGF. Based on the AIC and R2 
values (Table 55), dissolution of CBZ from CBZ-SAC cocrystals made by UMAX methods 
follows first-order kinetics and kinetic pattern is not affected by the presence of single or 
mixed micelles. The presence of both types of micelles enhances drug solubilisation. 
 
Figure 43. Mean % dissolved (± SD) of CBZ from CBZ-SACumax in various media using USP apparatus 4. [Red 
arrow indicates media change]. 
Table 54. Summary of f1, area values comparing dissolution profiles of CBZ-SACumax in various media. 
 
SGF/SIF 
 (as reference) 
CBZ-SACumax 
MGM/MIM-I MGM/MIM-II FaSSGF/FaSSIF-V2 









Table 55. Dissolution kinetic parameters (± SD) of CBZ-SACumax profiles. 
Parameters Zero-order kinetics 
SGF/SIF MGM/MIM-I MGM/MIM-II FaSSGF/FaSSIF-V2 
k0 [h-1] 15.43 ± 0.99 27.09 ± 2.22 29.56 ± 0.38 19.36 ± 0.57 
R2 0.68 ± 0.12 0.68 ± 0.06 0.58 ± 0.07 0.86 ± 0.02 
AIC 184.92 ± 4.49 214.19 ± 9.07 224.65 ± 3.70 181.02 ± 3.40 
                              First-order kinetics 
Wmax [%] 52.30 ± 6.78 90.18 ± 4.29 94.04 ± 1.56 76.87 ± 3.40 
k1 [h-1] 0.71 ± 0.15 0.72 ± 0.08 0.85 ± 0.08 0.47 ± 0.03 
R2 0.99 ± 0.00 0.99 ± 0.00 0.99 ± 0.00 0.99 ± 0.00 
AIC 88.46 ± 8.91 128.51 129.16 ± 7.60 116.80 ± 1.78 
                                3-parameter Weibull  function 
Wmax [%] 53.91 ± 7.76 96.52 ± 5.72 92.71 ± 2.70 102.84 ± 21.34 
α  [h] 1.50 ± 0.33 1.45 ± 0.26 1.16 ± 0.13 3.03 ± 0.81 
β 0.95 ± 0.04 0.96 ± 0.18 1.05 ± 0.06 0.85 ± 0.09 
R2 0.99 ± 0.00 0.99 ± 0.00 0.99 ± 0.00 0.99 ± 0.00 
AIC 88.17 ± 12.35 118.13 ± 14.81 129.69 ± 6.88 111.50 ± 4.52 
 
5.7.1.2.3.4 CBZ-NICss samples 
Dissolution profiles of CBZ from CBZ-NICss cocrystals in different media tested using USP 
apparatus 4 are presented in Figure 44. Dissolution of CBZ from CBZ-NICss cocrystal in both 
modified and biorelevant media follows zero-order kinetics (Table 57), while samples tested 
in modified media had sigmoidal shape curves (“S” curve), as a consequence of extensive 
enhancement  of dissolution  in modified media. This enhancement could be attributed to the 
solubilisation properties of NIC.  Nicotinamide is a well known hydrotrope, that is able to 
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solubilise hydrophobic compounds in aqueous solution (314). However, the amounts of NIC 
released from CBZ-NICss cocrystal were insufficient to provide solubilisation effect. Hence, 
the presence of SLS in the media assured the synergetic effect. Generally, Weibull function 
can be used to characterise dissolution kinetics of sigmoidal shape profiles. Unfortunately, 
fittings resulted in insufficient parameters. For instance Wmax exceeded extensively 100% 
despite the attempt of setting it to optimal 100%.   
 
Figure 44. Mean % dissolved (± SD) of CBZ from CBZ-NICss in various media using USP apparatus 4. [Red 
arrow indicates media change]. 
 
Table 56. Summary of f1, area values comparing dissolution profiles of CBZ-NICss in various media. 
 
SGF/SIF 
 (as reference) 
CBZ-NICss 
MGM/MIM-I MGM/MIM-II FaSSGF/FaSSIF-V2 







Table 57. Dissolution kinetic parameters (± SD) of CBZ-NICss profiles. 
Parameters Zero-order kinetics 
SGF/SIF MGM/MIM-I MGM/MIM-II FaSSGF/FaSSIF-V2 
k0 [h-1] 13.05 ± 2.24 24.17 ± 1.76 22.74 ± 1.40 15.30 ± 1.38 
R2 0.82 ± 0.01 0.96 ± 0.01 0.98 ± 0.01 0.97 ± 0.02 
AIC 164.00 ± 9.21 176.89 ± 2.91 137.38 ± 17.86 132.63 ± 9.49 
                              First-order kinetics 
Wmax [%]  49.32 ± 9.88 - - - 
k1 [h-1]  0.51 ± 0.03 - - - 
R2 0.99 ± 0.00 - - - 
AIC 89.65 ± 5.98 - - - 
                               3-parameter Weibull  function 
Wmax [%] - 96.96 ± 3.74 - - 
α  [h] - 8.20 ± 1.11 - - 
β - 2.26 ± 0.01 - - 
R2 - 1.00 ± 0.00 - - 
AIC - 125.27 ± 4.94 - - 
 
5.7.1.2.4 Effect of type of coformer 
Dissolution profiles of CBZsp, CBZ-SACss and CBZ-NICss in biorelevant media were studied 
in order to verify the effect of the coformer type on the enhancement of dissolution (Figure 
45). CBZ-SACss cocrystal demonstrated a significant enhancement of dissolution of CBZ (f1, 
area: 0.75).  
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 Figure 45. Mean % dissolved (± SD) of CBZ from cocrystals made by sonic-slurrying method and tested in 
biorelevant media using USP apparatus 4. CBZsp samples were used as control. [Red arrow indicates media 
change]. 
Interestingly, the formulation of CBZ-NICss had no statistically significant effect on 
dissolution of CBZ (f1, area: 0.05). NIC due to its hydrotropic properties should have a 
synergetic effect with mixed micelles from biorelevant media and enhance dissolution of 
CBZ. There may be a few potential justifications. It could be that in comparison to high doses 
of CBZ (200 mg), the amount of NIC (103 mg) in cocrystal might not be sufficient to produce 
micelles. Also, NIC which is a highly soluble compound (1000 mg/mL) (74) could dissolve 
very quickly during the initial sample collection time, thus the synergetic effect could never 
be triggered. CBZ-SAC cocrystal made by sonic-slurrying method resulted in significant 
enhancement in CBZ dissolution (f1, area: 0.75). 
5.7.1.2.5 Effect of method of preparation 
Dissolution profiles of CBZ-SACss and CBZ-SACumax in biorelevant media were compared 
against dissolution of CBZsp samples in order to assess which cocrystallisation method 
resulted in the highest improvement of dissolution (Figure 46). f1, area values indicate that both 
SAC cocrystals significantly improved dissolution of poorly soluble CBZ. SAC cocrystals 
made by sonic-slurrying method resulted in two-fold higher dissolution (f1, area: 0.75) than 
cocrystals made using UMAX technology (f1, area: 0.37) when compared against dissolution of 
CBZsp samples. It can be clearly noted from Figure 46, that cocrystallisation reduces the 
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variability (%CV: CBZsp < 22%; CBZ-SACss < 14%; CBZ-SACumax < 11%) between 
individual dissolution curves.  
 
Figure 46. Mean % dissolved (± SD) of CBZ from CBZ-SAC cocrystals made by different cocrystallisation 
methods and tested in biorelevant media using USP apparatus 4. CBZsp samples were used as a control. [Red 
arrow indicates media change]. 
5.7.1.2.6 Effect of cocrystal and its mechanism of dissolution 
5.7.1.2.6.1 Saccharin types of CBZ cocrystals 
The aim of this study was to evaluate if the improvement in dissolution rate of CBZ was due 
to the cocrystal formation. Dissolution of CBZ from a physical blend made of CBZ and SAC 
tested in biorelevant media was compared to the dissolution of CBZ from CBZ-SAC 
cocrystals (Figure 47).  It was found that physical blends of CBZ and SAC (CBZ--SAC) 
significantly enhanced dissolution of CBZ (Table 58). Nevertheless, CBZ-SAC cocrystal 
made by sonic-slurrying method enhances dissolution of CBZ the most (f1, area: 0.75). f1, area 
between blend (CBZ--SAC) and CBZ-SACumax cocrystal indicate that dissolution 
performance of this cocrystal is as good as the blend (f1, area: 0.09). Thus, only 
cocrystallisation by sonic-slurrying proved to make a complex compound that enhanced 
dissolution better than the physical mixture of the two components.  
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 Figure 47. Mean % dissolved (± SD) of CBZ from different CBZ-SAC formulations in biorelevant media. 
Dissolution of CBZsp was used as a control. [Red arrow indicates media change]. 
 
Table 58. Summary of f1, area values comparing dissolution profiles of different CBZ-SAC formulations in 
biorelevant media. 
 
CBZsp (as reference) 
FaSSGF/FaSSIF-V2 
CBZ—SAC CBZ-SACss CBZ-SACumax 
f1, area 0.42 0.75 0.34 
 
Gao et al. reported that cocrystallisation of BCS class III drug; Adefovir dipivoxil with 
Saccharin greatly enhanced the dissolution of Adefovir dipivoxil when compared with its 
physical mixture and API (315). Dissolution studies were performed in 500 mL of either 
0.1M HCl, water or phosphate buffer pH 6.8 at 50 rpm using USP 2 dissolution apparatus. 
The data in 0.1M HCl were inconclusive as API is highly soluble in this pH and all drug 
dissolved within 5 minutes. Dissolution of cocrystal in pH 6.8 was significantly faster that it’s 
API (f1: 223.06). According to difference factor (f1: 10.74) there was not a statistically 
significant difference between dissolution profiles of API and physical blend in this buffer 
(315). It was concluded that the enhancement in dissolution was due to the fact that 
cocrystallisation with Saccharin changed crystal packing and arrangement, which favoured 
the dissolution of Adefovir dipivoxil.  
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Further investigation, during which the dissolution of SAC from cocrystals was measured 
simultaneously with dissolution of CBZ, showed that SAC from CBZ-SACss cocrystal was 
dissolving at a slower rate than SAC from the physical blend (Figure 48), despite the fact that 
both SAC dissolved within the first 90 minutes of the experiment.  This could be attributed to 
the fact that, upon contact with water, weak hydrogen bonds between hydrophobic CBZ and 
the highly soluble coformer SAC in cocrystal break down immediately. 
 
Figure 48. Mean % dissolved (± SD) of SAC from CBZ-SACss cocrystal and physical blend formulations. [Red 
arrow indicates media change]. 
Dissolution of SAC from the cocrystal form follows a zero-order kinetics pattern (in both 
media separately) and it is slower than that from the physical blend (first-order kinetics 
observed in both media). The observed differences on dissolution can be related to the 
solubility properties of the coformer used (SAC- 3.45 mg/mL). The larger undissolved 
amounts of SAC from the cocrystal were available for water to dissolve (controlled and 
continuous access of the dissolution medium around the drug molecule) and thus allowing 
water to penetrate between poorly soluble CBZ at the same time, leading to dissolution 
enhancement of CBZ (Figure 48).  
The findings that the same ratio of API and coformer formed as cocrystal or physical blend 
can lead to different dissolution performance leads to the conclusion that crystal packing and 
arrangement in these two formulations are different and play an important role in 
enhancement of dissolution of poorly soluble compounds by cocrystallisation.  
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5.7.1.2.6.2 Nicotinamide type of CBZ cocrystals 
Dissolution of CBZ from CBZ-NICss cocrystal and physical blend (CBZ--NIC) in biorelevant 
media was studied using USP apparatus 4 and compared against the CBZsp sample (Figure 
49). The dissolution performance of CBZ-NICss did not result in any changes (f1, area: 0.05) 
compared to CBZsp dissolution characteristics. On the other hand, the physical blend of CBZ 
and NIC resulted in significantly slower (f1, area: 0.32) dissolution than those of CBZsp. 
 
Figure 49. Mean % dissolved (± SD) of CBZ from different CBZ-NIC formulations in biorelevant media. 
Dissolution of CBZ was used as a control. [Red arrow indicates media change]. 
This could be attributed to a different arrangement of CBZ and NIC in the blend in 
comparison to the cocrystal lattice arrangement. The hydrophobic part of NIC could repel the 
water, resulting in higher hydrophobicity which consequently would decrease solubility of 
CBZ. Another reason for it could be the particle size of the physical blend, which is probably 
greater than CBZ itself.  
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 Figure 50. Mean % dissolved (± SD) of NIC from CBZ-NICss cocrystal and physical blend formulations. 
According to Figure 50, NIC from both cocrystal and physical blends dissolved within the 
first 30 minutes.  
Dissolution of NIC is three times faster than for previously mentioned SAC.  This could 
related to the solubility properties of the coformers used (NIC 1000 mg/mL; SAC 3.45 
mg/mL) (74).  
It can be clearly seen that dissolution of CBZ from cocrystal strongly depends on the 
solubility properties of the coformer. SAC dissolves slowly which allows water to be present 
for longer between CBZ particles, while NIC is rapidly dissolved and CBZ could not benefit 
from the presence of water. 
Qiao et al. investigated the intrinsic dissolution rates of CBZ-NIC cocrystals and physical 
blends and its ability to transform to a dihydrate form of CBZ (316). According to these 
studies, the initial (at 3 min) intrinsic dissolution rate of CBZ--NIC physical mixture is much 
higher (0.0248 mg/min/cm2) than for cocrystal (0.0123 mg/min/cm2) and API (0.0103 
mg/min/cm2). After 35 minutes, the intrinsic dissolution rate of physical mixture decreased to 
values of CBZ dihydrate form (0.0080 mg/min/cm2), while the intrinsic dissolution rate of 
cocrystal remained stable.  
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5.7.2 Indomethacin case 
5.7.2.1 USP apparatus 1 
The dissolution profile of Indomethacin from 25mg Indocid® capsules was determined in 
compendial media (SGF and SIF) using USP apparatus 1. Indomethacin is a weak acid (pKa 
4.3) which is characterised by limited solubility in an acidic environment and high solubility 
in a basic environment. This trend can be clearly seen in Figure 51. 85% of IND dissolved 
within twenty minutes in SIF, whereas only three percent of Indomethacin dissolved within 
one hour.  
 
Figure 51. Mean % dissolved (± SD) of IND from 25 mg Indocid® in compendial media using USP apparatus 1 
(100 rpm). 
Dissolution of IND from 25 mg Indocid® capsules follows first-order kinetics (Table 59). R2 
and AIC values indicate that the dissolution profile in SGF can be slightly better described by 
3-parameters Weibull function. However, β > 1 indicates that the dissolution profile of IND 
from 25 mg Indocid® capsules in SIF has sigmoidal shape. This may be misleading as whole 







Table 59. Dissolution kinetic parameters (± SD) of Indocid® capsule profiles. 
Parameters                     Zero-order kinetics 
SGF SIF 
k0 [h-1] - - 
R2 - - 
AIC - - 
                                                  First-order kinetics 
Wmax [%] 10.88 ± 1.70 85.91± 4.48 
k1 [h-1] 2.95 ± 0.11 32.03 ± 11.76 
R2 0.97 ± 0.02 1.00 ± 0.00 
AIC -12.73 ± 8.92 12.87 ± 12.88 
                           3-parameter Weibull  function 
Wmax [%] 3.10 ± 0.10 - 
α  [h] 3.10 ± 0.65 - 
β 2.12 ± 0.90 - 
R2 0.98 ± 0.02 - 
AIC -17.22 ± 17.25 - 
Similar dissolution profiles were observed for Indocid® capsule that had similar composition 
to the conventional formulation (310).  Around 10% of the drug dissolved in SGF and 85% in 
SIF within the first hour. The performance in SIF was slower reaching 60% drug dissolved at 
20 minutes but still meeting the one hour specification for IR formulation. The discrepancies 
in the profiles could be related to formulation and methodology (USP 2, 100rpm, 900 mL). 
Bijanzadeh et al. tested 25 mg Indocid® capsules supplied by MSD according to USP 
monograph (USP 1, 750 mL, pH 7.2, 100rpm) and reported 90% of the IND dissolved within 
10 minutes (317). This is in agreement with findings reported in Figure 51. 
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Due to the fact that Indocid® dissolves rapidly in basic conditions, this dissolution method 
will not be discriminative enough to characterise the dissolution profile of IND cocrystals. 
Further experiments were performed using flow-through cell dissolution apparatus. 
5.7.2.2 USP apparatus 4 
5.7.2.2.1     Dissolution studies of commercial formulation 
Indomethacin IR and PR conventional formulations were withdrawn from the market and are 
no longer available in UK.  They were known under the brand name Indocid® and have been 
manufactured by MSD. Currently in UK, Indocid® is available as 100 mg suppositories. 
Indocid® capsules that were used for these studies were supplied by MSD (Australia). 
Dissolution profiles of 25 mg Indocid® IR capsules were tested using USP apparatus 4.  
5.7.2.2.1.1   Indocid® IR capsules 
Indocid® capsule is a complete formulation that contains excipients such as lactose, lecithin 
and silica – colloidal anhydrous, which aid the dissolution of poorly soluble Indomethacin. 
Figure 52 illustrates the dissolution profiles of Indocid® capsules tested in various conditions. 
A similar trend to the USP apparatus 1 experiment was observed during the first hour of the 
test, during which Indomethacin was exposed to media that simulate gastric conditions: only 
4% of Indomethacin dissolved, followed by rapid dissolution in intestinal conditions.  
 
Figure 52. Mean % dissolved (± SD) of IND from 25 mg Indocid® capsules in various media using USP 
apparatus 4. [Red arrow indicates media change]. 
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The dissolution profile of Indocid® capsule in compendial media is similar to that in 
MGM/MIM-I (f1, area: 0.05) (Table 60). However, the precipitation percentage in compendial 
media is highly statistically significant (p < 0.001) when compared to MGM/MIM-I (Figure 
54). There is also no significant difference between dissolution profiles in MGM/MIM-II and 
biorelevant media (f1,area: 0.06). It looks that the species (Phosphate salts vs Maleic acids) 
present in MIM-I and MIM-II buffers have significant effect on dissolution (f1,area: 0.05; 
0.27). Performing dissolution of ionic compounds in one medium may not be sufficient to 
predict what happens in vivo. This can be clearly seen based on Indocid® formulation. 
Considered separately, minimal dissolution in gastric fluids and maximum in intestinal fluids, 
do not reflect the real nature of in vivo precipitation. Thus, there is a need for an in vitro 
technique that would be able to closely mimic this process. USP apparatus 4 offers the benefit 
of changing the dissolution environment, but the extent of precipitation strongly depends on 
the composition of the selected media (Figure 54). For instance, biorelevant media causes the 
smallest fraction of the dose to precipitate (Figure 54). Schamp et al. claim that inhibited 
precipitation may occur due to fact that dissolving drug is automatically interpolated in the 
micelles, which protects it from nucleation and subsequent precipitation (318). Biorelevant 
media consider drug solubilisation in mixed micelles; therefore, they mimic the physiological 
situation better than buffer solutions (319, 320). 
 
Table 60. Summary of f1, area values comparing dissolution profiles of Indocid® capsules in various media. 
 
SGF/SIF 
 (as reference) 
25 mg Indocid® capsules 
MGM/MIM-I MGM/MIM-II FaSSGF/FaSSIF-V2 
f1, area 0.05 0.27 0.32 
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 Figure 53. Non-cumulative profile of mean amount of IND dissolved from 25 mg Indocid® capsules in various 
media using USP apparatus 4. [Red arrow indicates media change]. 
Non-cumulative interpretation of the amount of the IND dissolved from Indocid® capsule 
allows confirmation that the fastest dissolution profile obtained in biorelevant media is due to 
the highest amount of IND dissolved (~ 3 mg) after the media change (Figure 53) and the 
least % of the dose precipitated (Figure 54).  
 
Figure 54. Percent (± SD) of dose and sample collected at 70 min of Indocid® precipitated in various media. 
Due to the solubility pH-dependent nature of IND, fitting zero and first-order kinetics to the 
whole profile was not achievable.  Thus, zero- and first-order kinetics were applied separately 
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to the profiles pre (up to 1h) and post media change (after 1h) (Table 61). Weibull function 
was fitted using the whole data profile. 
According to the data presented in Table 61, dissolution of IND from 25 mg Indocid® 
capsules in gastric stage follows zero-order kinetics in compendial and biorelevant media. On 
the other hand, dissolution kinetics in modified media can be better characterised by a first-
order equation. Rapid onset after media change in all the media can be described by first-
order kinetics. The Wmax value and S-shape (β > 1) of the dissolution curve can be 
successfully captured using 3-parameters Weibull function. 
Table 61. Dissolution kinetic parameters (± SD) of Indocid® capsules profiles. 
Parameters Gastric phase  











   
   
 
k0 [h-1] 2.92 ± 0.51 3.95 ± 0.38 3.33 ± 0.31 3.75 ± 0.63 
R2 0.99 ± 0.01 0.97 ± 0.01 0.97 ± 0.04 0.99 ± 0.01 
AIC -18.92 ±7.07 -4.04 ± 8.00 -10.73 ± 7.68 -12.98 ± 5.08 
 Intestinal phase 
k0 [h-1] 27.85 ± 1.39 38.59 ± 1.04 50.49 ± 1.96 36.35 ± 1.00 
R2 0.04 ± 0.09 0.28 ± 0.14 0.65 ± 0.10 -0.15 ± 0.11 
AIC 166.43 ± 1.38 107.24 ± 3.07 106.27 ± 4.82 177.47 ± 1.68 











Wmax [%] - 5.79 ± 1.88 6.75 ± 2.52 - 
k1 [h-1] - 1.22 ± 0.69 0.80 ± 0.52 - 
R2 - 1.00 ± 0.00 1.00 ± 0.01 - 
AIC - 21.29 ± 4.30 -23.38 ± 10.29 - 
 Intestinal phase 
Wmax [%] 60.50 ± 3.48 58.14 ± 1.33 84.32 ± 1.93 78.23 ± 2.35 
k1 [h-1] 1.97 ± 0.14 2.48 ± 0.34 1.54 ± 0.25 2.15 ± 0.14 
R2 0.96 ± 0.01 0.94 ± 0.02 0.98 ± 0.01 0.99 ± 0.00 
AIC 105.70 ± 2.88 77.15 ± 4.27 76.89 ± 6.45 88.26 ± 2.96 















n Wmax [%] 57.47 ± 3.21 54.26 ± 1.29 74.41 ± 1.44 75.45 ± 2.23 
α  [h] 11.73 ± 1.97 102.34 ± 79.26 12.97 ± 3.38 7.20 ± 0.34 
β 6.41 ± 0.89 14.23 ± 5.95 5.82 ± 1.19 5.13 ± 0.20 
R2 0.98 ± 0.00 0.99 ± 0.00 0.99 ± 0.00 0.99 ± 0.00 
AIC 144.29 ± 2.01 95.12 ± 7.23 105.30 ± 5.41 144.22 ± 3.15 
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5.7.2.2.1    Pharmaceutical cocrystals 
Indomethacin cocrystals were tested under the same conditions as Indocid® commercial 
formulations. INDsp samples were used as a control formulation.  
5.7.2.2.1.1    INDsp samples 
Dissolution of INDsp in various media was presented in Figure 55. In all cases INDsp 
significantly benefited from the presence of the single or mixed surfactants present in the 
media. 
 
Figure 55. Mean % dissolved (± SD) of INDsp in various media using USP apparatus 4. [Red arrow indicates 
media change]. 
The greatest dissolution enhancement (f1, area: 1.35) was obtained when INDsp samples were 
tested in MGM/MIM-II media (Table 62). This was confirmed with the findings that in this 
case larger amounts of IND were dissolved between 70 to 140 minutes of the test when 
compared with other non-cumulative profiles (Figure 56). 
 
Table 62. Summary of f1, area values comparing dissolution profiles of INDsp formulations in various media. 
 
SGF/SIF 
 (as reference) 
INDsp 
MGM/MIM-I MGM/MIM-II FaSSGF/FaSSIF-V2 
f1, area 0.38 1.35 0.51 
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 Figure 56. Non – cumulative profiles of mean amounts of INDsp dissolved in various media using USP 
apparatus 4. [Red arrow indicates media change]. 
As in the Indocid® case, biorelevant media inhibited the precipitation of the dose. Overall, 
smaller proportions of the INDsp dose were prone to precipitation in comparison to Indocid® 
capsules (Figure 57). It seems that precipitation was more likely to occur with the excipients 
used in the Indocid® formulation. Consequently, greater precipitation from Indocid® capsules 
than from INDsp samples in vivo could reduce the amount of the IND arriving at the 
absorption site. 
 
Figure 57. Percent (± SD) of dose and sample collected at 70 min of INDsp precipitated in various media. 
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Dissolution of INDsp in all media followed zero-order kinetics within the first hour and then 
upon the change of the media, the kinetics altered to first-order dissolution kinetics as 
presented in Table 63. Whole dissolution profiles of INDsp can be well described using 
Weibull function according to which β > 1 indicated that all the curves had S-shape (Table 
63). 
Table 63. Dissolution kinetic parameters (± SD) of INDsp profiles. 
Parameters Gastric phase 











   
   
 
k0 [h-1] 0.18 ± 0.14 0.69 ± 0.13 0.74 ± 0.05 0.65 ± 0.04 
R2 0.97 ± 0.03 0.98 ± 0.00 0.97 ± 0.01 0.97 ± 0.01 
AIC -53.81 ± 3.66 -33.30 ± 2.51 -26.49 ± 2.42 -29.96 ± 1.55 
 Intestinal phase 
k0 [h-1] 15.99 ± 2.57 21.82 ± 1.50 35.46 ± 0.78 23.70 ± 3.24 
R2 0.97 ± 0.01 0.94 ± 0.00 0.78 ± 0.03 0.94 ± 0.02 
AIC 89.79 ± 11.03 113.49 ± 4.66 154.39 ± 2.63 116.09 ± 2.36 











Wmax [%] 31.18 ± 50.81 - - - 
k1 [h-1] 0.33 ± 0.49 - - - 
R2 0.97 ± 0.03 - - - 
AIC -54.55 ± 3.01 - - - 
 Intestinal phase 
Wmax [%] 75.21 ± 10.13 84.82 ± 16.53 95.24 ± 3.15 89.92 ± 20.29 
k1 [h-1] 0.29 ± 0.05 0.40 ± 0.10 0.80 ± 0.06 0.42 ± 0.06 
R2 1.00 ± 0.00 1.00 ± 0.00 0.99 ± 0.00 1.00 ± 0.00 
AIC 31.20 ± 13.52 66.19 ± 1.38 92.47 ± 6.93 29.16 ± 14.85 















n Wmax [%] 43.79 ± 6.22 56.09 ± 5.59 80.86 ± 1.55 63.12 ± 9.15 
α  [h] 12.29 ± 0.89 11.55 ± 1.25 10.31 ± 0.79 9.88 ± 1.04 
β 2.66 ± 0.03 2.81 ± 0.02 3.36 ± 0.13 2.54 ± 0.09 
R2 0.99 ± 0.00 0.99 ± 0.00 0.99 ± 0.00 0.99 ± 0.00 




5.7.2.2.1.2 IND-SACss samples 
Dissolution of IND from IND-SACss cocrystal samples was determined in compendial, 
modified and biorelevant media (Figure 58). Dissolution of IND-SACss in both modified and 
biorelevant media greatly enhanced the dissolution profile of IND cocrystal (Table 64). The 
fact that the enhancement in dissolution is due to presence of single or mixed type of micelles 
in the composition of those media indicate that dissolution of IND is driven by solubilisation 
mechanism. This is in agreement with its high logP value of 4.27 (290). It has been reported 
previously that for compounds with low logP values (1-2) wettability is the predominant 
mechanism, whereas in the case of drugs with high logP values, solubilisation accounts for 
increased powder dissolution rate (320). In addition, dissolution profiles of IND from IND-
SACss cocrystals in MIM-II and FaSSIF-V2 resulted in similar dissolution profiles (f1, area: 
0.07), which indicate that blank FaSSIF with SLS (MIM-II) could be potentially used to 
mimic dissolution behaviour of IND formulations to the same extent as biorelevant media.  
 
Figure 58. Mean % dissolved (± SD) of IND from IND-SACss in various media using USP apparatus 4. [Red 
arrow indicates media change]. 
Table 64. Summary of f1, area values comparing dissolution profiles of CBZ-SACss in various media. 
 
SGF/SIF 
 (as reference) 
IND-SACss 
MGM/MIM-I MGM/MIM-II FaSSGF/FaSSIF-V2 
f1, area 0.40 0.48 0.57 
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A closer look at the amount of IND dissolved over the time, shows that despite those 
cumulative profiles in MGM/MIM-II and FaSSGF/FaSSIF-V2 are similar (f1,area: 0.07) the 
amount of IND that dissolves after 70 minutes is slightly higher in modified media (Figure 
59).  The similarity observed in cumulative profiles is compensated by the fact that IND-
SACss precipitated upon the change of media by a significantly greater extent in MGM/MIM-
II (p < 0.001). 
 
Figure 59. Non-cumulative profiles of mean amounts of IND dissolved from IND-SACss samples in various 
media using USP apparatus 4. [Red arrow indicates media change]. 
According to Figure 60, the smallest fraction of the dose precipitated in biorelevant media, 
which was over 30 times smaller than compendial media. 
 
Figure 60. Percent (± SD) of dose and sample at 70 min of IND-SACss precipitated in various media. 
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Dissolution of IND-SACss in all media simulating gastric conditions followed zero-order 
kinetics, whereas upon the change of the media, dissolution kinetics can be better 
characterised by first-order kinetics (Table 65). Predicted Weibull parameters characterise the 
whole dissolution profiles of IND-SACss indicating that dissolution profile has S-shape (β > 
1). 
Table 65. Dissolution kinetic parameters (± SD) of IND-SACss profiles. 
Parameters Gastric phase 











   
   
 
k0 [h-1] 3.98 ± 0.65 3.38 ± 0.48 3.68 ± 0.08 7.21 ± 1.12 
R2 0.99 ± 0.01 0.97 ± 0.02 0.98 ± 0.01 0.99 ± 0.00 
AIC -10.89 ± 4.61 -10.88 ± 6.95 -11.91 ± 4.00 -5.18 ± 1.90 
 Intestinal phase 
k0 [h-1] 26.64 ± 1.71 37.49 ± 1.28 40.35 ± 0.75 41.70 ± 0.74 
R2 0.37 ± 0.07 0.39 ± 0.10 0.60 ± 0.07 0.39 ± 0.24 
AIC 157.43 ± 3.76 171.54 ± 3.88 167.94 ± 1.89 172.84 ± 5.51 











Wmax [%] - 6.49 ± 1.33 8.46 ± 3.17 - 
k1 [h-1] - 0.75 ± 0.36 0.61 ± 0.25 - 
R2 - 1.00 ± 0.00 1.00 ± 0.00 - 
AIC - -25.10 ± 4.38 -29.97 ± 8.86 - 
 Intestinal phase 
Wmax [%] 60.12 ± 3.72 85.64 ± 2.09 97.94 ± 4.98 96.51 ± 4.14 
k1 [h-1] 1.47 ± 0.10 1.42 ± 0.14 1.09 ± 0.12 1.37 ± 0.33 
R2 0.98 ± 0.00 0.98 ± 0.01 0.99 ± 0.00 1.00 ± 0.00 
AIC 97.84 ± 1.77 106.80 ± 8.08 100.73 ± 4.89 44.71 ± 13.67 















n Wmax [%] 57.09 ± 3.42 79.95 ± 2.07 88.45 ± 2.73 91.43 ± 2.39 
α  [h] 5.68 ± 1.03 9.34 ± 1.94 9.26 ± 0.82 5.64 ± 0.56 
β 3.37 ± 0.60 4.37 ± 1.94 3.72 ± 0.07 3.12 ± 0.37 
R2 0.99 ± 0.00 0.99 ± 0.00 0.99 ± 0.00 0.99 ± 0.00 





5.7.2.2.1.3 IND-SACsd samples 
Dissolution of IND-SACsd cocrystal samples was examined in various media using USP 
apparatus 4 (Figure 61). Samples of IND-SACsd were produced during the first step of 
preparation of IND and SAC cocrystals by the UMAX process. Thus, it was very interesting 
to test the performance of the intermediate form to see if UMAX technology provides any 
advantages. Presence of the surfactants in the media led to a significant enhancement in 
dissolution rate of IND-SACsd cocrystal samples (Table 66). Greatest enhancement in 
comparison to reference profile (SGF/SIF) was achieved in MGM/MIM-I (f1, area: 0.39), that 
contains the highest concentration of SLS (0.2%).  This enhancement corresponded to the fact 
that in this media, the precipitated sample collected after media change at 70 minutes was 
significantly lower (p < 0.001) than in the other media (Figure 63). This was confirmed by 
observation from the graph that illustrates the amount of the IND dissolved from IND-SACsd 
cocrystal samples at certain time intervals (Figure 62). It can be clearly seen that up to 30 
minutes after media change, significant amounts of IND were dissolved  when tested in MIM-
I. 
 
Figure 61.  Mean % dissolved (± SD) of IND from IND-SACsd in various media using USP apparatus 4. [Red 






Table 66. Summary of f1, area values comparing dissolution profiles of CBZ-SACsd in various media. 
 
SGF/SIF 
 (as reference) 
IND-SACsd 
MGM/MIM-I MGM/MIM-II FaSSGF/FaSSIF-V2 
f1, area 0.39 0.18 0.24 
 
Dissolution of IND-SACsd in all media simulating gastric conditions followed first-order 
kinetics, and continue to be dissolved with the same kinetics after the media change (Table 
67). Predicted Weibull parameters characterised the whole dissolution profiles of IND-SACsd 
indicating that all profiles has sigmoidal shape (β > 1). 
 
Figure 62. Non-cumulative profiles of mean amounts of IND dissolved from IND-SACsd samples in various 
media using USP apparatus 4. [Red arrow indicates media change]. 
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 Figure 63. Percent (± SD) of dose and sample at 70 min of IND-SACsd precipitated in various media. 
Interestingly, cocrystals made by the spray-drying method significantly reduced the fraction 
of the dose that precipitated in MGM/MIM-I (sd: 3.61%; ss: 16.45%) and compendial media in 
















Table 67. Dissolution kinetic parameters (± SD) of IND-SACsd profiles. 
Parameters Gastric phase 











   
   
 
k0 [h-1] 5.27 ± 0.13 3.61 ± 0.24  4.21 ± 0.35 13.21 ± 1.14 
R2 0.98 ± 0.01 0.93 ± 0.03  0.92 ± 0.03 0.99 ± 0.00 
AIC -1.98 ± 1.65 -2.64 ± 4.20 1.01 ± 1.31 3.15 ± 3.24 
 Intestinal phase 
k0 [h-1] 32.46 ± 1.22 43.13 ± 1.74 37.60 ± 1.08 38.50 ± 1.97 
R2 0.67 ± 0.04 0.27 ± 0.08 0.55 ± 0.09 0.46 ± 0.24 
AIC 156.10 ± 3.27 178.45 ± 1.39 166.36 ± 1.58 167.93 ± 9.00 











Wmax [%] - 4.48 ± 0.48 4.88 ± 0.84 83.37 ± 40.96 
k1 [h-1] - 1.35 ± 0.36 1.49 ± 0.26 0.23 ± 0.18 
R2 - 1.00 ± 0.00 1.00 ± 0.00 0.99 ± 0.00 
AIC - -25.63 ± 3.01 -18.08 ± 2.57 3.09 ± 1.91 
 Intestinal phase 
Wmax [%] 80.68 ± 2.30 96.75 ± 4.71 89.73 ± 5.41 90.35 ± 0.46 
k1 [h-1] 0.99 ± 0.07 1.57 ± 0.11 1.17 ± 0.14 1.29 ± 0.34 
R2 1.00 ± 0.00 0.99 ± 0.00 0.99 ± 0.00 1.00 ± 0.00 
AIC 77.61 ± 3.22 89.03 ± 4.36 89.31 ± 7.95 74.91 ± 10.15 















n Wmax [%] 73.32 ± 2.10 91.80 ± 4.10 82.26 ± 3.43 86.73 ± 0.27 
α  [h] 6.76 ± 0.17 7.51 ± 0.37 7.95 ± 0.95 4.75 ± 0.39 
β 2.94 ± 0.13 4.09 ± 0.12 3.54 ± 0.02 2.92 ± 0.64 
R2 0.99 ± 0.00 0.99 ± 0.00 0.99 ± 0.00 0.99 ± 0.00 









5.7.2.2.1.4 IND-SACumax samples 
Dissolution of IND-SACumax cocrystal samples was studied in a range of compendial, 
modified and biorelevant media (Figure 64). Dissolution patterns are similar to those 
presented for IND-SACsd (Figure 61). Micelles present in the media significantly enhance the 
dissolution of IND-SACumax (Table 68). MGM/MIM-II generated a similar profile (f1,area: 
0.07) to that in FaSSGF/FaSSIF-V2. Dissolution in MGM/MIM-I is faster than in biorelevant 
and MIM-II media.  Consistency with the results observed for IND-SACsd proved that both 
dissolution profiles of IND-SACsd and IND-SACumax in MIM-I were actual and the greater 
enhancement in dissolution in MIM-I might be due to the interactions between IND-SAC and 
SLS. 
  
Figure 64.  Mean % dissolved (+/- SD) of IND from IND-SACumax in various media using USP apparatus 4. 
[Red arrow indicates media change]. 
Table 68. Summary of f1, area values comparing dissolution profiles of CBZ-SACumax in various media. 
 
SGF/SIF 
 (as reference) 
IND-SACumax 
MGM/MIM-I MGM/MIM-II FaSSGF/FaSSIF-V2 
f1, area 0.41 0.27 0.32 
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 Figure 65. Non-cumulative profiles of mean amounts of IND dissolved from IND-SACumax samples in various 
media using USP apparatus 4. [Red arrow indicates media change]. 
Processing IND-SACsd cocrystals with UMAX technology did not change the trend 
previously seen in Figure 62. The highest amount of IND dissolved within first 30 minutes 
after media change when tested in MIM-I (Figure 65).  
 





Presence of the micelles in the media significantly reduces (p < 0.001) the percentage of the 
dose that precipitates upon changing media (Figure 66). Thus, testing formulations in 
biorelevant media is very important to aid better understanding of formulation and closely 
mimic in vivo performance. Investigating dissolution in just compendial media can lead to 
overestimated precipitation values. From the pharmacokinetic point of view, the less drug that 
precipitates, the greater the dose available at the absorption site. However, there are other 
factors that can affect the dose available at absorption site such as solubility. 
Dissolution of IND-SACumax in compendial media simulating gastric conditions followed 
zero-order kinetics, whereas at the same stage in modified and biorelevant media, dissolution 
of IND followed first-order kinetics (Table 69). After changing the media, IND-SACumax 
dissolution can be characterised using first-order kinetics. Predicted Weibull parameters well 
characterised the whole dissolution profiles of IND-SACumax. Values of β > 1 indicate that all 


















Table 69. Dissolution kinetic parameters (± SD) of IND-SACumax profiles. 
Parameters Gastric phase 











   
   
 
k0 [h-1] 0.94 ± 0.14 2.48 ±0.46 2.44 ± 0.13 5.51 ± 0.87 
R2 0.96 ± 0.03 0.98 ± 0.02 0.98 ± 0.00 0.99 ± 0.02 
AIC -24.41 ± 6.37 -19.18 ± 9.38 -15.01 ± 0.38 2.32 ± 2.88 
 Intestinal phase 
k0 [h-1] 32.28 ± 0.68 43.48 ± 1.09 40.97 ± 0.34 43.06 ± 1.48 
R2 0.43 ± 0.05 -0.11 ± 0.07 0.46 ± 0.06 0.62 ± 0.07 
AIC 165.46 ± 2.21 184.73 ± 2.22 173.84  ± 1.43 169.00 ± 4.48 











Wmax [%] - 7.88 ± 3.77 14.77 ± 9.16 7.09 ± 1.46 
k1 [h-1] - 0.52 ± 0.4 0.23 ± 0.13 1.24 ± 0.22 
R2 - 1.00 ± 0.00 0.98 ± 0.00 1.00 ± 0.00 
AIC - -24.62 ± 5.13 -14.00 ± 0.85 -19.09 ± 2.05 
 Intestinal phase 
Wmax [%] 74.11 ± 0.85 94.02 ± 2.27 95.44 ± 2.12 105.44 ± 0.63 
k1 [h-1] 1.37 ± 0.07 2.10 ± 0.01 1.29 ± 0.09 1.05 ± 0.10 
R2 0.98 ± 0.00 0.98 ± 0.01 0.98 ±0.00 0.99 ± 0.00 
AIC 106.98 ± 3.63 104.86 ± 7.68 115.50 ± 2.41 88.86 ± 9.09 















n Wmax [%] 68.53 ± 1.06 90.44 ± 2.57 88.07 ± 1.12 95.71 ± 2.08 
α  [h] 11.29 ± 1.12 9.63 ± 0.81 11.66 ± 0.71 7.88 ± 0.20 
β 4.75 ± 0.38 5.79 ± 0.33 4.54 ± 0.12 3.32 ± 0.19 
R2 0.99 ± 0.00 0.99 ± 0.00 0.99 ± 0.00 0.99 ± 0.00 
AIC 148.96 ± 0.60 143.19 ± 12.77 140.53 ± 2.21 137.76 ± 7.39 
 
5.7.2.2.1.5   IND-NICss samples 
Dissolution of IND-NICss was determined in various media using USP apparatus 4 (Figure 
67). Biorelevant media significantly (f1, area: 0.28) enhanced dissolution of IND-NICss (Table 
70). However, the dissolution of this formulation in MGM/MIM-II did not appear to have a 
similar profile (f1, area: 0.15) to that in FaSSGF/FaSSIF-V2 which was seen in all previously 
tested IND formulations. This is probably due to the different effect of the single (in MIM-II) 
versus mixed (in FaSSIF-V2) micelles on NIC, which have solubilisation properties (299). 
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The fastest dissolution profile was observed in MGM/MIM-I, this is illustrated by the highest 
dissolution rate constant (k = 2.10) (Table 71). 
 
Figure 67. Mean % dissolved (± SD) of IND from IND-NICss in various media using USP apparatus 4. [Red 
arrow indicates media change]. 
 
Table 70. Summary of f1, area values comparing dissolution profiles of CBZ-NICss in various media. 
 
SGF/SIF 
 (as reference) 
IND-NICss 
MGM/MIM-I MGM/MIM-II FaSSGF/FaSSIF-V2 
f1, area 0.18 0.12 0.28 
 
The fastest dissolution profile in MGM/MIM-II can be supported with the fact that the 
greatest amount of IND dissolved for the first 20 minutes after the media change and 
formulation completely dissolved within three hours of the experiment (Figure 68).  
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 Figure 68. Non-cumulative profiles of mean amounts of IND dissolved from IND-NICss samples in various 
media using USP apparatus 4. [Red arrow indicates media change]. 
Furthermore, the complete dissolution of IND-NICss in MGM/MIM-I occurred faster due to 
the fact that 20% of the dose (5 mg) precipitated after the media change and less of the 
formulation remained for dissolution (Figure 69). As in previous formulations, biorelevant 
media resulted in the smallest fraction of the IND-NICss dose precipitating.  
 
Figure 69. Percent (± SD) of dose and sample at 70 min of IND-NICss precipitated in various media. 
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Dissolution of IND-NICss followed first-order kinetics in the gastric and intestinal phases 
media (Table 71). Predicted Weibull parameters well characterised the whole dissolution 
profiles of IND-NICss, indicating that all of them have S-shape.  
Table 71. Dissolution kinetic parameters (± SD) of IND-NICss profiles. 
Parameters Gastric phase 











   
   
 
k0 [h-1] 4.24 ± 0.85 2.67 ± 0.65 2.97 ± 0.64 4.60 ± 0.79 
R2 0.82 ± 0.04 0.54 ± 0.11 0.41 ± 0.10 0.82 ± 0.01 
AIC 6.26 ± 1.23 4.46 ± 5.05 7.66 ± 4.14 7.21 ± 1.98 
 Intestinal phase 
k0 [h-1] 37.27 ± 1.37 52.87 ± 1.55 42.14 ± 1.00 45.52 ± 0.38  
R2 0.63 ± 0.06 0.47 ± 0.01 0.71 ± 0.09 0.16 ± 0.08 
AIC 164.00 ± 3.61 112.83 ± 1.04 164.71 ± 5.58 183.10 ± 1.25 











Wmax [%] 4.08 ± 1.06 2.08 ± 0.44 2.24 ± 0.45 4.30 ± 0.79 
k1 [h-1] 2.21 ± 0.32 4.48 ± 0.87 5.71 ± 1.04 2.31 ± 0.08 
R2 0.98 ± 0.01 0.98 ± 0.00 0.98 ± 0.00 1.00 ± 0.00 
AIC -9.25 ± 2.20 -16.29 ± 5.01 -14.99 ± 3.66 -19.33 ± 2.63 
 Intestinal phase 
Wmax [%] 91.46 ± 3.13 82.83 ± 2.29 108.95 ± 3.17 100.94 ± 0.09 
k1 [h-1] 1.05 ± 0.09 1.96 ± 0.03 0.90 ± 0.15 1.71 ± 0.11 
R2 0.99 ± 0.00 0.95 ± 0.00 0.99 ± 0.00 0.99 ± 0.00 
AIC 101.46 ± 7.56 85.24 ± 1.82 105.68 ± 5.35 105.97 ± 5.18 















n Wmax [%] 84.75 ± 2.20 76.14 ± 2.03 94.86 ± 0.67 96.27 ± 0.51 
α  [h] 0.79 ± 0.09 20.11 ± 3.11 10.42 ± 0.52 8.94 ± 0.86 
β 1.34 ± 0.09 7.90 ± 0.51 3.55 ± 0.29 4.71 ± 0.04 
R2 1.00 ± 0.00 0.99 ± 0.00 1.00 ± 0.00 1.00 ± 0.00 
AIC 72.12 ± 2.17  99.50 ± 0.94 136.81 ± 1.81 135.36 ± 3.13 
 
Precipitation kinetics 
The in vitro IND kinetics of the precipitation was determined using USP apparatus 4. USP 
apparatus 4 allows changing of the media during a continuous dissolution run, which closely 
mimics human gastrointestinal conditions. Due to the large differences in the solubility of 
IND in acidic and basic conditions, precipitation of IND occurred after media change. The 
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precipitated samples were treated according to the method described in section 4.4.11.1.1. 
However, it was observed that remaining precipitated samples left on the side of the bench 
salt-out further. Thus, it was important to treat the samples immediately after collection. The 
kinetics of the precipitation was determined using samples collected from dissolution 
experiments of IND-SACss and IND-NICss cocrystals in MGM/MIM-II media using USP 
apparatus 4.  
Samples of IND-SACss and IND-NICss cocrystals collected after media change resulted in 
85% of the sample precipitated 2 hours after collection (Figure 70). In contrast, when the 
sample was treated immediately 63 and 34% were reported for precipitated samples of IND-
SACss and IND-NICss cocrystals, respectively. These findings proved that treatment of 
precipitated samples is a crucial step that should be performed immediately after collection. 












Figure 70. Kinetics of the precipitation (± SD) of IND-SACss and IND-NICss cocrystals. Precipitated samples 







5.7.2.2.2 Effect of type of coformer 
Dissolution profiles of INDsp, IND-SACss, and IND-NICss in biorelevant media, were 
compared in order to verify which coformer type enhances dissolution of IND most efficiently 
(Figure 71). Dissolution profiles in biorelevant media were selected for comparison as the 
precipitation of the dose for all these formulations is lower than 1%. Both of the cocrystals 
made by sonic-slurrying demonstrated to significantly enhance the dissolution of IND. 
According to the difference factor f1,area, Nicotinamide cocrystal of IND (f1,area: 1.16) 
improves dissolution of IND more than the Saccharin cocrystal (f1, area: 0.95). The difference 
between both cocrystals is also statistically significant (f1, area: 0.19).  
 
Figure 71. Mean % dissolved (± SD) of IND from cocrystals made by sonic-slurrying method and tested in 
biorelevant media using USP apparatus 4. INDsp samples were used as the control. [Red arrow indicates media 
change]. 
Interestingly, NIC cocrystals of CBZ did not demonstrate any dissolution enhancement of 
CBZ. Two observations could aid the understanding of this behaviour. Firstly, the dose of 
IND (25 mg) is eight times smaller than that of CBZ (200 mg). Thus, amounts of NIC in 
CBZ-NICss cocrystal may not be sufficient to impact its dissolution. Secondly, according to 
Hörter and Dressman, for compounds with high logP, solubilisation is the predominant 
mechanism (IND logP 4.27), whereas for compounds with low logP (CBZ logP 2.45), 
wettability is the mechanism which accounts for enhancement of the powder dissolution rate 
(320). It seems that it was easier to solubilise small amounts of IND than wet large amounts 
of CBZ. 
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5.7.2.2.3 Effect of method of preparation 
Dissolution profiles of IND-SACss, IND-SACsd and IND-SACumax in one of the modified 
media (MGM/MIM-II) were compared against dissolution of INDsp samples in order to assess 
which cocrystallisation method resulted in the highest improvement of dissolution (Figure 
72). Dissolution profiles in modified media (MGM/MIM-II) were selected for comparisons, 
as the precipitation of the dose for all these formulations was similar and ranged from 6.8 to 
7.4 %.  f1, area values indicate that cocrystals made by sonic-slurrying and UMAX techniques 
significantly improved dissolution of poorly soluble INDsp samples (Table 72). Cocrystals 
made by UMAX technology provided the greatest enhancement of dissolution rate (f1, area: 
0.21). 
 
Figure 72. Mean % dissolved (± SD) of IND from IND-SAC cocrystals made by different cocrystallisation 
methods and tested in MGM/MIM-II media using USP apparatus 4. INDsp samples were used as control. [Red 
arrow indicates media change]. 
According to difference factor, spray-drying did not significantly improve the dissolution of 
INDsp (f1, area: 0.11). This is due to the similarity in particle size between these two samples. 






Table 72. Summary of f1, area values comparing dissolution profiles of different IND-SAC formulations in 
MGM/MIM-II. 
 
INDsp (as reference) 
MGM/MIM-II 
IND-SACss IND-SACsd CBZ-SACumax 
f1, area 0.18 0.11 0.21 
 
Interestingly, despite having the largest particle size, IND-SACumax cocrystals provided the 
greatest dissolution improvement. This indicates that UMAX technology may bring some 
additional benefits in terms of API and coformer packing and arrangement in cocrystals. 
Table 73. Comparison of PSD (± SD) of INDsp and IND-SAC cocrystals made by various cocrystallisation 
methods.  
 D10 ± SD D50 ± SD D90 ± SD 
INDsp 4.74 ± 0.04 µm 24.86 ± 0.13 µm 55.21 ± 0.74 µm 
IND-SACss 1.89 ± 0.01 µm 15.40 ± 0.14 µm 57.45 ± 0.62 µm 
IND-SACsd 3.27 ± 0.09 µm 22.63 ± 0.28 µm 49.59 ± 1.36 µm 
IND-SACumax 5.89 ± 0.10 µm 32.27 ± 1.81 µm 67.34 ± 3.63 µm 
 
5.7.2.2.4 Effect of cocrystal and its mechanism of dissolution 
5.7.2.2.4.1 Saccharin types of IND cocrystals 
Dissolution of the physical mixture of IND and SAC was performed in biorelevant media and 
its profile was compared against INDsp and all IND-SAC cocrystals produced using various 
cocrystallisation methods (Figure 73). Physical blend of IND and SAC significantly improved 
dissolution of IND (f1, area: 0.17); however to much smaller extent than all other IND-SAC 
cocrystals (Table 74). IND-SAC cocrystals made by sonic-slurrying and UMAX methods 
resulted in the fastest dissolution profiles reaching almost 100% within four hours. All 
samples apart from IND-SACsd (8.88%) demonstrated precipitation of the dose below 1%. In 
all of the mentioned cases, IND benefited from the presence of SAC. 
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 Figure 73. Mean % dissolved (± SD) of different IND-SAC formulations in biorelevant media. [Red arrow 
indicates media change]. 
Table 74. Summary of f1, area values comparing dissolution profiles of different IND-SAC formulations in 
biorelevant media. 
 
INDsp (as reference) 
FaSSGF/FaSSIF-V2 
IND - - SAC IND-SACss IND-SACsd IND-SACumax 
f1, area 0.17 0.95 0.83 0.96 
 
In order to gain understanding of the mechanism by which SAC improves dissolution of IND, 
IND-SACss cocrystals were selected to study the dissolution of SAC from the cocrystal. 
Closer investigation showed that SAC from IND-SACss cocrystal dissolved at a slower rate 
than SAC from the physical blend (Figure 74) despite the fact that both SAC dissolved within 
the first 2 hours of the experiment. A similar trend was observed during examination of SAC 
formulations of CBZ (Saccharin types of CBZ cocrystals section 5.7.1.2.6.1).  The packing 
and arrangement of the SAC and IND in both the physical blend and cocrystal plays an 
important role in the enhancement of dissolution of IND. 
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 Figure 74.  Mean % dissolved (± SD) of SAC from different IND-SAC formulations. 
Dissolution of Saccharin from the cocrystal form follows a zero-order kinetics pattern in 
FaSSGF and it is much slower than that from the physical blend, which follows first-order 
kinetics in both media. After the change of media, dissolution of SAC from cocrystal seems to 
follow first-order characteristics. This could be due to solubilisation of SAC by bile salts 
present in FaSSIF-V2.    
5.7.2.2.4.2 Nicotinamide types of IND cocrystals 
Dissolution of the physical blend of IND and NIC was performed in biorelevant media and its 
profile was compared against INDsp and all IND-NIC cocrystals produced using the sonic-
slurrying method (Figure 75). The dissolution profile of the physical blend was significantly 
slower than IND-NICss cocrystals (f1, area: 0.41) but significantly faster (f1, area: 0.53) than 
dissolution of INDsp samples. IND-NICss cocrystal provided the greatest dissolution 
enhancement of IND (f1, area: 1.16).  
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 Figure 75. Mean % dissolved (± SD) of IND from different IND-NIC formulations in biorelevant media. 
According to Figure 76, NIC from both the cocrystal and the physical blend dissolved within 
the first 30 minutes. These dissolution profiles of NIC were measured simultaneously with 
dissolution of IND. Despite the fact that the dissolution of NIC from cocrystal is as fast as 
from the physical blend; this still leads to a discrepancy between cumulative dissolution 
profiles of IND-NICss and IND--NIC.  This leads to the conclusion that it might be the 
packing and arrangement of the NIC and IND in both the physical blend and cocrystal that 
plays an important role in the enhancement of dissolution of IND.  
 
 
Figure 76. Mean % dissolved (± SD) of NIC from different IND-NIC formulations. 
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5.7.2.2.5 Effect of media on IND precipitation  
Indomethacin precipitation depends on the medium used and type of formulation investigated. 
According to Figure 77, species that are present in SGF and SIF provoke precipitation of 
samples collected at 70 minutes, resulting in higher percentage of the dose precipitated. On 
the other hand, biorelevant media inhibited sample precipitation.  
 
Figure 77. % precipitated (± SD) of the sample collected at 70min during dissolution of different IND 
formulations in various media. 
Overall, the largest fraction of the Indocid® dose precipitated across all investigated media, 
whereas the smallest fraction of dose precipitated from INDsp formulations (Figure 78). This 
might lead to the conclusion that excipients and coformers present in Indocid® formulation 
contribute to the extent of precipitation. 
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Figure 78. % of dose precipitated (± SD) during dissolution of different IND formulations in various media 
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6 Development of IVIVC 
6.1 Carbamazepine case 
6.1.1 Model-dependent approach 
Intravenous and oral solution CBZ formulations are not available on the market, hence it was 
not possible to perform numerical deconvolution technique (226). When the drug follows a 
one-compartmental model and its elimination obeys first-order kinetics, then Wagner-Nelson 
deconvolution can be applied (243, 321). However, the CBZ follows a two-compartmental 
model; deconvolution technique for Tegretol® IR and PR formulations were still implemented 
with care. Deconvoluted profiles using Wagner-Nelson method for IR Tegretol® tablets are 
presented in Figure 79 . 
 
(a) 
Figure 79. Mean in vivo absorption of CBZ from Tegretol® IR tablets obtained using Wagner-Nelson method. 
(a) Original in vivo data extracted from Meyer et al.(286). 
According to Figure 79, 80% of CBZ is absorbed within 8 hours. In vivo fraction absorbed 
was compared with fractions dissolved obtained from experiments using USP apparatus 1 and 
USP apparatus 4. Volumes of the media used in USP apparatus 1 were not able to provide 
sink conditions. Thus, the plateau of the dissolution profile for Tegretol® IR was reached at 
50%. Attempts at developing point-to-point Level A IVIVC using original and normalised (*) 
dissolution data were made and are presented in Figure 80. 
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 Figure 80. IVIVC of Tegretol® IR formulation using dissolution data obtained  USP apparatus 1 experiments.* 
indicates normalised data. 
Poor (R2 ≤ 0.93) IVIVC correlation was obtained using USP 1 dissolution data despite the 
normalisation (Figure 80). Dissolution profiles from USP 1 experiments were faster than 
absorption, which enabled 1:1 correlation.  
 
Figure 81. IVIVC of Tegretol® IR formulation using dissolution data obtained from USP apparatus 4 
experiments. 
Successful point-to-point Level A IVIVC was obtained using in vitro data tested in 
biorelevant media (Figure 81). The intercept of this linear regression is close to zero (-0.07) 
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together with a slope value close to 1 (0.81) and goodness of fit (R2: 0.98) indicates good in 
vitro-in vivo correlation. 
Deconvolution of the oral plasma concentration curve of 400 mg PR Tegretol® formulation 




Figure 82.  Mean in vivo absorption of CBZ from Tegretol® PR tablets using Wagner - Nelson method. 
 (a) Original in vivo data extracted from Kovacevic et al. (82). 
Fractions absorbed in vivo were related to fractions of CBZ dissolved in vitro by fitting linear 
regression model to the data (Figure 83). Correlations were performed using mean dissolution 
data tested using flow-through cell dissolution apparatus. Dissolution data for 400 mg 
Tegretol® PR tablets had similar dissolution profiles, thus correlations resulted in similar 
regression parameters. Dissolution data in biorelevant media (FaSSGF/FaSSIF-V2/FaSSCoF) 
allowed development of point-to-point Level A IVIVC. Goodness of fit value (R2: 0.99) is 
close to one, intercept parameter (0.03) close to zero together with slope value (1.01) close to 
1 indicate the desired method specifications that can be used to facilitate product development 
and serve as quality control tool during the manufacture process. 
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 Figure 83. IVIVC of Tegretol® IR formulation using dissolution data obtained from USP apparatus 4 
experiments. 
6.1.2 PBPK model 
6.1.2.1 IR formulation (200 mg Tegretol® tablets) 
Physiological, physicochemical, pharmacokinetic and formulation parameters of Tegretol® 
(CBZ) were inserted into the Simcyp® software.  The ability of Simcyp® software to predict 
dissolution data using solubility and particle size data was investigated. The dissolution data 
were predicted using the Wang-Flanagan (WF) equation. The predicted dissolution profiles 
aided then the prediction of Tegretol® in vivo performance (Figure 84). In comparison to 
existing in vivo data from Meyer et al. (283), the predicted plasma concentration profiles were 
overestimated (Table 75). The reason for overestimation could be due to the fact that WF 
approach does not take into the consideration formulation properties, which are essential for 
absorption modelling. Thus, an attempt to develop PBPK model using raw dissolution data 
from previously performed in vitro experiments was made. 
 160
 Figure 84. Mean (+ SD) simulated plasma concentration time profiles of PBPK IR Tegretol® model using 
predicted dissolution profile obtained by the Wang-Flanagan equation. 
Table 75. Summary of indices for a PBPK IR Tegretol® model using predicted dissolution profiles obtained by 
the WF equation. 
 f1 




Prediction of plasma concentration time profiles of PBPK Tegretol® model using dissolution 
data was attempted. The same physiological, physicochemical, pharmacokinetic parameters as 
in WF approach were used in this model.  Different type of dissolution data were used to 
predict in vivo behaviour of Tegretol® IR tablets. Figure 85 compares predicted plasma 
concentration profile from raw dissolution data obtained using USP apparatus 1 with observed 
in vivo profile reported by Meyer et al. (283). This predicted profile using USP apparatus 1 
data is significantly slower (f1: 35.44), and its Cmax, Tmax and AUC values are much lower than 
that reported for the observed profile (Table 77).  Underestimation could be due to failure of 
providing sink conditions for CBZ in USP apparatus 1.  
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 Figure 85. Mean (+ SD) simulated plasma concentration time profiles of PBPK IR Tegretol® model using 
dissolution profile obtained using USP apparatus 1. [in vivo data extracted from Meyer et al.(1992) (286)] 
Predicted plasma concentration profiles using raw dissolution data of Tegretol® IR 
formulations tested using USP apparatus 4 are shown in Figure 86. As can be seen from Table 
77, predicted plasma concentration time profiles that used dissolution data obtained from 
flow-though cell dissolution apparatus tested in compendial (f1: 33.68) and both modified 
conditions (MGM/MIM-I f1: 45.24; MGM/MIM-II f1: 37.69) resulted in similar f1 values to 
that in USP apparatus 1 (f1: 35.44), despite the fact that USP apparatus 4 provided sink 
conditions. Also, plasma concentration time profiles predicted using dissolution data in 
compendial (Cmax: 1.12; AUC: 95.15) and both modified conditions (MGM/MIM-I: Cmax: 0.95; 
AUC: 81.98; MGM/MIM-II: Cmax: 1.10; AUC: 94.10) resulted in similar (p > 0.05) Cmax and 
AUC values (Cmax: 1.02; AUC: 83.99) to data obtained using USP apparatus 1 (Appendix 8). It 
can be clearly seen from Figure 86 that dissolution in biorelevant media resulted in the best 
prediction (f1: 6.94) of in vivo performance of 200 mg IR Tegretol® tablets (Table 77). 
Despite discrepancies in Cmax and Tmax values, the predicted profile resulted in similar AUC 
values (Table 76). The successful IVIVC was developed with the PBPK model using raw 
dissolution data tested in biorelevant media using flow-through cell dissolution apparatus. 
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 Figure 86. Mean (+ SD) simulated plasma concentration time profiles of PBPK IR Tegretol® model using 
dissolution profiles obtained using USP apparatus 4. [in vivo data extracted from Meyer et al.(1992) (283)] 
Table 76. Mean simulated CBZ pharmacokinetic parameters for PBPK IR Tegretol® model. 
 Cmax [mg/L] Tmax [h] AUC [mg/L.h] 
In vivo 1.89 15.90 134.80 
USP 1sim 1.02 8.40 83.99 
SGF/SIFsim 1.12 17.68 95.15 
MGM/MIM-Isim 0.95 16.83 81.98 
MGM/MIM-IIsim 1.10 16.82 94.10 
FaSSGF/FaSSIF-V2sim 1.57 10.96 127.88 
 
Table 77. f1 values comparing in vivo plasma concentration time profile with simulated plasma concentration 
time profiles of PBPK IR Tegretol® model using different dissolution profiles. 
 f1 
(in vivo data as reference) 







According to the literature, the bioavailability of CBZ following oral administration is slow 
reaching approximately 70-90 % of CBZ being absorbed (322). The slow absorption of CBZ 
has been attributed to slow dissolution rate of CBZ in the GI tract in contrast to rapid GI 
transit time (323). Thus, CBZ absorption is primarily dissolution-rate limited (324, 325). The 
successful PBPK model resulted in an average 71 % of the CBZ absorbed, which is in 
agreement with reported values from the literature (Figure 87). Most of the CBZ was 
absorbed within 12 hours of oral administration. The absorption constant of ka 0.37 h-1 was 
estimated using first-order kinetics. 
 
Figure 87. Mean predicted cumulative fraction of CBZ absorbed from Tegretol® IR tablets predicted using 
successful PBPK model.  
 
Further examination of the Tegretol® IR PBPK model indicates that a large percentage (18%) 
of CBZ is absorbed from the colon (Figure 88). A similar value (25%) was reported for CBZ 
IR formulations under fasted state using ACAT model (248). The overall trend in the regional 
absorption was the same, however, some small differences in values were observed. These 
discrepancies could be due to discrepancies between PK parameters used for model 
development, quality of in vitro data used and features related to integrated ACAT and 





 Figure 88. Mean predicted regional distribution of the fraction of the CBZ dose absorbed from 200 mg 
Tegretol® IR formulation. 
6.1.2.2 PR formulation (400 mg Tegretol® tablets) 
The same pharmacokinetic and physiological parameters were further used to develop the 
PBPK model for 400 mg PR Tegretol® tablets. 400 mg PR Tegretol® tablets were selected for 
these simulations for which two sets of clinical data were found (Figure 89) (82, 284).   
 
Figure 89. Mean (+ SD) predicted plasma concentration time profile of 400 mg PR Tegretol® tablets using the 
PBPK model for CBZ after oral administration of an IR Tegretol® tablets. [in vivo data extracted from 
Kovacevic et al. (82) and Larkin et al. (284)] 
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Dissolution profile performed in the biorelevant media (FaSSGF/FaSSIF-V2/FaSSCoF) was 
used to develop the PBPK model for 400 mg PR Tegretol® tablets. Predicted plasma 
concentration profiles of 400 mg PR Tegretol® tablets were similar to observed profiles 
obtained from two separate clinical studies (in vivo data II: f1: 9.46 and in vivo data I: 18.91). 
The predicted mean plasma concentration profile of PR Tegretol® formulation is more 
significantly similar (f1: 9.46) to the observed profiles reported by Larkin et al. (in vivo data 
II) (284). However, the comparison with this profile was only performed until 56 hours. Thus, 
comparison with in vivo I data may be more reliable. 
 
The ADAM model was also used to predict the regional absorption of CBZ from 400 mg 
Tegretol® PR tablets (Figure 90). PR formulation might have a significant impact on the 
regional absorption. In previously examined IR formulation, CBZ was to the same extent 
absorbed in the jejunum and colon, whereas in the case of PR formulation there was more 
than 2.5 times increase in absorption in the colon compared to the jejunum. One quarter of the 
dose was absorbed in the colon resulting in the overall absorption around 60 %. 
 
Figure 90. Mean predicted regional distribution of the fraction of the CBZ dose absorbed from 400 mg 
Tegretol® PR formulation. 
 
The ACAT model developed by Zhang et al. showed that up to 50 % of 400 mg Tegretol XR 
formulation can be absorbed in the colon (248). The colon is considered as an important 
absorption site for CR formulations and often it can be referred as targeted drug delivery. An 
extensive study of 42 compounds in human showed that BCS class I drugs were well 
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absorbed in the colon (326). Thus, understanding of the impact of solubility and dissolution 
rate on the absorption in the colon is essential.  
6.1.2.3 Sensitivity analysis 
6.1.2.3.1 Sensitivity analysis for PBPK model after administration of IR Tegretol® 
tablets. 
Sensitivity analysis was performed for two types of parameters. The first group was related to 
absorption processes and include parameters such as solubility, particle size, logP and human 
effective permeability (Peff). The second group consists of parameters that describe the 
distribution of the drug in the human body such as volume of distribution (Vd) and clearance 
after oral administration (CLpo). Increasing solubility by 10 folds would have a minimal effect 
on the Cmax and Tmax (Table 78). However, if CBZ would be less soluble (by 10 folds) then 
there would be significant reduction in AUC and Cmax. Time to reach Tmax would be twice as 
long as that at the current solubility. Micronisation of the API will slightly enhance Cmax and 
AUC. On the other hand, 10 times larger particle size would result in lower AUC and Cmax and 
significantly delayed Tmax (nearly 2 fold). Lipophilicity of the CBZ was insensitive to any 
changes (Figure 91). Human effective permeability may affect the PBPK model if lower 
values than 3.1 x 10-4 cm/s would be selected. CBZ belongs to BCS class II drugs which are 
characterised by high permeability, thus it was unlikely that human permeability will be 
sensitive to changes. The human permeability value of 4.3 x 10-4 cm/s was determined using 
very accurate regional human jejunal perfusion technique. It is worth of noting that too fast 
dissolution rate may cause saturation process, which may affect rate of permeation.  
Table 78. Sensitivity analysis of absorption related parameters of Tegretol® IR PBPK model. 
 AUC [mg*h/L] Cmax [mg/mL] Tmax [h] 
Control 177.08 2.43 5.90 
Solubility x10 182.73 2.57 5.05 
Solubility / 10 53.10 0.58 10.93 
PS x10 155.99 1.98 10.11 











Figure 92. Sensitivity analysis of distribution parameters: Vd (L/kg) and Clpo (L/h). 
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Figure 92 illustrates that clearance and volume of distributions are the two parameters that are 
the most susceptible to any changes. For instance, small changes in the clearance value will 
cause significant changes in AUC and Tmax levels. However, it will have only minimal effect 
on the Cmax value. Similarly to clearance parameter, Vd value will affect the Tmax and AUC 
levels the most and it will have the least impact on Cmax.  
6.1.2.4 Reported IVIVC for CBZ 
Several studies have been conducted in order to develop IVIVC of Carbamazepine products. 
In 1984, Kaneniwa et al. found a correlation between in vitro time required for 30, 50, 60 and 
80% to be dissolved and the in vivo absorption rate constant by using two liters of gastric 
fluid as dissolution media and 100rpm (327). A year later, Neuvonen reported a good 
agreement between in vitro release of Carbamazepine in 1L of 0.1M HCl using USP 
apparatus 1 at 100rpm and the absorption profile in vivo (328). The similar dissolution 
specifications (0.1M HCl, 100rpm) using paddle instead of basket apparatus allowed Hartley 
et al. to assess the bioavailability of two formulations in epileptic children at steady state 
(329) .   
Moreover, Meyer et al. developed an IVIVC using three generic 200 mg tablets products and 
innovator product using 900 mL of water containing 1% SLS stirred at 75 rpm in paddle 
apparatus. The relationship between the percentage dissolved during the first 45 minutes and 
the Cmax and AUC values was found to be more useful in predicting the bioequivalence of 
CBZ (Multiple Level C) (330). The same group attempted to establish Level A IVIVC for 
three generic CBZ formulations and reformulated innovator product, which was shown to be 
approximately 6% more bioavailable than the old formulation (331). They have failed to 
establish Level A IVIVC but again successfully developed Multiple C correlation. This time 
they found a correlation between Tmax and Cmax  and percentage dissolved in vitro at 5, 10, 15, 
20 and 30 minutes using the same dissolution method (paddle, 900 mL, 75 rpm, water 
containing 1% SLS).  
Jung et al. failed to find Level A IVIVC using the same dissolution method but have achieved 
linear correlation between AUC and percentage drug dissolved of four formulations at 45, 60 
and 90 minutes in intestinal medium (Level C) (332). Another Level C correlation was 
established by Lake et al. who obtained linear relationships between Cmax values of four 
formulations and percentage dissolved in vitro at 20, 40 and 50 minutes in water containing 
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1% SLS (paddle, 900 mL, 75 rpm) (240). In 2000, Veng-Pedersen et al. successfully 
developed Level A IVIVC using a scaled convolution based predictive approach using data 
from four CBZ formulations (331). In this case, dissolution data in water containing 1% SLS 
(paddle, 900 mL, 75 rpm) were convoluted by a single exponential and the estimated unit 
impulse response function and time scaled and mapped with drug concentration data. 
Kovacevic et al. established successful Level A IVIVC for immediate (IR) and controlled 
(CR) release CBZ formulations using Physiologically Based Pharmacokinetic (PBPK) 
modeling (82). To achieve this gastrointestinal simulation based on the advanced 
compartmental absorption and transit (ACAT) model built – in GastroPlus® software was 
used. The in vivo drug absorption and disposition was simulated based on CBZ 
physicochemical and pharmacokinetic properties and drug dissolution kinetics observed in 
vitro. Also, in this case, the dissolution method used water containing 1%SLS (paddle, 900 
mL, 75 rpm) resulted in the best prediction. Despite the proven effectiveness of this medium, 
the physiological relevance of this dissolution method can be questioned. 
6.2 Indomethacin case 
6.2.1 Model-independent approach 
Numerical deconvolution of the Indomethacin in vivo data using PCDCON resulted in the 
profile presented in Figure 93. It can be clearly seen that the absorption of IND is delayed and 
only around 20 mg of Indomethacin was absorbed within four hours. Incomplete absorption 
supports the findings that were observed during dissolution using USP apparatus 4 that relates 
to low solubility in acidic pH and the precipitation upon media change. Also, it may be 
concluded that due to the fact that solubility of IND is very low in acidic environment, gastric 
emptying may be responsible for slower initial absorption onset. Possibly Indomethacin 
precipitated in vivo after GE which resulted in lower amounts absorbed (20 mg within 4 h). 
This may indicate that probably 20% (remaining 5 mg of the dose) of the IND precipitated, 
and this is in agreement with in vitro studies performed. According to the dissolution studies 
of IND, 15% of Indocid® dose precipitated in biorelevant media. Some discrepancies could be 
due to variability of in vivo data. 
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 (a) 
Figure 93. Mean in vivo absorption profile after oral administration of 25 mg Indocid® capsules. 
(a) Original in vivo data extracted from Yeh et al. (285). 
Dissolution data in various media were then compared with in vivo absorption Indocid® data 
(Figure 94) and Level A IVIVC were made. Level A IVIVC was not achievable with the 
original dissolution data obtained from USP apparatus 4 presented as cumulative amount 
dissolved (Figure 95). Time at which media were changed (1 h) limited the comparison with 
in vivo absorption of Indomethacin data and resulted in non-linear correlation (Figure 95). 
This indicated that the absorption is faster than dissolution, thus dissolution in gastric 
conditions is a rate limiting step. Thus, attempts to correlate only dissolution data from an 
intestinal part were made (Figure 96). It is worth noting that due to precipitation that was 
measured in vitro, the dissolution profiles reached plateau at around one and a half hours of 
experiment. Taking into consideration the values after the plateau is reached will result in 
many points close to each other at the terminal part of the correlation (as seen in Figure 95). 
Terminal points from dissolution profiles (after plateau) will affect the goodness of fit of the 
linear regression. Thus for the further correlations in vivo and in vitro data until two hours 
were used. 
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 Figure 94. Mean in vivo amount absorbed and in vitro amount dissolved data of Indocid® IR capsules. 
 
Figure 95. Mean in vivo amount absorbed versus in vitro amount dissolved for Indocid® IR capsules. 
Using dissolution profiles from the part of profile that was performed using simulated 
intestinal media resulted in non-linear correlation (R2 0.73 – 0.91) indicating that dissolution 





Figure 96. Level A IVIVC using dissolution data simulating only intestinal conditions using USP apparatus 4. 
As IND absorbed faster than dissolved, thus time scaling using Levy’s plot was applied 
(Figure 96).  
 
Figure 97. Levy's plot. 
 
Levy’s plot was not a straight line thus the scaling factor was not clearly calculated; however, 
observed rupture in the Levy’s plot denotes at which time the in vitro and in vivo processes 
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diverged (Figure 97). At the turning point, amount absorbed at 0.25 hour (15 min) 
corresponds to amount dissolved at 1.17 h (70 minutes). The time 0.25 hour indicates the time 
shifting required for development of linear correlation. Since, minimal dissolution (3%) of 
IND was observed up to the first hour, the in vitro data were handled in order to mimic the 
dissolution experiment with media change occuring at an earlier time point than the one hour 
performed (Figure 98). The in vitro dissolution data for Indocid® capsules tested in various 
media using USP apparatus 4, where shifted this way to simulate media change occuring at 20 
minutes. The shifted profiles were then correlated with amount absorbed in vivo (Figure 98).  
  
 
Figure 98. Level A IVIVC using time scaled dissolution data at 20 min in all media using USP apparatus 4. 
For all correlations, the extent of fit (R2) of linear regression is in the range of 0.96 – 0.99 
which indicates that very good correlations were made. According to the R2 values, 
dissolution data in biorelevant media tested using USP apparatus 4 provided the best IVIVC 
correlations. Time scaling that was applied highlights the fact that more attention should be 
paid to parameters such as GE time and media change as they may have crucial impact on the 
quality of IVIVC obtained. 
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6.2.2 PBPK modelling 
6.2.2.1 IR formulation (25 mg Indocid® capsules) 
Physiological, physicochemical, pharmacokinetic and formulation parameters of Indocid® 
(IND) were inserted into the Simcyp® software.  The ability of Simcyp® software to predict 
dissolution data using solubility and particle size data was investigated. The dissolution data 
were predicted using the Wang-Flanagan (WF) equation. The predicted dissolution profiles 
were then used for the prediction of Indocid® in vivo performance (Figure 99). When the 
Wang-Flanagan equation was used to predict in vivo behaviour of IND, it was found that 
gastric emptying (GE) time became a crucial parameter. Initially, GE time was set up at 1 
hour, in accordance with a change of media during dissolution experiments using USP 
apparatus 4. The commercial formulation of Indomethacin, Indocid®, is available in a capsule 
form. According to Kaus et al. gastric emptying time of Perspex non-disintegrating 
radiolabelled capsules ranges between 15-197 min, and strongly depends on the migrating 
motor complex (MMC) (333). Simulation with GE time at 1 h resulted in a lower Cmax and 
delayed Tmax (Figure 99). GE time in Simcyp® software is set to 20 minutes (0.4 h) as a 
default value; therefore, attempts at simulation using a shorter GE time was made. The 
predicted profile with GE time set up to 0.4 hour provided better similarity (f1: 22.86) to the 
observed data than that with GE occurring at 1 hour (Table 79). As can be seen from Figure 
99, simulations resulted in a closer Cmax value and Tmax was reached faster. Thus for further 
predictions GE time was set to 0.4 hour default value in Simcyp® software 
 
Figure 99. Mean (+ SD) simulated plasma concentration time profiles of PBPK Indocid® model using predicted 
dissolution profile obtained by the Wang-Flanagan equation. [in vivo data extracted from Yeh et al. 1982 (285)] 
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Table 79. Indices for a PBPK Indocid® model using predicted dissolution profiles obtained by the Wang-
Flanagan equation at different GE time. 
 f1 
(in vivo data as reference) 
WF – compendial – GE at 0.4 h 22.86 
WF – compendial – GE at 1 h 36.20 
 
According to Figure 100, when the Wang-Flanagan approach was supported with solubility 
values of IND in compendial and biorelevant media, the simulated profile similar to the 
observed in vivo data (Table 80) and no difference was observed between the two simulated 
profiles (f1: 0.03). The slight insignificant decrease was probably due to some discrepancies in 
solubility of IND in these two types of media. This model predicted better absorption phase 
than distribution and elimination phases. More care should be taken when selecting 
distribution and clearance parameters for a PBPK model development of IND.  
 
Figure 100. Mean (+ SD) simulated plasma concentration time profiles of PBPK Indocid® model using 






Table 80. Indices for a PBPK Indocid® model using predicted dissolution profiles obtained by the Wang-
Flanagan equation. 
 f1 
(in vivo data as reference) 
WF - compendial 22.86 
WF - biorelevant 22.83 
 
According to the literature, the absorption of IND following oral administration is fast and 
complete. The successful PBPK model resulted in an average of 100 % IND absorption, 
which is in agreement with reported values from the literature (Figure 101). IND was 
absorbed within 3 hours of oral administration. The absorption constant of ka 0.97 h-1 was 
estimated using first-order kinetics. 
 
Figure 101. Mean predicted cumulative fraction of IND absorbed from Indocid® IR capsules predicted using 
predicted dissolution data using the Wang-Flanagan equation. 
According to predicted regional fraction absorbed presented in Figure 102, a quarter of the 
dose was absorbed in duodenum, and around 64 % of the IND dose was absorbed in both 
compartments of the jejunum. A smaller fraction of the drug was absorbed in the duodenum 
than in the jejunum due to relatively short transit times, which are 14 and 71 minutes, 
respectively (174). 
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 Figure 102. Mean predicted regional distribution of the fraction of the IND dose absorbed from 25 mg Indocid® 
IR formulation. 
Despite small discrepancies between Tmax and AUC values of predicted and observed data; it 
seems that point-to-point Level A IVIVC was developed with the PBPK model using 
predicted dissolution data. 
 Furthermore, the ability of Simcyp® software to predict dissolution data using raw dissolution 
data was investigated (Figure 103). All simulations using dissolution data tested using USP 
apparatus 1 were under-predicted. However, simulations using dissolution profiles in SIF 
resulted in better predictions than when both media SGF and SIF were considered. 
Indomethacin is a weak acid (pKa 4.3) which characterises low solubility in an acidic 
environment and high solubility in a basic environment. This trend was also present when 
data from USP apparatus 4 were used (Figure 104).  Simulated Cmax and AUC were 
significantly lower and Tmax had delayed onset. The attempt of simulating in vivo profiles 
using only data extracted from intestinal part of the USP apparatus 4 was made (data not 
shown). The simulated profiles were improved in comparison to those profiles presented in 
Figure 104; however, they were still under-predicted.  
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 Figure 103. Mean (+ SD) simulated plasma concentration time profiles of PBPK Indocid® model using 
dissolution profiles tested in USP apparatus 1. 
 
 
Figure 104. Mean (+ SD) simulated plasma concentration time profiles of PBPK Indocid® model using 
dissolution profiles tested in USP apparatus 4. 
It was not possible to develop IVIVC for Indocid® capsules using PBPK model developed 
with raw dissolution data. This could be due to the fact that in vivo precipitation was not 
adequately characterised by the in vitro experiment. WF approach at least simulated 
absorption phase of IND from Indocid® capsules. Also, Indocid® capsules were withdrawn 
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from many countries including the UK. Therefore, availability of other than 25 mg Indocid® 
capsules formulations was restricted.  
6.2.3 Sensitivity analysis 
Sensitivity analysis was performed for three types of parameters. The first group was related 
to absorption process and included parameters such as solubility, particle size, logP and 
apparent permeability coefficient. Papp value was selected for sensitivity studies due to 
absence of in vivo human jejunal permeability data. Therefore,  Peff value was predicted using 
apparent permeability coefficient obtained from Caco-2 in vitro experiment. The second 
group consisted of parameters that describe the distribution of drug in the human body such as 
volume of distribution (Vd) and clearance after oral administration (CLpo). The third group 
related to physiological parameters, such as gastric emptying time that is a crucial parameter 
especially for ionisable drugs.  Increasing or decreasing solubility by 10 fold will not affect 
the AUC (Table 81). Decreased solubility resulted in a lower Cmax value. Interestingly, 
improving solubility of IND would result in similar in vivo performance when micronising the 
drug to a tenth of the size. On the other hand, decreasing solubility (by 10 fold) would result 
in similar in vivo performance to that when larger particles would be tested.  Lipophilicity of 
the IND was insensitive to any changes (Figure 105). Also, apparent permeability coefficient 
was not sensitive to any alterations in the tested range 210 - 300 x 10-6 cm/s. 
Table 81. Sensitivity analysis of absorption related parameters of Indocid® IR PBPK model. 
 AUC [mg*h/L] Cmax [mg/mL] Tmax [h] 
Control 3.66 1.52 1.09 
Solubility x10 3.63 1.45 1.23 
Solubility / 10 3.63 1.32 1.32 
PS x10 3.62 1.36 1.32 







Figure 105. Sensitivity analysis of absorption parameters: log P (unitless) and Papp (x10-6 cm/s). 
Likewise, in the case of the PBPK model for Tegretol®, clearance and volume of distribution 
affected the model the most. Higher clearance resulted in lower Cmax, Tmax and AUC values 
(Figure 106). The volume of distribution did not affect AUC, but had impact on Tmax and Cmax. 
Failure of predicting well IND distribution and elimination phases during WF approach could 
be due to inappropriate selection of clearance and volume of distribution parameters. 
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 Figure 106. Sensitivity analysis of distribution parameters. 
In the case, when ionisable compounds are subject to in vivo performance, changing of the pH 
in the GI environment will be one of the most important parameters that may define the 
overall performance. GE time does not have any influence on the AUC, but the faster the GE, 




Figure 107. Sensitivity analysis of physiological parameters. 
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7 Predictions of absorption of cocrystals 
7.1 Carbamazepine case 
Tegretol® PBPK models were used to predict absorption of cocrystals based on their 
dissolution data. Both models were developed for commercial formulations which contained 
various excipients that aid dissolution. Thus, in order to avoid misleading interpretations, the 
CBZsp profile in biorelevant media was used as the control.  
It was found that overall bioavailability of CBZ from CBZ cocrystals did not increase 
dramatically. An overall 2 % increment was observed when compared against the CBZsp 
sample (Table 83). However, the rate of absorption for CBZ-SACss samples was significantly 
faster (f1: 15.47) than the rate of CBZsp absorption (Table 82). This was confirmed by a higher 
value of the absorption constant (ka: 0.26) for CBZ-SACss when compared to that of the 
CBZsp control profile (ka: 0.16). Further comparison of fraction absorbed in individual GI 
segments was performed (Figure 109).  Both CBZ-SAC cocrystals (ss and umax) absorbed 
larger fractions of the dose in the first three segments of the GI tract responsible for 
absorption (duodenum, jejunum I and jejunum II) when compared with the CBZsp 
performance. However, this resulted in a lower fraction of the dose absorbed in the colon. 
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Table 83. Absorption constants (ka) and overall  in vivo absorption for different CBZ formulations. 
Formulations Absorption constant ka [h-1] Absorption [%] 
CBZsp 0.16 74 
CBZ-SACss 0.26 76 
CBZ-SACumax 0.21 73 
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7.2 Indomethacin case 
All formulations of IND completely absorbed within 3 hours, and IND-NICss cocrystal 
absorbed slightly faster than the others (Table 85). % absorbed of IND from IND-NICss 
cocrystal was 8% higher at 1 h in comparison to INDsp (Figure 110). However, overall the 
improvement was not statistically significant (f1 ≤ 4.72) (Table 84).  
 
Figure 110. Mean predicted cumulative fraction absorbed of IND from different IND formulations. 











Table 85. Absorption constants (ka) and overall  in vivo absorption for different IND formulations. 
Formulations Absorption constant ka [h-1] Absorption [%] 
INDsp 0.80 99 
IND-SACss 0.91 99 
IND-SACsd 0.90 99 
IND-SACumax 0.83 99 
IND-NICss 1.01 99 
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 A similar trend was observed when fractions absorbed of the IND dose in different GI tract 
segments were compared. According to Figure 111, slightly larger fractions of the IND were 
absorbed from IND-NICss in the duodenum when compared with IND formulation. Around 70 
% of the dose was absorbed in the jejunum segment.  
 
 












8 Conclusions and future work 
Conventional dissolution apparatus (USP apparatus 1) was not adequate to characterise in 
vitro performance of poorly soluble drugs. In the case of Tegretol® tablets, sink conditions 
were not provided, resulting in dissolving only 50 % of the formulation. Whereas, in the case 
of pH-dependent solubility IND compound present in Indocid® capsules, around 3 % of the 
IND dissolved in gastric conditions. Rapid dissolution of this formulation within five minutes 
occurred in SIF (pH 6.8). This method was unable to characterise dissolution of cocrystals. 
Flow-through cell dissolution (USP apparatus 4) provides infinite sink conditions and allowed 
the change of media, which helped to mimic the in vivo environments closely. USP apparatus 
4 allowed discrimination between performances in different media. Dissolution of Tegretol® 
tablets in biorelevant media resulted in the greatest enhancement by 1.5 fold due to the 
presence of bile salts. SAC cocrystals of CBZ significantly improved dissolution of poorly 
soluble CBZ. SAC cocrystals made by sonic-slurrying method resulted in two - fold higher 
dissolution than cocrystals made using UMAX technology when compared against dissolution 
of CBZsp samples.  
Moreover, it was found that physical blends of CBZ and SAC (CBZ--SAC) significantly 
enhanced dissolution of CBZ. Statistical analysis between blend (CBZ--SAC) and cocrystals 
indicated that only dissolution performance of cocrystal made by sonic-slurrying proved to 
make a complex compound that enhanced dissolution better than the physical blends of the 
two components. Further investigation showed that SAC from CBZ-SACss cocrystal was 
dissolving at a slower rate than SAC from the physical blend, despite the fact that both SAC 
dissolved within the first 90 minutes of the experiment. It was hypothesised that upon contact 
with water, weak hydrogen bonds between hydrophobic CBZ and the highly soluble coformer 
SAC immediately broke down. The SAC from the cocrystal was available for water to 
dissolve and thus allowing water to penetrate between poorly soluble CBZ at the same time, 
leading to dissolution enhancement of CBZ. The findings that the same ratio of API and 
coformer (depending if formed as cocrystal or physical blend) can lead to different dissolution 
performance led to the conclusion that crystal packing and arrangement in these two 
formulations are different and thus packing and arrangement play an important role in 
enhancement of dissolution by cocrystals. In order to fully understand and confirm the 
hypothesis of packing and arrangements in cocrystals, further examination of these cocrystals 
may be beneficial such as single X-ray diffraction, nuclear magnetic resonance (NMR), or 
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thermogravimetric analysis (TGA). Also, it may be interesting to investigate in future studies 
the effect of micelles on the dissolution of SAC itself, in order to gain understanding of 
whether the dissolution enhancement is due to solubilisation of an API or SAC or both 
components together.  
Interestingly, NIC cocrystals of CBZ did not demonstrate any dissolution enhancement. Two 
observations could aid the understanding of this behaviour. Firstly, the dose of IND (25 mg) 
is eight times smaller than that of CBZ (200 mg). Thus, amounts of NIC in CBZ-NICss 
cocrystal may not be sufficient to impact its dissolution. Secondly, according to Hörter and 
Dressman, for compounds with high logP, solubilisation is the predominant mechanism (IND 
logP 4.27), whereas for compounds with lower logP (CBZ 2.45) wettability is the mechanism 
which accounts for enhancement of powder dissolution rate (324). It seems that it was easier 
to solubilise small amounts of IND than wet large amounts of CBZ.  
In the case of Indomethacin and its cocrystals, USP apparatus 4 allowed quantification of the 
precipitation of the samples upon the media change. This phenomenon is known to occur in 
vivo; however its process is not fully understood yet. It has been observed that biorelevant 
media resulted in the smallest fraction of the dose precipitating, whereas compendial media 
led to the greatest fraction of IND precipitated in all formulations (control, commercial and 
cocrystal formulations). This could be explained by the fact that bile salts present in 
biorelevant media inhibited precipitation of IND. Overall, the largest fraction of the Indocid® 
dose precipitated across all investigated media, whereas the smallest fraction of dose 
precipitated form INDsp formulations. This led to the conclusion that excipients and coformers 
present in Indocid® formulations contributed to the extent of precipitation.  
Among SAC cocrystals, those made by UMAX technology provided the greatest 
enhancement of dissolution rate. Moreover, the dissolution profile of the physical blend was 
significantly slower than IND-SAC cocrystals but slightly faster than dissolution of INDsp 
samples. Both, SAC and NIC cocrystals made by sonic-slurrying demonstrated to 
significantly enhance the dissolution of IND. Nicotinamide cocrystal of IND improves 
dissolution of IND greater than Saccharin cocrystal. Also, the dissolution profile of the 
physical blend of IND and NIC was significantly slower than IND-NICss but significantly 
faster than dissolution of INDsp samples. Further investigation of the dissolution mechanism 
of NIC from cocrystal and physical blend revealed that NIC from both the cocrystal and the 
physical blend dissolved within the first 30 minutes. This led to the conclusion that it might 
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be the packing and arrangement of the NIC and IND in both physical blend and cocrystal that 
plays an important role in the enhancement of dissolution of IND.  
Successful IVIVC for Tegretol® tablets and Indocid® capsules were established using both 
traditional and PBPK approaches. Successful point-to-point Level A IVIVC for IR Tegretol® 
tablets was obtained using in vitro dissolution data tested in biorelevant media using USP 
apparatus 4. Also, dissolution data of PR Tegretol® tablets in biorelevant media 
(FaSSGF/FaSSIF-V2/FaSSCoF) allowed development of 1:1 in vitro – in vivo correlations. 
Successful point-to-point Level A IVIVC for Indocid® capsules was developed using 
numerical deconvolution method. Dissolution profiles obtained by testing formulations in 
biorelevant media using USP apparatus 4 provided the best IVIVC correlations. Development 
involved time scaling using Levy’s plot technique.  
Successful PBPK models were developed for IR and PR formulations of Tegretol® tablets 
using dissolution data (USP apparatus 4) tested in biorelevant media. The simulations using 
predicted dissolution profiles using the Wang-Flanagan equation were overestimated when 
compared against in vivo observed data. The reason for overestimation could be attributed to 
the limitations of Wang-Flanagan approach, which do not consider formulation properties. 
Also, inadequately measured values of particle size of CBZ could led to over-prediction. It 
seems that the particle size of CBZ in Tegretol® tablets is much larger than that measured 
using laser diffraction. Sonication process that samples were exposed to could break down the 
primary particle size further.  
When the Wang Flanagan equation was used to predict in vivo behaviour of Indocid® 
capsules, it was found that gastric emptying (GE) time became a crucial parameter. This is 
expected for ionisable compounds. The predicted profile with GE time set up to 0.4 hour was 
more similar to the observed data than that with GE occurring at 1 hour. When the Wang-
Flanagan approach was supported with solubility values of IND in biorelevant media, the 
profiles were similar to when using compendial media. On the other hand, it was not possible 
to develop IVIVC for Indocid® capsules using the PBPK model developed with raw 
dissolution data. Several factors affect the absorption modelling, it seems that not all of them 
were investigated.  
Development of the PBPK model for the neutral compound, CBZ was possible using raw 
dissolution data tested in biorelevant media using USP apparatus 4. Unfortunately, this was 
not the case when pH-solubility dependent drug, Indomethacin was investigated. In the case 
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of this compound, prediction using the Wang-Flanagan equation was able to predict 
absorption phase successfully. 
The successfully developed PBPK models were used further to predict in vivo performance of 
pharmaceutical cocrystals. It was found that predicted cumulative fraction absorbed of CBZ 
from CBZ cocrystals did not increase dramatically. An overall 2 % increment was observed 
when compared against the CBZsp sample. The rate of absorption for CBZ-SACss samples 
was significantly faster than the rate of CBZsp absorption. Among IND cocrystals, IND-NICss 
cocrystal was predicted to absorb slightly faster than other IND-SAC cocrystals. Predicted 
cumulative fraction absorbed of IND-NICss was 8% higher at 1 h in comparison to INDsp. 
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Appendix 1 
Detailed calculations for CBZ-SAC and CBZ-NIC cocrystals 
MW of CBZ = 236.27g/mol 
MW of SAC = 183.18g/mol 
MW of NIC = 122.12g/mol 
 
Amount of CBZ in Tegretol tablet = 200mg = 0.2g 
Amount of CBZ moles in 200mg  
M
mn                    
 where n – number of moles [mol]; 
m - mass of compound [g] 
















The same molar amount of coformers (SAC; NIC) must be obtained in order to achieve 1:1 molar ratio 
of CBZ:SAC and CBZ:NIC. Thus, above equation needs to be converted to: 
Mnm   
































1 26.2 31517.70 
2 26.2 31238.20 
3 26.2 30530.40 
4 26.4 32161.00 
5 26.2 31138.20 
6 26.3 31166.00 
7 26.1 30952.50 
8 26.3 30370.10 
9 26.4 31231.60 
10 26.2 30848.10 
MEAN 31115.38 





WEIGHT [MG] AREA 
1 41.5 30338.50 
2 41.6 30108.90 
3 41.6 30793.40 
4 41.7 29585.20 
5 41.4 29627.60 
6 41.4 30955.70 
7 41.7 30354.00 
8 41.5 29992.50 
9 41.5 30679.60 








WEIGHT [MG] AREA 
1 36.2 29308.10 
2 36.2 30044.80 
3 36.2 30407.50 
4 36.4 30211.70 
5 36.4 31029.60 
6 36.3 29916.70 
7 36.4 30357.40 
8 36.4 30129.00 
9 36.4 30686.30 
10 36.4 30897.30 
MEAN 30298.84 
















Detailed calculations for IND-SAC and IND-NIC cocrystals 
MW of IND = 357.79g/mol 
MW of SAC = 183.18g/mol 
MW of NIC = 122.12g/mol 
 
Amount of IND in Indocid capsule = 25mg = 0.025g 
Amount of IND moles in 25mg  
M
mn                    
 where n – number of moles [mol]; 
m - mass of compound [g] 
















The same molar amount of coformers (SAC; NIC) must be obtained in order to achieve 1:1 molar ratio 
of IND:SAC and IND:NIC. Thus, above equation needs to be converted to: 
Mnm   
































1 35.62 3141.40 
2 35.69 3175.30 
3 35.51 3005.30 
4 35.65 3024.97 
5 35.47 3010.60 
6 35.54 3069.69 
7 35.48 3093.60 
8 35.75 3041.84 
9 35.62 3111.20 
10 35.6 3131.60 
MEAN 3080.55 







1 35.86 3508.92 
2 35.89 3536.52 
3 35.9 3471.40 
4 35.79 3517.50 
5 35.78 3588.82 
6 35.88 3578.22 
7 35.75 3565.70 
8 35.94 3514.96 
9 35.88 3516.60 
10 35.78 3470.10 
MEAN 3526.87 





 Appendix 5 


























 CBZ CBZ-SACss CBZ-SACumax CBZ-NICss 
0.67 0.05 0.15 0.10 0.19 
0.99 0.06 0.21 0.13 0.24 
1.20 0.06 0.26 0.14 0.28 
1.40 0.05 0.30 0.16 0.30 
1.64 0.05 0.35 0.19 0.33 
1.99 0.04 0.41 0.23 0.37 
2.39 0.04 0.48 0.30 0.40 
2.84 0.04 0.54 0.40 0.42 
3.39 0.04 0.61 0.53 0.45 
3.99 0.06 0.67 0.68 0.47 
4.64 0.08 0.72 0.82 0.50 
5.48 0.12 0.76 0.97 0.55 
6.71 0.18 0.79 1.10 0.63 
8.22 0.26 0.76 1.15 0.74 
9.72 0.35 0.69 1.12 0.85 
11.46 0.45 0.60 1.06 0.94 
13.69 0.57 0.51 0.96 0.99 
16.43 0.72 0.46 0.83 0.97 
19.44 0.86 0.44 0.67 0.87 
22.91 1.01 0.46 0.52 0.73 
27.39 1.17 0.51 0.35 0.56 
32.86 1.32 0.55 0.21 0.40 
39.34 1.44 0.54 0.11 0.26 
46.83 1.46 0.45 0.05 0.15 
55.78 1.28 0.30 0.03 0.07 
66.73 0.84 0.15 0.01 0.02 
79.69 0.32 0.05 0.01 0.00 





 IND IND-SACss IND-SACsd IND-SACumax IND-NICss 
0.67 0.06 0.13 0.11 0.04 0.12 
0.99 0.08 0.17 0.13 0.05 0.16 
1.20 0.08 0.19 0.14 0.06 0.19 
1.40 0.09 0.22 0.13 0.07 0.21 
1.64 0.09 0.24 0.13 0.07 0.25 
1.99 0.10 0.28 0.13 0.08 0.29 
2.39 0.11 0.32 0.12 0.09 0.35 
2.84 0.13 0.36 0.11 0.11 0.41 
3.39 0.15 0.40 0.11 0.13 0.48 
3.99 0.18 0.43 0.12 0.16 0.55 
4.64 0.21 0.45 0.12 0.18 0.62 
5.48 0.26 0.47 0.15 0.22 0.70 
6.71 0.32 0.48 0.19 0.27 0.80 
8.22 0.38 0.47 0.26 0.31 0.88 
9.72 0.45 0.48 0.37 0.34 0.95 
11.46 0.53 0.51 0.53 0.39 1.01 
13.69 0.63 0.56 0.76 0.45 1.05 
16.43 0.76 0.60 1.01 0.55 1.05 
19.44 0.88 0.62 1.21 0.66 0.96 
22.91 1.01 0.63 1.32 0.80 0.80 
27.39 1.15 0.65 1.34 0.98 0.56 
32.86 1.25 0.70 1.24 1.16 0.30 
39.34 1.26 0.79 1.08 1.31 0.12 
46.83 1.12 0.84 0.87 1.36 0.03 
55.78 0.84 0.76 0.63 1.26 0.00 
66.73 0.49 0.53 0.36 0.97 0.00 
79.69 0.21 0.29 0.14 0.58 0.00 
94.66 0.07 0.14 0.00 0.23 0.00 
112.56 0.02 0.06 0.00 0.05 0.00 




 Appendix 7 
Two Way Repeated Measures ANOVA (Two Factor Repetition)Wednesday, December 
14, 2011, 12:12:17 
Data source: Data 1 in CBZ-solubility data-TW AnovaRM across medium 
Balanced Design 
Dependent Variable: Solubility  
Normality Test (Shapiro-Wilk) Passed (P = 0.600) 
Equal Variance Test: Passed (P = 0.297) 
Source of Variation  DF   SS   MS    F    P   
Sample no 2 75.003 37.501    
Medium 4 81376.916 20344.229 338.917 <0.001  
Medium x Sample no 8 480.218 60.027    
Formulation 3 113358.493 37786.164 267.943 <0.001  
Formulation x Sample no 6 846.140 141.023    
Medium x Formulation 12 97507.867 8125.656 66.185 <0.001  
Residual 24 2946.509 122.771    
Total 59 296591.145 5026.969    
 
 
Main effects cannot be properly interpreted if significant interaction is determined. This is 
because the size of a factor's effect depends upon the level of the other factor. 
 
The effect of different levels of Medium depends on what level of Formulation is present.  
There is a statistically significant interaction between Medium and Formulation.  (P = <0.001) 
 
Power of performed test with alpha = 0.0500:  for Medium : 1.000 
Power of performed test with alpha = 0.0500:  for Formulation : 1.000 




 Least square means for Medium :  
Group Mean  
SGF 264.238  
SIF 223.020  
Std Err of LS Mean = 2.237 
Least square means for Formulation :  
Group Mean  
CBZ-MCC 284.531  
CBZ-NIC-MCC 238.135  
CBZ-SACss-MCC237.830  
Std Err of LS Mean = 3.066 
Least square means for Medium x Formulation :  
Group Mean  
SGF x CBZ-MCC 250.819  
SGF x CBZ-NIC-MCC 208.116  
SGF x CBZ-SACss-MCC 232.076  
SIF x CBZ-MCC 199.523  
SIF x CBZ-NIC-MCC 226.397  
SIF x CBZ-SACss-MCC 210.054  
SIF x CBZ-SACumax-MCC 256.104  
FaSSGF x CBZ-MCC 416.517  
FaSSGF x CBZ-NIC-MCC 258.011  
FaSSGF x CBZ-SACss-MCC197.166  
FaSSGF x CBZ-SACumax-MCC 467.287  
FaSSIF-V2 x CBZ-MCC 287.473  
FaSSIF-V2 x CBZ-NIC-MCC273.125  
FaSSIF-V2 x CBZ-SACss-MCC285.806  
FaSSIF-V2 x CBZ-SACumax-MCC 324.318  
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Std Err of LS Mean = 6.397 
All Pairwise Multiple Comparison Procedures (Bonferroni t-test): 
Comparisons for factor: Medium 
Comparison Diff of Means t P P<0.050   
FaSSGF vs. SIF 111.726 35.323 <0.001 Yes   
FaSSGF vs. SGF 70.507 22.291 <0.001 Yes   
FaSSGF vs. acetate 69.086 21.842 <0.001 Yes   
FaSSGF vs. FaSSIF-V2 42.065 13.299 <0.001 Yes   
FaSSIF-V2 vs. SIF 69.661 22.024 <0.001 Yes   
FaSSIF-V2 vs. SGF 28.442 8.992 <0.001 Yes   
FaSSIF-V2 vs. acetate 27.021 8.543 <0.001 Yes   
acetate vs. SIF 42.640 13.481 <0.001 Yes   
acetate vs. SGF 1.422 0.449 1.000 No   
SGF vs. SIF 41.218 13.031 <0.001 Yes   
 
Comparisons for factor: Formulation 
Comparison Diff of Means t P P<0.050   
CBZ-SACumax- vs. CBZ-SACss-MC105.947 24.433 <0.001 Yes   
CBZ-SACumax- vs. CBZ-NIC-MCC105.643 24.363 <0.001 Yes   
CBZ-SACumax-MCC vs. CBZ-MCC59.246 13.663 <0.001 Yes   
CBZ-MCC vs. CBZ-SACss-MCC 46.701 10.770 <0.001 Yes   
CBZ-MCC vs. CBZ-NIC-MCC 46.396 10.700 <0.001 Yes   
CBZ-NIC-MCC vs. CBZ-SACss-MCC 0.305 0.0702 1.000 No 
  
Comparisons for factor: Formulation within SGF 
Comparison Diff of Means t P P<0.05   
CBZ-SACumax- vs. CBZ-NIC-MCC157.825 17.191 <0.001 Yes   
CBZ-SACumax- vs. CBZ-SACss-MC133.865 14.582 <0.001 Yes   
CBZ-SACumax-MCC vs. CBZ-MCC115.123 12.540 <0.001 Yes   
CBZ-MCC vs. CBZ-NIC-MCC 42.703 4.651 <0.001 Yes   
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CBZ-MCC vs. CBZ-SACss-MCC 18.742 2.042 0.301 No   
CBZ-SACss-MCC vs. CBZ-NIC-MCC23.960 2.610 0.084 No   
 
Comparisons for factor: Formulation within acetate 
Comparison Diff of Means t P P<0.05   
CBZ-SACumax- vs. CBZ-NIC-MCC80.212 8.737 <0.001 Yes   
CBZ-SACumax- vs. CBZ-SACss-MC41.188 4.487 <0.001 Yes   
CBZ-SACumax-MCC vs. CBZ-MCC36.913 4.021 0.002 Yes   
CBZ-MCC vs. CBZ-NIC-MCC 43.299 4.716 <0.001 Yes   
CBZ-MCC vs. CBZ-SACss-MCC 4.275 0.466 1.000 No   
CBZ-SACss-MCC vs. CBZ-NIC-MCC39.024 4.251 0.001 Yes   
 
Comparisons for factor: Formulation within SIF 
Comparison Diff of Means t P P<0.05   
CBZ-SACumax-MCC vs. CBZ-MCC56.581 6.163 <0.001 Yes   
CBZ-SACumax- vs. CBZ-SACss-MC46.049 5.016 <0.001 Yes   
CBZ-SACumax- vs. CBZ-NIC-MCC29.707 3.236 0.018 Yes   
CBZ-NIC-MCC vs. CBZ-MCC 26.874 2.927 0.039 Yes   
CBZ-NIC-MCC vs. CBZ-SACss-MCC16.343 1.780 0.511 No   
CBZ-SACss-MCC vs. CBZ-MCC 10.531 1.147 1.000 No   
 
Comparisons for factor: Formulation within FaSSGF 
Comparison Diff of Means t P P<0.05   
CBZ-SACumax- vs. CBZ-SACss-MC270.121 29.423 <0.001 Yes   
CBZ-SACumax- vs. CBZ-NIC-MCC209.276 22.796 <0.001 Yes   
CBZ-SACumax-MCC vs. CBZ-MCC50.770 5.530 <0.001 Yes   
CBZ-MCC vs. CBZ-SACss-MCC 219.350 23.893 <0.001 Yes   
CBZ-MCC vs. CBZ-NIC-MCC 158.506 17.266 <0.001 Yes   




Comparisons for factor: Formulation within FaSSIF-V2 
Comparison Diff of Means t P P<0.05   
CBZ-SACumax- vs. CBZ-NIC-MCC51.193 5.576 <0.001 Yes   
CBZ-SACumax- vs. CBZ-SACss-MC38.512 4.195 0.001 Yes   
CBZ-SACumax-MCC vs. CBZ-MCC36.845 4.013 0.002 Yes   
CBZ-MCC vs. CBZ-NIC-MCC 14.348 1.563 0.772 No   
CBZ-MCC vs. CBZ-SACss-MCC 1.667 0.182 1.000 Do Not Test   
CBZ-SACss-MCC vs. CBZ-NIC-MCC12.681 1.381 1.000 Do Not Test   
 
Comparisons for factor: Medium within CBZ-MCC 
Comparison Diff of Means t P P<0.05   
FaSSGF vs. SIF 216.994 25.682 <0.001 Yes   
FaSSGF vs. SGF 165.698 19.611 <0.001 Yes   
FaSSGF vs. acetate 148.192 17.539 <0.001 Yes   
FaSSGF vs. FaSSIF-V2 129.044 15.273 <0.001 Yes   
FaSSIF-V2 vs. SIF 87.950 10.409 <0.001 Yes   
FaSSIF-V2 vs. SGF 36.654 4.338 0.001 Yes   
FaSSIF-V2 vs. acetate 19.148 2.266 0.308 No   
acetate vs. SIF 68.802 8.143 <0.001 Yes   
acetate vs. SGF 17.506 2.072 0.469 No   
SGF vs. SIF 51.296 6.071 <0.001 Yes   
 
Comparisons for factor: Medium within CBZ-NIC-MCC 
Comparison Diff of Means t P P<0.05   
FaSSIF-V2 vs. SGF 65.009 7.694 <0.001 Yes   
FaSSIF-V2 vs. acetate 48.099 5.693 <0.001 Yes   
FaSSIF-V2 vs. SIF 46.728 5.530 <0.001 Yes   
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FaSSIF-V2 vs. FaSSGF 15.114 1.789 0.837 No   
FaSSGF vs. SGF 49.895 5.905 <0.001 Yes   
FaSSGF vs. acetate 32.985 3.904 0.005 Yes   
FaSSGF vs. SIF 31.614 3.742 0.008 Yes   
SIF vs. SGF 18.281 2.164 0.386 No   
SIF vs. acetate 1.371 0.162 1.000 Do Not Test   
acetate vs. SGF 16.910 2.001 0.544 Do Not Test   
 
Comparisons for factor: Medium within CBZ-SACss-MCC 
Comparison Diff of Means t P P<0.05   
FaSSIF-V2 vs. FaSSGF 88.639 10.491 <0.001 Yes   
FaSSIF-V2 vs. SIF 75.751 8.965 <0.001 Yes   
FaSSIF-V2 vs. SGF 53.730 6.359 <0.001 Yes   
FaSSIF-V2 vs. acetate 21.756 2.575 0.152 No   
acetate vs. FaSSGF 66.883 7.916 <0.001 Yes   
acetate vs. SIF 53.995 6.391 <0.001 Yes   
acetate vs. SGF 31.974 3.784 0.007 Yes   
SGF vs. FaSSGF 34.910 4.132 0.003 Yes   
SGF vs. SIF 22.022 2.606 0.141 No   
SIF vs. FaSSGF 12.888 1.525 1.000 No   
 
Comparisons for factor: Medium within CBZ-SACumax-MCC 
Comparison Diff of Means t P P<0.05   
FaSSGF vs. SIF 211.183 24.994 <0.001 Yes   
FaSSGF vs. acetate 162.049 19.179 <0.001 Yes   
FaSSGF vs. FaSSIF-V2 142.969 16.921 <0.001 Yes   
FaSSGF vs. SGF 101.346 11.995 <0.001 Yes   
SGF vs. SIF 109.837 13.000 <0.001 Yes   
SGF vs. acetate 60.703 7.184 <0.001 Yes   
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SGF vs. FaSSIF-V2 41.624 4.926 <0.001 Yes   
FaSSIF-V2 vs. SIF 68.214 8.073 <0.001 Yes   
FaSSIF-V2 vs. acetate 19.080 2.258 0.314 No   
acetate vs. SIF 49.134 5.815 <0.001 Yes   
 
A result of "Do Not Test" occurs for a comparison when no significant difference is found 
between two means that enclose that comparison.  For example, if you had four means sorted 
in order, and found no difference between means 4 vs. 2, then you would not test 4 vs. 3 and 3 
vs. 2, but still test 4 vs. 1 and 3 vs. 1 (4 vs. 3 and 3 vs. 2 are enclosed by 4 vs. 2: 4 3 2 1).  
Note that not testing the enclosed means is a procedural rule, and a result of Do Not Test 
should be treated as if there is no significant difference between the means, even though one 





















 Appendix 8 
 
Two Way Repeated Measures ANOVA (Two Factor Repetition)Wednesday, December 
14, 2011, 12:26:08 
Data source: Data 1 in Notebook3 
Balanced Design 
Dependent Variable: solubility  
Normality Test (Shapiro-Wilk) Failed (P < 0.050) 
Equal Variance Test: Passed (P = 0.278) 
Source of Variation  DF   SS   MS    F    P   
Sample no 2 6359.718 3179.859    
medium 4 11906067.398 2976516.850 2428.842 <0.001  
medium x Sample no 8 9803.905 1225.488    
formulation 4 1038696.570 259674.142 150.404 <0.001  
formulation x Sample no 8 13812.065 1726.508    
medium x formulation 16 2036485.716 127280.357 134.450 <0.001  
Residual 32 30293.496 946.672    
Total 74 15041518.868 203263.768    
 
 
Main effects cannot be properly interpreted if significant interaction is determined. This is 
because the size of a factor's effect depends upon the level of the other factor. 
 
The effect of different levels of medium depends on what level of formulation is present.  
There is a statistically significant interaction between medium and formulation.  (P = <0.001) 
Power of performed test with alpha = 0.0500:  for medium : 1.000 
Power of performed test with alpha = 0.0500:  for formulation : 1.000 




 Least square means for medium :  
Group Mean  
SGF 1.280  
acetate 8.998  
SIF 960.147  
FaSSGF 1.864  
FaSSIF-V2610.675  
Std Err of LS Mean = 9.039 
 
Least square means for formulation :  
Group Mean  
IND [sigma] 188.938  
IND-NICss 526.766  
IND-SACss 299.159  
IND-SACumax227.677  
IND-SACsd 340.425  
Std Err of LS Mean = 10.728 
 
Least square means for medium x formulation :  
Group Mean  
SGF x IND [sigma] 0.243  
SGF x IND-NICss 1.414  
SGF x IND-SACss 1.205  
SGF x IND-SACumax 1.132  
SGF x IND-SACsd 2.404  
acetate x IND [sigma] 5.617  
acetate x IND-NICss 9.361  
acetate x IND-SACss 12.243  
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acetate x IND-SACumax 8.041  
acetate x IND-SACsd 9.728  
SIF x IND [sigma] 541.767  
SIF x IND-NICss 1545.749  
SIF x IND-SACss 903.582  
SIF x IND-SACumax 582.657  
SIF x IND-SACsd 1226.982  
FaSSGF x IND [sigma] 0.988  
FaSSGF x IND-NICss 1.731  
FaSSGF x IND-SACss 2.272  
FaSSGF x IND-SACumax 2.374  
FaSSGF x IND-SACsd 1.957  
FaSSIF-V2 x IND [sigma]396.073  
FaSSIF-V2 x IND-NICss1075.574  
FaSSIF-V2 x IND-SACss 576.494  
FaSSIF-V2 x IND-SACumax544.182  
FaSSIF-V2 x IND-SACsd 461.052  
Std Err of LS Mean = 17.764 
All Pairwise Multiple Comparison Procedures (Bonferroni t-test): 
Comparisons for factor: medium 
Comparison Diff of Means t P P<0.050   
SIF vs. SGF 958.868 75.013 <0.001 Yes   
SIF vs. FaSSGF 958.283 74.967 <0.001 Yes   
SIF vs. acetate 951.149 74.409 <0.001 Yes   
SIF vs. FaSSIF-V2 349.472 27.339 <0.001 Yes   
FaSSIF-V2 vs. SGF 609.395 47.673 <0.001 Yes   
FaSSIF-V2 vs. FaSSGF 608.811 47.628 <0.001 Yes   
FaSSIF-V2 vs. acetate 601.677 47.069 <0.001 Yes   
acetate vs. SGF 7.718 0.604 1.000 No   
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acetate vs. FaSSGF 7.134 0.558 1.000 Do Not Test   
FaSSGF vs. SGF 0.585 0.0457 1.000 Do Not Test   
Comparisons for factor: formulation 
Comparison Diff of Means t P P<0.050   
IND-NICss vs. IND [sigma] 337.828 22.266 <0.001 Yes   
IND-NICss vs. IND-SACumax 299.089 19.713 <0.001 Yes   
IND-NICss vs. IND-SACss 227.607 15.001 <0.001 Yes   
IND-NICss vs. IND-SACsd 186.341 12.282 <0.001 Yes   
IND-SACsd vs. IND [sigma] 151.487 9.984 <0.001 Yes   
IND-SACsd vs. IND-SACumax 112.748 7.431 <0.001 Yes   
IND-SACsd vs. IND-SACss 41.266 2.720 0.263 No   
IND-SACss vs. IND [sigma] 110.222 7.265 <0.001 Yes   
IND-SACss vs. IND-SACumax 71.482 4.711 0.015 Yes   
IND-SACumax vs. IND [sigma] 38.739 2.553 0.340 No   
 
Comparisons for factor: formulation within SGF 
Comparison Diff of Means t P P<0.05   
IND-SACsd vs. IND [sigma] 2.161 0.0797 1.000 No   
IND-SACsd vs. IND-SACumax 1.272 0.0469 1.000 Do Not Test   
IND-SACsd vs. IND-SACss 1.199 0.0442 1.000 Do Not Test   
IND-SACsd vs. IND-NICss 0.990 0.0365 1.000 Do Not Test   
IND-NICss vs. IND [sigma] 1.171 0.0432 1.000 Do Not Test   
IND-NICss vs. IND-SACumax 0.282 0.0104 1.000 Do Not Test   
IND-NICss vs. IND-SACss 0.209 0.00773 1.000 Do Not Test   
IND-SACss vs. IND [sigma] 0.962 0.0355 1.000 Do Not Test   
IND-SACss vs. IND-SACumax 0.0723 0.00267 1.000 Do Not Test   





 Comparisons for factor: formulation within acetate 
Comparison Diff of Means t P P<0.05   
IND-SACss vs. IND [sigma] 6.625 0.244 1.000 No   
IND-SACss vs. IND-SACumax 4.202 0.155 1.000 Do Not Test   
IND-SACss vs. IND-NICss 2.882 0.106 1.000 Do Not Test   
IND-SACss vs. IND-SACsd 2.515 0.0928 1.000 Do Not Test   
IND-SACsd vs. IND [sigma] 4.110 0.152 1.000 Do Not Test   
IND-SACsd vs. IND-SACumax 1.687 0.0622 1.000 Do Not Test   
IND-SACsd vs. IND-NICss 0.367 0.0135 1.000 Do Not Test   
IND-NICss vs. IND [sigma] 3.743 0.138 1.000 Do Not Test   
IND-NICss vs. IND-SACumax 1.320 0.0487 1.000 Do Not Test   
IND-SACumax vs. IND [sigma] 2.423 0.0894 1.000 Do Not Test   
 
Comparisons for factor: formulation within SIF 
Comparison Diff of Means t P P<0.05   
IND-NICss vs. IND [sigma] 1003.983 37.030 <0.001 Yes   
IND-NICss vs. IND-SACumax 963.093 35.522 <0.001 Yes   
IND-NICss vs. IND-SACss 642.168 23.685 <0.001 Yes   
IND-NICss vs. IND-SACsd 318.767 11.757 <0.001 Yes   
IND-SACsd vs. IND [sigma] 685.216 25.273 <0.001 Yes   
IND-SACsd vs. IND-SACumax 644.326 23.765 <0.001 Yes   
IND-SACsd vs. IND-SACss 323.401 11.928 <0.001 Yes   
IND-SACss vs. IND [sigma] 361.815 13.345 <0.001 Yes   
IND-SACss vs. IND-SACumax 320.925 11.837 <0.001 Yes   
IND-SACumax vs. IND [sigma] 40.890 1.508 1.000 No   
 
Comparisons for factor: formulation within FaSSGF 
Comparison Diff of Means t P P<0.05   
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IND-SACumax vs. IND [sigma] 1.386 0.0511 1.000 No   
IND-SACumax vs. IND-NICss 0.643 0.0237 1.000 Do Not Test   
IND-SACumax vs. IND-SACsd 0.416 0.0154 1.000 Do Not Test   
IND-SACumax vs. IND-SACss 0.101 0.00374 1.000 Do Not Test   
IND-SACss vs. IND [sigma] 1.285 0.0474 1.000 Do Not Test   
IND-SACss vs. IND-NICss 0.542 0.0200 1.000 Do Not Test   
IND-SACss vs. IND-SACsd 0.315 0.0116 1.000 Do Not Test   
IND-SACsd vs. IND [sigma] 0.970 0.0358 1.000 Do Not Test   
IND-SACsd vs. IND-NICss 0.227 0.00836 1.000 Do Not Test   
IND-NICss vs. IND [sigma] 0.743 0.0274 1.000 Do Not Test   
 
Comparisons for factor: formulation within FaSSIF-V2 
Comparison Diff of Means t P P<0.05   
IND-NICss vs. IND [sigma] 679.501 25.062 <0.001 Yes   
IND-NICss vs. IND-SACsd 614.522 22.666 <0.001 Yes   
IND-NICss vs. IND-SACumax 531.392 19.599 <0.001 Yes   
IND-NICss vs. IND-SACss 499.079 18.408 <0.001 Yes   
IND-SACss vs. IND [sigma] 180.421 6.655 <0.001 Yes   
IND-SACss vs. IND-SACsd 115.442 4.258 0.001 Yes   
IND-SACss vs. IND-SACumax 32.313 1.192 1.000 No   
IND-SACumax vs. IND [sigma] 148.109 5.463 <0.001 Yes   
IND-SACumax vs. IND-SACsd 83.130 3.066 0.040 Yes   
IND-SACsd vs. IND [sigma] 64.979 2.397 0.217 No   
 
Comparisons for factor: medium within IND [sigma] 
Comparison Diff of Means t P P<0.05   
SIF vs. SGF 541.524 20.948 <0.001 Yes   
SIF vs. FaSSGF 540.779 20.919 <0.001 Yes   
SIF vs. acetate 536.149 20.740 <0.001 Yes   
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SIF vs. FaSSIF-V2 145.694 5.636 <0.001 Yes   
FaSSIF-V2 vs. SGF 395.830 15.312 <0.001 Yes   
FaSSIF-V2 vs. FaSSGF 395.085 15.283 <0.001 Yes   
FaSSIF-V2 vs. acetate 390.456 15.104 <0.001 Yes   
acetate vs. SGF 5.374 0.208 1.000 No   
acetate vs. FaSSGF 4.630 0.179 1.000 Do Not Test   
FaSSGF vs. SGF 0.745 0.0288 1.000 Do Not Test   
 
Comparisons for factor: medium within IND-NICss 
Comparison Diff of Means t P P<0.05   
SIF vs. SGF 1544.335 59.739 <0.001 Yes   
SIF vs. FaSSGF 1544.019 59.727 <0.001 Yes   
SIF vs. acetate 1536.389 59.432 <0.001 Yes   
SIF vs. FaSSIF-V2 470.176 18.188 <0.001 Yes   
FaSSIF-V2 vs. SGF 1074.160 41.551 <0.001 Yes   
FaSSIF-V2 vs. FaSSGF 1073.843 41.539 <0.001 Yes   
FaSSIF-V2 vs. acetate 1066.213 41.244 <0.001 Yes   
acetate vs. SGF 7.947 0.307 1.000 No   
acetate vs. FaSSGF 7.630 0.295 1.000 Do Not Test   
FaSSGF vs. SGF 0.317 0.0122 1.000 Do Not Test   
 
Comparisons for factor: medium within IND-SACss 
Comparison Diff of Means t P P<0.05   
SIF vs. SGF 902.377 34.906 <0.001 Yes   
SIF vs. FaSSGF 901.309 34.865 <0.001 Yes   
SIF vs. acetate 891.339 34.479 <0.001 Yes   
SIF vs. FaSSIF-V2 327.087 12.653 <0.001 Yes   
FaSSIF-V2 vs. SGF 575.290 22.254 <0.001 Yes   
FaSSIF-V2 vs. FaSSGF 574.222 22.212 <0.001 Yes   
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FaSSIF-V2 vs. acetate 564.251 21.827 <0.001 Yes   
acetate vs. SGF 11.038 0.427 1.000 No   
acetate vs. FaSSGF 9.970 0.386 1.000 Do Not Test   
FaSSGF vs. SGF 1.068 0.0413 1.000 Do Not Test   
 
Comparisons for factor: medium within IND-SACumax 
Comparison Diff of Means t P P<0.05   
SIF vs. SGF 581.524 22.495 <0.001 Yes   
SIF vs. FaSSGF 580.283 22.447 <0.001 Yes   
SIF vs. acetate 574.616 22.228 <0.001 Yes   
SIF vs. FaSSIF-V2 38.475 1.488 1.000 No   
FaSSIF-V2 vs. SGF 543.049 21.007 <0.001 Yes   
FaSSIF-V2 vs. FaSSGF 541.808 20.959 <0.001 Yes   
FaSSIF-V2 vs. acetate 536.141 20.739 <0.001 Yes   
acetate vs. SGF 6.909 0.267 1.000 No   
acetate vs. FaSSGF 5.667 0.219 1.000 Do Not Test   
FaSSGF vs. SGF 1.241 0.0480 1.000 Do Not Test   
 
Comparisons for factor: medium within IND-SACsd 
Comparison Diff of Means t P P<0.05   
SIF vs. FaSSGF 1225.025 47.387 <0.001 Yes   
SIF vs. SGF 1224.579 47.370 <0.001 Yes   
SIF vs. acetate 1217.255 47.087 <0.001 Yes   
SIF vs. FaSSIF-V2 765.930 29.628 <0.001 Yes   
FaSSIF-V2 vs. FaSSGF 459.095 17.759 <0.001 Yes   
FaSSIF-V2 vs. SGF 458.648 17.742 <0.001 Yes   
FaSSIF-V2 vs. acetate 451.324 17.458 <0.001 Yes   
acetate vs. FaSSGF 7.770 0.301 1.000 No   
acetate vs. SGF 7.324 0.283 1.000 Do Not Test   
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SGF vs. FaSSGF 0.447 0.0173 1.000 Do Not Test   
A result of "Do Not Test" occurs for a comparison when no significant difference is found 
between two means that enclose that comparison.  For example, if you had four means sorted 
in order, and found no difference between means 4 vs. 2, then you would not test 4 vs. 3 and 3 
vs. 2, but still test 4 vs. 1 and 3 vs. 1 (4 vs. 3 and 3 vs. 2 are enclosed by 4 vs. 2: 4 3 2 1).  
Note that not testing the enclosed means is a procedural rule, and a result of Do Not Test 
should be treated as if there is no significant difference between the means, even though one 





























Table Analyzed Data 1     
      
Two-way ANOVA      
       
Source of Variation % of total variation P value    
Column Factor 2.27 0.4546    
Row Factor 93.27 < 0.0001    
       
Source of Variation P value summary Significant?    
Column Factor ns No    
Row Factor *** Yes    
       





Column Factor 5 895.1 179.0 1.022
Row Factor 2 36718 18359 104.8
Residual 10 1752 175.2  
       
Number of missing values 0     
       
Bonferroni posttests      
       
In vivo vs USP 1sim      
Row Factor In vivo USP 1sim Difference 95% CI of diff.
Cmax [mg/L]  1.890 1.020 -0.8700 -72.52 to 70.78
Tmax [h] 15.90 8.400 -7.500 -79.15 to 64.15
AUC [mg/L.h] 134.8 83.99 -50.81 -122.5 to 20.84
       
Row Factor Difference t P value Summary
Cmax [mg/L]  -0.8700 0.04647 P > 0.05 ns
Tmax [h] -7.500 0.4006 P > 0.05 ns
AUC [mg/L.h] -50.81 2.714 P > 0.05 ns
       
In vivo vs SGF/SIFsim      
Row Factor In vivo SGF/SIFsim Difference 95% CI of diff.
Cmax [mg/L]  1.890 1.120 -0.7700 -72.42 to 70.88
Tmax [h] 15.90 17.68 1.780 -69.87 to 73.43
AUC [mg/L.h] 134.8 95.15 -39.65 -111.3 to 32.00
       
Row Factor Difference t P value Summary
Cmax [mg/L]  -0.7700 0.04113 P > 0.05 ns
Tmax [h] 1.780 0.09508 P > 0.05 ns
AUC [mg/L.h] -39.65 2.118 P > 0.05 ns





In vivo vs MGM/MIM-Isim      
Row Factor In vivo
MGM/MIM-
Isim Difference 95% CI of diff.
Cmax [mg/L]  1.890 0.9500 -0.9400 -72.59 to 70.71
Tmax [h] 15.90 16.83 0.9300 -70.72 to 72.58
AUC [mg/L.h] 134.8 81.98 -52.82 -124.5 to 18.83
       
Row Factor Difference t P value Summary
Cmax [mg/L]  -0.9400 0.05021 P > 0.05 ns
Tmax [h] 0.9300 0.04968 P > 0.05 ns
AUC [mg/L.h] -52.82 2.821 P > 0.05 ns
       
In vivo vs MGM/MIM-IIsim      
Row Factor In vivo
MGM/MIM-
IIsim Difference 95% CI of diff.
Cmax [mg/L]  1.890 1.100 -0.7900 -72.44 to 70.86
Tmax [h] 15.90 16.82 0.9200 -70.73 to 72.57
AUC [mg/L.h] 134.8 94.10 -40.70 -112.4 to 30.95
       
Row Factor Difference t P value Summary
Cmax [mg/L]  -0.7900 0.04220 P > 0.05 ns
Tmax [h] 0.9200 0.04914 P > 0.05 ns
AUC [mg/L.h] -40.70 2.174 P > 0.05 ns
       
In vivo vs FaSSGF/FaSSIF-
V2sim      
Row Factor In vivo
FaSSGF/FaS
SIF-V2sim Difference 95% CI of diff.
Cmax [mg/L]  1.890 1.570 -0.3200 -71.97 to 71.33
Tmax [h] 15.90 10.96 -4.940 -76.59 to 66.71
AUC [mg/L.h] 134.8 127.9 -6.920 -78.57 to 64.73
       
Row Factor Difference t P value Summary
Cmax [mg/L]  -0.3200 0.01709 P > 0.05 ns
Tmax [h] -4.940 0.2639 P > 0.05 ns
AUC [mg/L.h] -6.920 0.3696 P > 0.05 ns
       
 
